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ABSTRACT 
 
Shiga toxin-producing E. coli (STEC) is an important food- and water-borne 
pathogen of humans, causing Hemorrhagic Colitis and Haemolytic Uremic Syndrome. 
Colonization of both cattle and human hosts is mediated through the action of effector 
molecules secreted via a type III secretion system (T3SS), which forms attaching and 
effacing lesions (A/E). The necessary effectors which form A/E by manipulation of host 
signalling and actin nucleation are present on a pathogenicity island called the Locus of 
Enterocyte Effacement (LEE).  
It has been reported that vaccination of cattle with Type III-secreted proteins 
(T3SPs) from STEC O157 resulted in decreased shedding. In order to extend this to non-
O157 STEC serotypes, we examined the serological cross-reactivity of T3SPs of 
serotypes O26:H11, O103:H2, O111:NM and O157:H7. Groups of cattle were vaccinated 
with T3SPs produced from each of the serotypes and the magnitude and specificity of the 
responses were measured resulting in limited cross reactivity.  Overall, results suggest 
that vaccination of cattle with T3SPs as a means of reducing the risk of STEC 
transmission to humans will induce protection that is serotype specific. 
 To pursue the possibility of a cross-protective vaccine, we investigated the 
protective properties of a chimeric Tir protein against STEC serotypes. Several studies 
have reported that Tir is highly immunogenic and capable of producing high antibody 
titers. Potter and colleagues also demonstrated that the vaccination of cattle with ∆tir 
STEC O157 strain did not protect as well as the wildtype strain. We constructed thirty-
mer peptides to the entire STEC O157 Tir protein, as well as to the intimin binding 
domain of the Tir protein from STEC serotype O26, O103 and O111. Using sera raised 
against STEC O157 and non-O157 T3SPs, we identified a number of immunogenic 
peptides containing epitopes unique to a particular serotype. Two different chimeric Tir 
proteins were constructed containing the STEC O157 Tir protein fused with six STEC 
non-O157 peptides with or without the Leukotoxin produced by Mannheimia 
haemolytica. However, the vaccination of mice with the chimeric protein did not protect 
against challenge with STEC O157 or STEC O111. These results suggest that to achieve 
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cross protection against STEC serotypes using a recombinant protein vaccine, other 
immunogenic and protective antigens must also be included. 
In order to identify other immunogenic and cross-protective antigens we cloned 
and expressed the genes coding for 66 effectors and purified each as histidine-tagged 
proteins. These included 37 LEE-encoded proteins and 29 non-LEE effectors.  The 
serological response against each protein was measured by Western blot analysis and an 
enzyme-linked immunosorbent assay (ELISA) using sera from rabbits immunized with 
T3SPs from four STEC serotypes, experimentally infected cattle and human sera from 6 
HUS patients.  A total of 20 proteins were recognized by at least one of the STEC T3SP- 
vaccinated rabbits using Western blots. Sera from experimentally infected cattle and HUS 
patients were tested using an ELISA against each of the proteins. Tir, EspB, EspD, EspA 
and NleA were recognized by the majority of the samples tested. Overall, proteins such 
as Tir, EspB, EspD, NleA and EspA were highly immunogenic for both vaccinated and 
naturally infected subjects.  
 Based on the above results, two different mixtures of secreted proteins (5 proteins 
and 9 proteins) were used to vaccinate mice and test the level of shedding following 
challenge with STEC O157. Overall, the cocktail vaccine containing 9 immunogenic 
effectors including Tir, EspB, EspD, NleA and EspA was capable of reducing shedding 
as effectively as the current STEC T3SPs vaccine, Econiche®.  
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1.0 LITERATURE REVIEW 
 
1.1 Escherichia coli 
 
1.1.1 Nomenclature 
Escherichia coli (E. coli) is a Gram-negative, non-sporulating, facultative 
anaerobic member of the family Enterobacteriaceae. This bacterium is approximately 2 
μm  long, with a diameter of 5 μm,  and a cell volume of 0.6-0.7 μm3  (Kubitschek 1990). 
Its primary environment is the gastrointestinal tract of mammals and birds, and in humans 
it remains the predominant facultative anaerobe of the colonic flora (Karmali, Petric et al. 
2004). The optimal growth temperature for E. coli is 37ºC, but some laboratory strains 
can multiply at temperatures as high as 49ºC (Fotadar, Zaveloff et al. 2005). This 
organism, which is also found in soil and water, is commonly transmitted by fecal 
contamination. Escherichia coli colonize the gastrointestinal tract of infants in the first 
hours of life, where a mutual relationship quickly develops between the bacterium and 
host. This organism tends to be harmless in the intestinal lumen but in an 
immunosuppressed host, or when gastrointestinal barriers are broken, even non-
pathogenic strains can cause infection.  
Serological typing of E. coli is based on the characterization of its dominant O 
(lipopolysaccharide), K (capsular) and H (flagellar) antigens (Sojka 1965; Gyles 1994; 
Sussman 1997). The H antigen represents the distinctive serological epitopes located on 
the flagellin protein, which are responsible for the formation of the flagella. To date, 53 
different H antigens have been identified in E. coli (Sojka 1965). The K antigen 
represents a class of thermolabile polysaccharides that form sheaths, envelopes, or 
capsules. This antigen was first identified through bacterial agglutination tests. The 
somatic O antigen represents the cell wall lipopolysaccharide complex, and over 170 
different O antigens have been identified (Gyles 1994). This antigen is able to remain 
active at high temperatures ranging from 100○C to 121○C (Sojka 1965).  The combination 
of the O and H antigen defines the serotype, and over 700 different E. coli serotypes have 
been recognized to date. Some of these serotypes are pathogenic and are defined by their 
virulence characteristics. 
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Shiga toxin-producing E. coli (STEC), also known as Enterohemorrhagic E. coli 
(EHEC) or Verotoxigenic E. coli (VTEC), is a zoonotic pathogen that causes bloody 
diarrhea and hemorrhagic colitis in humans (Thorpe, Hurley et al. 1999; Tuttle, Gomez et 
al. 1999; Karmali, Petric et al. 2004). This organism was first recognized as a pathogen in 
1982, after two outbreaks of hemorrhagic colitis and abdominal cramps among 
individuals who ate undercooked hamburgers at a fast food restaurant (Riley, Remis et al. 
1983). The Centre for Disease Control and Prevention (CDC) isolated an E. coli 
O157:H7 strain from these infected individuals, and it was soon discovered that this class 
of E. coli expressed a set of toxins called Shiga toxins (Stx) (Riley, Remis et al. 1983). 
These enterotoxins were isolated from fecal samples, and were found to be responsible 
for the development of hemolytic-uremic syndrome (HUS) (Karmali, Steele et al. 1983).  
 
1.1.2 Shiga toxin-producing E. coli O157:H7 
Shiga toxin-producing E. coli O157:H7 is the most common STEC serotype, 
initially described in 1977 by Konowalchuk and colleagues (Konowalchuk, Speirs et al. 
1977). This serotype has been the cause of numerous infections worldwide, where at least 
30 countries in 6 different continents have reported outbreaks (Nataro and Kaper 1998; 
Yoon and Hovde 2008). In North America, STEC O157:H7 is the most dominant 
serotype associated with hemorrhagic colitis and HUS. In the United States alone, this 
serotype is responsible for 73,480 cases, 2,168 hospitalizations and 61 deaths annually 
(Mead, Slutsker et al. 1999). Annual losses in medical care are understood to range from 
300 to 700 million dollars, where the elderly and the young suffer the most severe 
manifestations of the disease (Paton, Ratcliff et al. 1996; Tuttle, Gomez et al. 1999; Yoon 
and Hovde 2008).  
Shiga toxin-producing E. coli O157:H7 has also been responsible for the most 
severe STEC outbreaks reported worldwide. In Canada, the largest occurred in 
Walkerton, Ontario when the water system became contaminated with STEC O157:H7 
through fecal matter, resulting in 2,100 cases and 7 deaths (Holme 2003). The biggest 
European STEC outbreak occurred in Scotland, where meat purchased from a single 
butcher shop infected 501 people resulting in 20 deaths (Dundas, Todd et al. 2001). The 
largest Asian outbreak ever recorded occurred in Japan, where an STEC O157:H7 
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outbreak related to white radish sprouts was responsible for thousands of  school children 
becoming ill (Watanabe, Wada et al. 1996). A number of large outbreaks have also been 
reported in Africa, which resulted in a significant number of cases and fatalities (Cunin, 
Tedjouka et al. 1999; Effler, Isaacson et al. 2001). 
Pathogenic STEC serotypes share biological characteristics that set them apart 
from non-pathogenic E. coli strains. An important feature which defines STEC O157:H7 
from other STEC strains is its inability to ferment D-sorbitol, whereas roughly 75% to 
94% of all E. coli serotypes ferment sorbitol (March and Ratnam 1986; Nataro and Kaper 
1998). This allows for rapid identification by plating on sorbitol-MacConkey medium. 
Another important characteristic of STEC O157:H7 is its inability to produce β-
glucuronidase. Upon hydrolysis, β-glucuronidase can be detected by the use of 4-methyl-
umbelliferyl-D-glucuronide through fluorescence (Thompson, Hodge et al. 1990).  
Several important differences were revealed when the genome sequences of 
STEC O157:H7 and E. coli K12, a common laboratory strain, were compared. Both 
genomes share approximately 4.1Mb of a homologous sequence, while the STEC 
O157:H7 sequence contains an additional 1.34Mb of genomic  Deoxyribonucleic acid 
(DNA) made up of 1387 genes, not present within the E. coli K12 genome (Perna, 
Plunkett et al. 2001). These additional genes are found in 177 O-islands scattered 
throughout the STEC O157:H7 chromosome. However, the STEC genome is missing a 
region of approximately 0.53Mb genomic DNA found on the E. coli K12 genome. It is 
supposed that throughout its evolution, STEC O157 acquired large amounts of foreign 
DNA through lateral gene transfer. This uniquely acquired DNA contains virulence 
factors, alternative metabolic capacities and numerous prophages. Through the study of 
phylogenetic trees, STEC O157 has been suggested to have evolved from the less 
pathogenic E. coli O55:H7 serotype (Whittam, Wachsmuth et al. 1988). 
 
1.1.3. Non-O157 serotypes 
Over the last fifteen years, non-O157 serotypes have emerged as important enteric 
pathogens. In fact, over a decade ago, only 50% of USA clinical labs would run 
diagnostics on stool samples for STEC serotypes other than STEC O157:H7 (Tarr and 
Neill 1996). Non-O157 serotypes are responsible for sporadic outbreaks both in North 
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America and in other continents. In the USA alone, these serotypes cause 36,740 
illnesses, 1,084 hospitalizations and 30 deaths annually (Mead, Slutsker et al. 1999). 
Depending on the region, non-O157 strains are responsible for up to 50% of all STEC 
outbreaks, while in Europe, non-O157 illnesses are more common than STEC O157 
(Park, Gates et al. 1996; Brooks, Sowers et al. 2005). Overall, the reported cases of non-
O157 infections are likely to be an understatement of the actual prevalence due to the 
inability of clinical isolation and identification.  
An extensive study completed by Brooks and colleagues, analyzed 940 human 
non-O157 STEC isolates collected by the CDC between 1983 and 2000 (Brooks, Sowers 
et al. 2005). This study reported that the most common non-O157 serotypes were STEC 
O26, O111, O103, O121, O45 and O145, where O111, O26 and O103 accounted for over 
50% of all isolates. Numerous outbreaks in countries such as Japan, Argentina, Chile, 
Germany, Australia, USA and Ireland have been attributed to non-O157 infections 
(Nataro and Kaper 1998; Bettelheim 2007). In countries such as Argentina, non-O157 
strains are responsible for the majority of outbreaks and HUS cases reported (Rivero, 
Padola et al. 2004).  
The clinical isolation and identification of non-O157 serotypes is challenging 
compared to STEC O157. Identification of STEC O157 is relatively simple because of its 
inability to ferment D-sorbitol (Nataro and Kaper 1998). However, non-O157 serotypes 
and most non-pathogenic E. coli strains ferment D-sorbitol. The current identification 
method involves the detection of toxin genes such as Stx present in STEC serotypes. 
Another explanation why non-O157 serotypes are not often reported is because many 
laboratories do not have the facilities to isolate, identify and characterize these strains 
(Bettelheim 2007). Interestingly, the increase in identified non-O157 outbreaks over the 
last few years could be related to better and stricter testing, regardless if a sample is 
positive for STEC O157:H7, since co-infections can occur with multiple STEC serotypes.  
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1.1.4 Human diseases 
 
1.1.4.1 Diarrhea and hemorrhagic colitis 
 Human infections by STEC produce either no symptoms, watery diarrhea, or 
watery diarrhea involving speckled or grossly bloody stools (Figure 1.1). The bloody 
watery diarrhea is known as hemorrhagic colitis, and involves feverless cramping, 
abdominal pain and vomiting (Cleary 2004). Chronic diarrhea is extremely rare with 
STEC infections, while common diarrhea can last over a week. Fever is only found in a 
small fraction of patients infected with STEC. Patients who develop fever usually also 
develop HUS at some stage of hemorrhagic colitis. Several complications can arise from 
STEC inflammation of the gastrointestinal tract. These complications range from 
gangrene with peritonitis and sepsis, to rectal prolapse, coma, hemiplegia, pancreatitis 
and seizures (Lopez, Devoto et al. 1989; Nataro and Kaper 1998; Cleary 2004). 
Shiga toxin-producing E. coli can also produce a number of toxins and secreted 
proteins which induce watery diarrhea in humans. During digestion, cells secrete fluid 
into the lumen with the help of chloride channels. These channels are activated via 
receptors such as guanylate cyclase C, which cause a change in intracellular second 
messenger levels (Uzzau and Fasano 2000). Heat stable enterotoxins, such as EAST1, 
initiate diarrhea by activating the cyclic guanosine monophosphate (GMP) pathway that  
phosphorylates the chloride channels on the apical membranes of intestinal epithelial 
cells (IECs). This phosphorylation stimulates chloride secretion, and the inhibition of 
sodium chloride absorption by the villus tips of cells. This event leads to an increase in 
luminal ion content, causing water to pull through the paracellular pathway, resulting in 
osmotic diarrhea (Nataro and Kaper 1998).  Shiga toxins are involved in diarrhea by 
killing absorptive villus tips on epithelial cells, resulting in an imbalance in intestinal 
absorption and secretion (Kandel, Donohue-Rolfe et al. 1989; Nataro and Kaper 1998). 
The bloody diarrhea observed with STEC is attributed to the role of Stx on endothelial 
cells, thrombotic microangiopathy, and the lesions on small blood vessels in the gut (Ray 
and Liu 2001).  
 Several secreted proteins play an important role in the production of diarrhea. For 
example, EspF disrupts the host intestinal barrier function, by inducing the redistribution  
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Figure 1.1 The pathophysiology of STEC infection. The onset of diarrhea occurs 
within the first 3 to 8 days, which can result in hemorrhagic colitis and complications 
such as HUS. Percentages represent patient likelihood of developing infection (diarrhea, 
hemorrhagic colitis, HUS and sequelae). Numbers (-3, -2, -1, etc…) represent days during 
infection Sequelae can range from central nervous system involvement, skeletal and 
myocardial involvement, renal disease, and mortality. Diagram was adapted and modified 
from (Scheiring, Andreoli et al. 2008). 
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of the protein occludin which is associated with the stability of tight junctions 
(McNamara, Koutsouris et al. 2001). This effect results in a loss of trans-epithelial 
electrical resistance and paracellular permeability, leading to fluid secretion. Other 
effectors such as EspG, and Map, also affect intestinal barrier function by causing loss of 
epithelial electrical resistance or by altering mitochondrial function (Dean and Kenny 
2004; Matsuzawa, Kuwae et al. 2005). The secretion of effectors causes an up-regulation 
in the host inflammatory response, by activating NF-κB, which leads to the production of  
IL-8 and the recruitment of neutrophils (Kaper, Nataro et al. 2004). The activation of NF-
κB also causes an increase in the galanin-1 receptor expressed by the epithelial cells in 
the gut, resulting in excessive fluid secretion.  
 
1.1.4.2 Hemolytic-Uremic Syndrome 
Hemolytic-uremic syndrome was first described in 1955 by von Gasser and 
colleagues in a study of five children with small vessel renal thrombosis and non-immune 
haemolytic anaemia (Gasser, Gautier et al. 1955). In 1965, a study by Barnard and Kibel 
hypothesized that HUS could be a result of enteric E. coli infections, without the 
knowledge of the existence of STEC (Barnard and Kibel 1965). Ten years later, Kaplan 
and colleagues reported the identification of HUS in a group of 83 siblings within 41 
families, and concluded that the clustering of cases in endemic areas was a result of an 
environmental infectious agent (Kaplan, Chesney et al. 1975). It was not until 1983 that 
Karmali and colleagues were able to identify an E. coli strain in the stool of HUS patients 
that produced an enterotoxin lethal to cultured Vero cells ( African monkey kidney cells) 
(Karmali, Steele et al. 1983; Karmali, Petric et al. 1985). Soon after, it was reported that 
this toxin was identical to Stx produced by Shigella dysenteriae serotype 1 (O'Brien, 
Lively et al. 1983). These initial studies led to the discovery that Stxs, along with 
virulence factors produced by STEC, were the main factors involved in the development 
of HUS. 
Typically, HUS occurs most frequently in the summer months and in children 
younger than 5 years of age (Ostroff, Kobayashi et al. 1989). The increase of summer 
cases correlates with reservoir shedding which is reported to increase during warm 
summer months (Chapman, Siddons et al. 1997). An in depth 20 year population study of 
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USA HUS occurrence in children under the age of 18 found an annual incidence ranging 
between 0.2 to 3.4 per 100,000 children (Siegler, Pavia et al. 1994). In Canada, annual 
incidences average 3.1 per 100,000 children under the age of five, while in Europe, 
countries such as Germany, Italy and Austria report annual incidences of HUS averaging 
0.71 in 100,000 children under the age of 15, and up to 2 per 100,000 in children under 
the age of five (Rowe, Orrbine et al. 1998; Gerber, Karch et al. 2002). However, the 
highest number of worldwide HUS cases is found in Argentina where 420 new cases are 
recorded each year with an annual incidence of 12.2 per 100,000 children under the age 
of five (Rivero, Padola et al. 2004). Overall, it is suggested that 83% of all worldwide 
HUS cases involving diarrhea are due to STEC infections (Amirlak and Amirlak 2006). 
Recently, a new study reported that of all STEC O157 infections, 15%  will eventually 
progress to HUS (Figure 1.1)  (Tarr, Gordon et al. 2005). This disease is the most 
common cause of acute renal failure in infants and young children worldwide. 
A typical case of HUS begins with an incubation period averaging between 3 to 8 
days. Soon after, a patient will develop watery diarrhea which can lead to hemorrhagic 
colitis with abdominal cramps. The involvement of bloody diarrhea in the gastrointestinal 
region can result in transmural necrosis with perforation and development of colonic 
stricture (Siegler 1994). Hemorrhagic colitis occurs in 90% of all HUS cases, which 
usually triggers the patient, or family members of the patient, to seek medical attention. 
On average, 50% of cases involve nausea and vomiting while 30% will involve fever 
(Scheiring, Andreoli et al. 2008). These symptoms lead to nephrological and 
hematological changes, where patients undergo thrombocytopenia, hemolytic anemia and 
renal failure. The haemolysis observed with HUS is a result of damage to erythrocytes in 
the small blood vessels. Although the main organs involved in HUS are the kidneys and 
the gastrointestinal area, other regions such as the pancreatic, skeletal, myocardial and the 
central nervous system can also be affected. Pancreatic involvement, indicated by glucose 
intolerance, edema and the elevation of pancreatic enzymes occurs in less than 10% of 
cases (Andreoli and Bergstein 1982). The involvement of the central nervous system 
during HUS was found to develop in up to 25% of cases and can lead to irritability, 
lethargy and seizures. Rarely, central nervous system involvement leads to cerebral 
edema and coma (Amirlak and Amirlak 2006; Scheiring, Andreoli et al. 2008). Skeletal 
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and myocardial involvement can also develop, however this is extremely unusual (Askiti, 
Hendrickson et al. 2004).  The majority of children who develop HUS will have some 
level of renal deficiency. Roughly two thirds of HUS patients will require dialysis 
therapy, while one third will have lesser renal involvement and dialysis will not be 
required (Gerber, Karch et al. 2002).  
Mortality rates in HUS patients range between 3-5% during acute phase, which 
usually involve renal disease and severe central nervous system (CNS) involvement 
(Amirlak and Amirlak 2006). Of the patients that developed HUS, 20-30% develop extra-
renal events, 20% of recovered patients show end-stage renal disease while 60% show 
signs of renal failure during acute phase. Several risk factors such as the administration of 
antibiotics, bloody diarrhea, elevated serum leukocyte count, fever, being under the age 
of ten, female gender and the use of antimotility agents, are believed to increase the 
susceptibility of developing HUS (Wong, Jelacic et al. 2000; Siegler and Oakes 2005).  
 
1.1.4.3 Thrombotic thrombocytopenic purpura 
Thrombotic microangiopathy (MIA) is distinguished by microvascular 
thrombosis, thrombocytopenia, microangiopathic hemolytic enemia and multi-organ 
injury. Thrombotic MIA is comprised of two syndromes called thrombotic 
thrombocytopenic purpura (TTP) and HUS, and both develop by separate mechanisms.  
These variants cause thrombocytopenia, microangiopathic hemolytic anemia, fever, renal 
abnormalities and neurological effects (Zheng and Sadler 2008).  Early studies suggested 
that STEC O157 was responsible for the development of TTP. A case study in 1986 
reported a 53 year old woman with bloody diarrhea, microangiopathic hemolytic enemia, 
neurological effects and fever consistent with TTP symptoms (1986). A later study in 
1990 reported similar symptoms where STEC O157 was isolated from stool samples 
(Kovacs, Roddy et al. 1990). Reported cases in adults involving neurological dysfunction 
were often diagnosed as TTP, while cases in children involving glomerular damage were 
diagnosed as HUS. 
It was not until the late 1990s that it was discovered that TTP patients suffer from 
a severe deficiency of a plasma metalloprotease called ADAMTS13 that cleaves von 
Willebrand factor (VWF), or an ADAMTS13 deficiency due to autoantibodies which 
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inhibit its activity or clear it from circulation (Furlan and Lammle 1998). Thrombotic 
thrombocytopenic purpura patients that do not produce this protease have large amounts 
of VWF agglutinated to circulating platelets in areas of intravascular shear stress (Chow, 
Turner et al. 1998). Although rare, Stx’s can impair ADAMTS13 cleavage of VWF 
multimers which results in damage to endothelial cells, and may induce renal 
microvascular thrombosis (Nolasco, Turner et al. 2005). Of TTP cases tested, 45% to 
100% of patients had reduced ADAMTS13 activity, while HUS patients rarely or simply 
did not demonstrate a deficiency in ADAMTS13 activity (Vesely, George et al. 2003). 
Thrombotic thrombocytopenic purpura is a rare disease with an incident rate of 
0.3 to 1 per 100,000 yearly in the USA  (Torok, Holman et al. 1995). Before the 
introduction of plasma exchange, 90% of TTP patients perished. However, plasma 
exchange has reduced mortality to between 8 to 15%, making it a curable disease 
(George 2000). The clinical presentation of TTP and HUS are at times, very similar. 
Some patients who develop TTP due to the deficiency of ADAMTS13 can develop organ 
dysfunction, including a lack of renal function (Vesely, George et al. 2003). 
Alternatively, HUS can also occur in adult patients and involve neurological symptoms. 
The similarity in symptoms makes diagnosis difficult, where occasionally HUS can be 
misdiagnosed as TTP and vice versa. 
 
1.1.5 Animal reservoirs for STEC 
 
1.1.5.1 Cattle 
Ruminants are considered to be the most important source of STEC human 
infections, due to their asymptomatically shedding of organism. Dairy cattle, as well as 
pastured and feedlot beef cattle, have been reported to shed STEC serotypes. Age plays 
an important factor where peak shedding is observed in post-weaning animals (Cray and 
Moon 1995). STEC O157 was isolated from less than 1.5% of calves under the age of 2 
months, while in calves aged 4 months to 2 years, isolation ranged from 1.8% to 5% 
(Zhao, Doyle et al. 1995; Faith, Shere et al. 1996; Meyer-Broseta, Bastian et al. 2001). 
This demonstrates that STEC O157 is isolated 3 times more frequently from post-weaned 
animals than pre-weaned animals. After the age of two, shedding of STEC O157 appears 
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to decrease as cattle get older (Hancock, Besser et al. 1998). However, in Japan a higher 
level of shedding was seen in a study using polymerase chain reaction (PCR) to amplify 
stx genes of STEC serotypes from fecal samples of 204 calves and 306 adult cattle. A 
prevalence of 39% in calves under the age of 2 months, 79% in calves aged 2 to 8 months 
and 41% in cattle aged 1 year and older was reported (Shinagawa, Kanehira et al. 2000).  
 An increased prevalence of STEC is also seen during the summer and early 
autumn months (Bonardi, Maggi et al. 1999; Tutenel, Pierard et al. 2002). Summer 
temperatures provide a more suitable environment for the survival of STEC outside the 
host, which results in a source of infection and re-infection (Edrington, Callaway et al. 
2006). A study described the collection of fecal samples monthly from 400 cattle, 
reported 4.8-36.8% shedding of STEC O157 where the highest level was found during 
late summer (Chapman, Siddons et al. 1997). Recently, a study was completed to 
determine if day length correlated with fecal shedding, as days are longer during summer 
months (Edrington, Callaway et al. 2006). After a period of 60 days, a significant 
difference in shedding was observed in the lighted pens compared to control groups with 
no light-treatment. Once the light-treatment was removed from the test group, shedding 
decreased to levels equivalent to the control group. 
 Various studies on the worldwide prevalence of STEC in cattle have been carried 
out. The majority of studies have focused on the shedding of STEC O157 because of its 
importance in human infections and outbreaks. The prevalence of  STEC O157 ranged 
from 0% to as high as 85%, where concentrations varied from 4 to 10
7
 colony forming 
units (CFU)/g, but 10 to 100 CFU/g is the average (Gyles 2007). In Japan, the duration 
and magnitude of serotype STEC O157 and O26 shedding was recently investigated in 
naturally infected cattle (Widiasih, Ido et al. 2004). The duration ranged between 10 
weeks for O157 and 3 weeks for O26, where shedding varied from 10
4
 CFU/mL for 
STEC O157 to 10
2
 CFU/mL for STEC O26. Shiga toxin-producing E. coli O157 shedding 
in cattle has been described in many countries such as Argentina, USA, Brazil, Australia, 
Japan, Korea, China, and numerous European countries where diarrhea outbreaks are 
commonly described (Cobbold and Desmarchelier 2000; Fairbrother and Nadeau 2006). 
On the other hand, STEC O157 shedding was not reported in India or Thailand, where 
STEC is uncommon. 
 12 
 Non-O157 STEC serotypes are also regularly isolated from cattle. The prevalence 
of these organisms varies from 10% to 20%, but may reach as high as 80% to 90% 
(Fairbrother and Nadeau 2006). However, variability in detection is commonly due to the 
sampling techniques and sensitivity. The prevalence measurement of these strains is 
difficult since identification is based of the presence of stx genes. Numerous countries, 
including China, Uganda, Argentina, Scotland, Germany, Canada, and the USA, have 
reported shedding of non-O157 serotypes such as O26, O103, O111 and O145 (Kaddu-
Mulindw, Aisu et al. 2001; Leung, Yam et al. 2001; Bettelheim 2003; Pearce, Evans et al. 
2006). A recent survey in Scotland, which described the prevalence of non-O157 STEC 
serotypes in 6,086 fecal samples from 338 farms, identified shedding of STEC O26 in 
23%, STEC O103 in 22% and STEC O145 in 10% of samples using immunomagnetic 
separation and slide agglutination (Pearce, Evans et al. 2006). 
 
1.1.5.2 Other ruminant species 
Ruminants other than cattle can play a significant role as STEC reservoirs.  Sheep 
have been identified as an important reservoir, although prevalence of STEC is lower 
than in cattle. A study in the USA identified  a transient STEC O157 prevalence of 31% 
in sheep (Kudva, Hatfield et al. 1996). Separate studies in European countries reported 
the prevalence of STEC O157 in sheep and lambs to range between 2.2% and 8.7% 
(Heuvelink, van den Biggelaar et al. 1998; Chapman 2000; Oporto, Esteban et al. 2008). 
Non-O157 serotypes are also important, as over 100 different STEC serotypes have been 
isolated from sheep (Urdahl, Beutin et al. 2003). Results from molecular amplification 
reported that 50% to 87% of sheep farms were positive for non-O157 STEC serotypes 
(Urdahl, Beutin et al. 2003; Oporto, Esteban et al. 2008). Shiga toxin-producing E. coli 
O157 has also been isolated from sheep meat and milk products (Chapman, Siddons et al. 
1997). 
 A recent study demonstrated that goats can carry and spread STEC. A number of 
serotypes were isolated from 39% of individual goats tested, and found that all farms 
sampled tested positive for STEC (Vu-Khac and Cornick 2008). Shiga toxin-producing 
E. coli has also been frequently isolated from unpasteurized goat milk and cheese 
(Bielaszewska, Janda et al. 1997; Stephan, Schumacher et al. 2008). Buffalo are also 
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believed to be a important source of STEC infections in developing countries, where 
STEC O157 is commonly isolated from herds (Caprioli, Morabito et al. 2005). A study 
found that 27% of individual buffalo and 70% of farms sampled were positive (Vu-Khac 
and Cornick 2008). In Asian countries such as Vietnam, buffalo are raised by farmers for 
field ploughing, transportation of farm products and food production. Such practices 
increase the chances of human infection due to the close proximity between humans and 
animals. 
 Wild ruminants such as deer have also been suggested to play an important role as 
reservoirs for infection of domestic ruminants, since they frequently share the same 
pasture. Several groups have isolated STEC serotypes from deer populations. A USA 
study reported that 2.4% of white-tailed deer tested positive for STEC O157,  while in 
Japan 1% of deer populations were positive (Asakura, Makino et al. 1998; Sargeant, 
Hafer et al. 1999). Several reports have also identified deer products such as meat and 
beef jerky as culprits in human infection (Keene, Sazie et al. 1997; Rabatsky-Ehr, 
Dingman et al. 2002). Although the prevalence of STEC in deer is low, their ability to 
roam pastures and farm land contributes to the spread of this organism, where wild deer 
were responsible for an outbreak from unpasteurized apple cider (Besser, Lett et al. 
1993). 
 
1.1.5.3 Other non-ruminant animals 
Although the prevalence of STEC among non-ruminants is minimal, several 
species present a risk to humans. Pigs are described as an STEC reservoir, where the 
prevalence of STEC O157 associated with slaughtered pigs was found to range between 
0% to 2% in USA and European countries (Johnsen, Wasteson et al. 2001; Bonardi, 
Brindani et al. 2003; Feder, Wallace et al. 2003; Oporto, Esteban et al. 2008). However, 
studies found an elevated STEC occurrence in Japan (14%) and South America (69%) 
(Rios, Prado et al. 1999; Kijima-Tanaka, Ishihara et al. 2005). These differences could be 
attributed to accidental exposure through contamination of manure and feed, or to poor 
husbandry and slaughter practices. Many of the isolated strains of STEC O157 are 
believed to be specific to pigs and associated with edema disease (Gannon, Gyles et al. 
1988). It has also been suggested that rabbits may play a role as a STEC reservoir. At this 
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time only one outbreak has been reported as a result of rabbits (Pritchard, Williamson et 
al. 2001). Several studies investigated the prevalence of STEC in rabbits and found all 
samples to be negative (Rodriguez-Calleja, Garcia-Lopez et al. 2006; Assies, Eggenkamp 
et al. 2007). 
House flies, which can carry and spread infectious organisms over vast areas, 
have been found to carry STEC (Sasaki, Kobayashi et al. 2000). These insects were 
believed to be responsible for an outbreak in a nursery school in a rural area of Japan in 
September 1996 (Kobayashi, Sasaki et al. 1999). Using electron microscopy, it was 
demonstrated that STEC O157 adhered to the surface of the house fly mouth and was 
able to proliferate. Shiga toxin-producing E. coli has also been recovered from several 
bird species. For example, strains were isolated from gull droppings collected from 
harbors in Japan and molecular analysis showed that the amino acid sequence of the 
avian Stx was closely associated with human-origin rather than animal-origin STEC 
(Makino, Kobori et al. 2000). Shiga toxin-producing E. coli strains which produce a 
variant of the Stx have also been regularly isolated from pigeons (Dell'Omo, Morabito et 
al. 1998). Neither birds nor house flies are thought to be true STEC reservoirs; instead 
they are considered potential vectors which can spread the organism by travelling through 
contaminated areas. Companion animals such as dogs, cats and even horses have been 
found to carry STEC O157 (Dell'Omo, Morabito et al. 1998). This could be a result of 
direct contact with farm animals or humans. 
 
1.1.6 Modes of transmission 
 
1.1.6.1 Environmental exposure 
Environmental factors play a role in the exposure of animals and humans to STEC 
serotypes (summarized in Figure 1.2). Run-off water from dairy farms and pastures due 
to heavy rainfall can contaminate surface water such as ponds, rivers, lakes, springs and 
water supplying wells, commonly used for outdoor activities 
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Figure 1.2 Sources of infection and spread of STEC in a farm environment. (1) Shiga 
toxin-producing E. coli is ingested by cattle or other ruminants. (2) The organism is then 
shed asymptomatically in fecal matter. (3) Run-off water from infected dairy farms and 
pastures, due to heavy rainfall can contaminate surface water such as ponds, rivers, lakes, 
springs and water supplying wells. (4) Water troughs can be easily contaminated by 
infected cattle, deer, birds and insects including flies. (5) Contamination of crop fields 
used for animal feed can occur through the spread of manure as fertilizer, fecal matter left 
by birds or wild ruminants, or from contaminated water run-off. (6) Fecal matter can also 
contaminate pastures, water troughs, animal pens and other animal species present in a 
farm environment, which in turn infect other cattle through their fecal remains. (7)  
Infection with STEC can also take place through direct contact between cattle. Diagram 
was adapted from (Fairbrother and Nadeau 2006). 
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 (McGowan, Wickersham et al. 1989; McCarthy, Barrett et al. 2001; Neely, Bell et al. 
2004). The dumping or spreading of sewage or wastewater from human origin can also 
play a role, since the persistence of STEC in soil, plants and plant roots allows the 
infection of cattle, and makes environmental exposure a hazard for human infections 
(Gagliardi and Karns 2002; Vernozy-Rozand, Montet et al. 2002). The practice of 
applying manure and slurry for fertilizer to crop land, and grazing is another source of 
contamination and re-introduction of STEC into cattle and other animals (Jiang, Morgan 
et al. 2002).  The application of manure followed by heavy periods of rainfall, allow the 
bacteria to leach into lower layers of the soil, which can then drain into rivers or other 
bodies of water (Gagliardi and Karns 2000). Contamination of crop fields used for animal 
feed such as soybean meal, grass hay, silage grasses and grain pellets can also occur 
through the spread of manure as fertilizer, fecal matter left by birds or wild ruminants, or 
from contaminated water run-off (Fairbrother and Nadeau 2006). An STEC prevalence of 
14.9% was found in  animal feed collected and tested from 54 feedlots in the USA (Dodd, 
Sanderson et al. 2003). Feed can also become contaminated during transportation to the 
mill where a strain found at a mill was believed to have been cross-contaminated from a 
farm sampled more than 5 km away (Davis, Hancock et al. 2003). Silage, which is often 
fed to cattle and sheep, can play a role in the spread of STEC if the contaminated grass 
and poor silage management are combined (Fenlon and Wilson 2000).   
Another important source of contamination is the water quality found in drinking 
troughs. This water can be easily contaminated through fecal matter or saliva from 
infected cattle, deer, birds and insects such as flies (Fairbrother and Nadeau 2006). Water 
troughs play a key factor in the spread of STEC, since the organism can survive and even 
thrive in fecal sediment found in troughs (LeJeune, Besser et al. 2001). Water 
contamination may also result from the original source, if water is not treated.  
However, the main exposure to cattle, including pastures, pen floors, and water 
troughs, is the cattle themselves (Shere, Bartlett et al. 1998). Animal pens, where cattle 
are raised, play a significant role in the transmission of STEC. Cattle kept in pens were 
shown to shed STEC for a period of 4 months, while animals from the same farm which 
were kept on pasture, did not shed for the period tested (Jonsson, Aspan et al. 2001). This 
variation in shedding is a result of the exposure to the bacteria, where poor husbandry can 
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affect the persistence of STEC. Animals which are kept in feedlot pens, where the floor is 
muddy or urine and fecal matter is allowed to accumulate, demonstrated higher 
prevalence of shedding than animals raised in normal pens (Smith, Blackford et al. 2001). 
Interestingly, the way in which an alleyway is cleaned can also have an effect on 
shedding. Farm alleyways cleaned by water jets were 8 times more likely to test positive 
for STEC O157 than alleyways which were scraped (Garber, Wells et al. 1999).   
 
1.1.6.2 Food and water 
The most common method by which humans are infected with STEC is through 
the consumption of contaminated foods (Figure 1.3) (Rangel, Sparling et al. 2005). The 
most frequent sources are ground beef products such as uncooked hamburgers (Chinen, 
Tanaro et al. 2001). One of the largest STEC O157 outbreaks in North America occurred 
between December 1992 and January 1993, resulting in 732 cases throughout multiple 
states, where 195 patients were hospitalized and 4 died (Bell, Goldoft et al. 1994). This 
outbreak was traced to undercooked hamburgers served in a fast-food restaurant. 
 Other animal products such as cheese, butter, milk and other milk products have 
also been the cause of infection (Figure 1.3) (Gomez, Miliwebsky et al. 2002; Karns, Van 
Kessel et al. 2007). In addition, since the early 1990s, produce such as lettuce, spinach, 
salad, apple cider, sprouts, and coleslaw have become an important source of outbreaks 
(Itoh, Sugita-Konishi et al. 1998; Soderstrom, Lindberg et al. 2005). These products 
become contaminated by irrigation with contaminated water, or contact with manure or 
slurry of infected animals. Between 1995-2006, a total of 22 STEC O157 produce 
outbreaks were documented in the USA and the majority were traced back to lettuce and 
spinach (Cooley, Carychao et al. 2007). The most recent STEC outbreak was reported in 
September 2006 involving fresh baby spinach. This outbreak affected Canada and 26 
USA states resulting in 205 cases and 3 deaths, and was attributed to cattle that tested 
positive for the same strain, a mile away from the spinach ranch (Jay, Cooley et al. 2007). 
Outbreaks related to water sources tend to be of greater scale, as observed in 2000 
in Walkerton, Ontario, when STEC O157 and Campylobacter jejuni contaminated the 
drinking water supply (Holme 2003). As a result, 2,100 individuals became ill and there  
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Figure 1.3 Human exposures to STEC. (1) Shiga toxin-producing E. coli is ingested by 
cattle or other ruminants. (2) The organism is then shed asymptomatically in fecal matter 
and contaminates surface water commonly used for drinking and summer outdoor 
activities such as swimming. (3) Vegetable products and fruit used for juice can become 
contaminated by irrigation with contaminated water or contact with slurry and manure of 
infected animals. Other animal products such as cheese, butter, and milk as well as 
ground beef contaminated at slaughter through infected carcasses, have also been a 
source of infection. (4) Individuals working at a farm and in slaughterhouses, petting 
zoos, and farm visits can lead to human infections through direct contact with animals or 
fecal matter. (5) Person to person distribution via the fecal-oral route is also an important 
source of transmission. Diagram was adapted from  (Fairbrother and Nadeau 2006). 
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were 7 fatalities. Another large outbreak occurred in a small city in rural Missouri where 
the main water supply was not treated with chorine. This outbreak led to 243 cases where 
32 patients were hospitalized resulting in 4 deaths (Swerdlow, Woodruff et al. 1992). 
Water supply outbreaks often occur after soiled surface water contaminates well water 
after heavy rainfall. These outbreaks tend to be of larger scale due to the accessibility of 
the contaminated water, and the incubation period of STEC O157 which can take up to 8 
days.  
 
1.1.6.3 Direct contact 
Person-to-person spread via the fecal-oral route is an important source of 
transmission, especially in day care centres, schools, and swimming pools, individual 
homes and communities where children are in close proximity (Vogelsang and Pulz 
1999). Poorly chlorinated water also plays a role in STEC infections where several 
outbreaks have been reported from swimming and paddling pools used for toddlers 
(Brewster, Brown et al. 1994; Hildebrand, Maguire et al. 1996; Friedman, Roels et al. 
1999). Common practices such as “shocking” a pool, which involves dumping large 
quantities of chlorine into a pool, helps with algae control and keeping the water clear, 
but it does not fully inhibit bacterial growth (Friedman, Roels et al. 1999). Experimental 
work has shown that STEC O157 can survive in water for as long as 10 weeks in varying 
temperatures of 8ºC to 25 ºC (Wang and Doyle 1998).  
Recently, petting zoos have been identified as an important source of transmission 
of STEC O157 to humans. Over the last few years the popularity of open farms and 
petting zoos has grown, where visitors including children can easily access various 
animals such as sheep, calves, rabbits, pigs, kittens and lambs. Practices such as feeding 
and handling these animals have lead to an increase in human infections.  Between 2004 
and 2005, three separate outbreaks of STEC occurred in an agricultural fair in North 
Carolina, a festival in Florida and a petting zoo in Arizona (DebRoy and Roberts 2006). 
A total of 173 cases were reported, including 22 cases of HUS. The outbreak in Florida 
was linked to goats, sheep and cows present at the petting zoo. Regular zoos have also 
begun to introduce interactive animal handling areas. These areas have led to human 
infections where two children were hospitalized following infection with STEC O157. 
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After officials sampled the area, they found that 15 of the 25 fecal samples collected 
contained STEC O157 (Stirling, Griffith et al. 2008). As a result, the interactive animal 
area was shut down. 
 Daycare centers are another source for STEC spreading. These centers are a prime 
location for direct contact between children from different locations. An outbreak in a 
Dublin Ireland daycare centre affected 10 out of 45 children and one staff member 
(O'Donnell, Thornton et al. 2002), while in Wales, a nursery reported 31 in 104 children 
became infected, resulting in 2 cases of HUS (Al-Jader, Salmon et al. 1999). The risk that 
these children will take the infection home or to school is quite high and can facilitate 
spread between children.  
 
1.2 STEC virulence factors 
Shiga toxin-producing E. coli contain a number of virulence factors that facilitate 
the colonization of a host. These factors include toxins, fimbrial adhesins, nonfimbrial 
adhesins, proteases and several elements found on the bacterial plasmids or chromosome 
(on Table 1.1).  
 
1.2.1 Shiga Toxins 
In 1977, it was reported that culture filtrates from several E. coli strains produced 
a cytotoxic effect on Vero cells that could be neutralised by antiserum to Stx from S. 
dysenteriae (Konowalchuk, Speirs et al. 1977; O'Brien, LaVeck et al. 1982). This 
observation led to the discovery that a pathogenic strain of E. coli O157:H7 produced 
Shiga-like toxins (O'Brien, Lively et al. 1983). Enteric pathogens such as S. dysenteriae 
and STEC, which harbour Stxs, play a significant role in disease and are responsible for 
extensive global morbidity and mortality (Kaper 1998; Paton and Paton 1998). For 
STEC, Stx is the main virulence factor involved in the development of HUS (Karmali, 
Steele et al. 1983; Karmali, Petric et al. 2004). The bloody diarrhea observed with STEC 
infection is attributed to the action of Stx on endothelial cells, thrombotic 
microangiopathy, and lesions formed on small blood vessels in the gut (Ray and Liu 
2001).  
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Table 1.1 List of known virulence factors from Shiga toxin-producing E. coli 
(STEC). Table was adapted and modified from  (Gyles 2007). 
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Shiga toxins belong to the family of AB5 protein toxins. These toxins contain an 
enzymatically active A subunit, and 5 B subunits responsible for binding to the cell 
surface. Shiga toxins are made up of a single 32 kDa subunit A, which  
is non-covalently bound to five 7.7 kDa B subunits which form a pentamer responsible 
for binding to a cellular receptor (O'Brien, Tesh et al. 1992). The A subunit consists of  
two minor subunits (A1 & A2) held together by a disulfide bond that is proteolytically 
cleaved by enzymes found in the endoplasmic reticulum (ER) and in the cytosol (Garred, 
van Deurs et al. 1995).   
Shiga toxin-producing E. coli produces two Stxs originally identified as Stx1 and 
Stx2 (Strockbine, Marques et al. 1986). The genes encoding for the production of Stxs 
are found on toxin-converting lamboid prophages (O'Brien, Newland et al. 1984; 
Newland, Strockbine et al. 1985). The Stx1 protein is highly conserved and has a 
homology of over 98% to the Stx produced by S. dysenteriae type 1 (Takao, Tanabe et al. 
1988; O'Loughlin and Robins-Browne 2001). The only apparent difference is a single 
amino acid located on the A subunit. A subtype of Stx1, called Stx1c, has been identified 
and is only isolated from eae-negative strains (Zhang, Bielaszewska et al. 2002). This 
subtype is found mainly in sheep STEC strains that cause mild or no disease (Brett, 
Ramachandran et al. 2003). The homology of Stx2 to Stx1 is less than 60%, due to the 
large variation in the amino acid sequence of the B subunit. In contrast to Stx1, several 
subtypes of Stx2 have been identified, consisting of Stx2c, Stx2d, Stx2dact , Stx2e and 
Stx2f (Gyles 2007). Of 626 STEC isolates tested, Stx2d and Stx2e were located in eae-
negative STEC strains, while subtype Stx2c was found in 5% of disease causing strains. 
Alternatively, none of the 626 STEC isolates contained Stx2f (Friedrich, Bielaszewska et 
al. 2002; Gyles 2007).  
Shiga toxin receptors include globotriasoyl ceramide (Gb3), globotetraosyl 
ceramide (Gb4) and PI (a blood group glycolipid antigen) which is present in red blood 
cells (Jacewicz, Clausen et al. 1986; Lindberg, Brown et al. 1987; Lingwood, Law et al. 
1987). The toxins bind to their glycolipid receptors in clathrin-coated pits and the Stx1–
Gb3 complex is internalized by receptor-mediated endocytosis (Sandvig, Olsnes et al. 
1989).  This process involves the pinching of a fragment of the cell membrane, which 
produces a toxin-surrounding vesicle that fuses with lysosomal vesicles leading to the 
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destruction of the toxin. However, in cells which are susceptible to internalization, the 
toxin proceeds via the endosomal system and the trans-Golgi network, in a process that 
by-passes late endosomes (Mallard, Tang et al. 2002).  
To inactivate ribosomes, the enzymatic A subunit of Stx must traverse the 
endoplasmic reticulum (ER) membrane. The A1 subunit is responsible for inhibiting 
protein synthesis in the cytosol by removing a specific adenine base from the 28S  
Ribonucleic acid (RNA) of the 60S ribosomal subunit (Sandvig 2001). This inhibition of 
protein synthesis can lead to apoptosis due to signalling by Stx or by the ribocytotoxic 
stress response (Cherla, Lee et al. 2003; Smith, Kane et al. 2003). In addition to its effect 
on eukaryotic cells, Stx has a similar effect on bacterial ribosomes resulting in decreased 
proliferation of susceptible bacteria such as E. coli (Suh, Hovde et al. 1998). This 
suggests that Stx may facilitate bacterial survival by inhibiting the growth of potential 
competitors in the lumen of the gastrointestinal tract. 
Both the expression of Stx and the quantity of Gb3 receptor play an important role 
in disease. The increase of Gb3 receptor using sodium butyrate, which is found in the 
peripheral circulation and the colon, can increase the susceptibility of cells to Stx 
(Louise, Kaye et al. 1995). This treatment can also increase trafficking of the toxin to the 
nuclear envelope and the ER (Sandvig, Garred et al. 1992). Sodium butyrate increases the 
fatty acid chains of Gb3, which are important for intracellular translocation of Stx 
(Sandvig, Garred et al. 1996). Elements of the host inflammatory response to Stx, such as 
IL-1β and TNF-α can also increase in the synthesis of Gb3 (Louise, Kaye et al. 1995). 
Although both Stxs share a significant homology, Stx2-producing strains are more 
likely to cause HUS than Stx1-producing strains (Kleanthous, Smith et al. 1990). One of 
the reasons for this is that Stx2 is 1000 times more toxic than Stx1 (Louise and Obrig 
1995). In a mouse model, Stx2, when injected intravenously or intraperitoneally, required 
a LD50 that was approximately 400 times lower than that of Stx1 (Tesh, Burris et al. 
1993). These observations were also confirmed when Stx2 was given intravenously to 
primates, were they developed progressive thrombocytopenia, hemolytic anemia and 
showed an increase in urinary IL-6 levels (Siegler, Obrig et al. 2003). On the other hand, 
animals injected with Stx1 showed no cytokine response, and no laboratory or clinical 
disease. 
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 Once the crystal structures were established, four major differences were 
identified between the Stx2 and the Stx1 structure (Fraser, Fujinaga et al. 2004). First, a 
greater accessibility of the active site of the A subunit was found in Stx2 when compared 
to Stx1, which is blocked by part of the polypeptide chain of A2. Secondly, a difference 
in the carboxy terminus of the A1 peptide of Stx2 allows for binding at a receptor-
binding site, while it remains unoccupied in the Stx1 structure. Thirdly, 1 of the 3 
carbohydrate binding sites is different for Stx2 than for Stx1, and this conformational 
variability may lead to different binding affinities for the Gb3 receptor. Last, a variation 
between the two toxins is found in the carboxy terminus of the A subunit of Stx2, which 
forms a short 2-turn α-helix after passing through the pore of the B-pentamer, in contrast 
to the tail of the A subunit of Stx.  This variability could result in different mechanisms of 
action that lead to the development of HUS.  
  
1.2.2 Haemolysin 
Haemolysin is a member of the pore-forming RTX family of toxins, produced by 
Gram-negative human or animal pathogens (Welch, Bauer et al. 1995). These toxins can 
be broad-range, lysing erythrocytes and nucleated cells from various species, or narrow-
range, lysing only leukocytes in a species-specific manner. The gene encoding the 
hemolysin found in STEC O157 is present on a large 90 kbp plasmid, pO157, and 
consists of 4 open reading frames (ORFs) called the EHEC-hlyCADB operon, with a 60% 
homology to the E. coli α-hemolysin (Schmidt, Kernbach et al. 1996). A study reported 
that 92% of eae-positive strains harbored the hemolysin toxin while only 35% of eae-
negative strains carried it (Eklund, Scheutz et al. 2001). It has been reported that all 
STEC O157 and 50% of STEC non-O157 strains tested where positive using PCR 
analysis for the hlyB gene (Schmidt, Beutin et al. 1995). This study also demonstrated 
that 19 out of 20 sera tested from HUS patients reacted with hemolysin, which confirms 
its production during the colonization of a host. 
Hemolysin contributes to the pathogenesis of STEC by lysing hemoglobin which, 
in turn, releases iron. This iron is then taken up by STEC and used for bacterial growth. 
The α-hemolysin produced by E. coli is cytotoxic to leukocytes and fibroblasts, and it is 
thought that cytotoxicity and growth stimulation is its main role in E. coli virulence 
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(Cavalieri, Bohach et al. 1984). Initial characterization of the STEC hemolysin 
demonstrated its ability to lyse bovine and sheep erythrocytes as well as human RBCs 
(Bauer and Welch 1996). The STEC hemolysin is also understood to play a role in 
inflammation by inducing the production of interleukin-1β, which is believed to be one of 
the serum markers of HUS (Taneike, Zhang et al. 2002). 
 
1.2.3 Other toxins 
 Shiga toxin-producing E. coli can express other enterotoxins which influence 
pathogenesis. Recently, a cdt gene cluster called cdt-V, responsible for a cytolethal 
distending toxin (CDT), was identified in STEC (Janka, Bielaszewska et al. 2003). The 
CDT belongs to a family of heat-labile toxins that interferes with the mammalian cell 
cycle, causes progressive cellular distension, arrest and eventual cell death (Cortes-Bratti, 
Karlsson et al. 2001). These genes are located on the chromosome with flanking regions 
homologous to lambda and P2 prophages, insinuating acquisition through phage 
transduction (Janka, Bielaszewska et al. 2003). The CDT gene cluster is made up of three 
genes called cdtA, cdtB and cdtC.  The toxin is considered tripartite where the CdtB 
protein is the active A subunit of an AB2 toxin, while the CdtA and CdtC make up the B 
subunit, which is required for the delivery of CdtB into the target endothelial cell (Lara-
Tejero and Galan 2002). 
The CDT is commonly found in sorbitol-fermenting O157 STEC strains. 
However, some non-fermenting STEC strains also possess this gene cluster. Of sorbitol-
fermenting O157 STEC strains tested, 86.9% carried the cluster, while only 6% of non-
sorbitol-fermenting O157 STEC strains harbored the gene cluster (Janka, Bielaszewska et 
al. 2003). STEC O157-purified CDT, when tested with human endothelial cells, resulted 
in irreversible damage. Using various endothelial cell lines, CDT toxin caused G2/M cell 
cycle arrest, which led to inhibition of proliferation, cellular distension and cell death 
(Bielaszewska, Sinha et al. 2005). However, in a human microvascular endothelial cell 
line, this toxin caused caspase-dependent apoptosis resulting from blockage of G2/M 
cycle. Interestingly, CDT is also capable of causing DNA damage via expression of the 
phosphorylated histone protein. Endothelial cells are found in lymphatic and blood 
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vessels and it has therefore been suggested that CDT plays a role in the systemic 
pathogenesis in combination with Stx or another toxin (Smith and Bayles 2006).  
The enterotoxin EAST1 is also found in a large number of STEC strains. The 
EAST1 toxin initiates diarrhea by activating the cyclic GMP pathway that phosphorylates 
the chloride channels on the apical membranes of IECs (Uzzau and Fasano 2000). This 
phosphorylation stimulates chloride secretion, and the inhibition of sodium chloride 
absorption by the villus tip cells. This event leads to an increase in luminal ion content 
causing water to pull through the paracellular pathway, resulting in osmotic diarrhea 
(Nataro and Kaper 1998). Genetic analysis identified the astA gene encoding the EAST1 
enterotoxin on all STEC O157 strains tested (Savarino, McVeigh et al. 1996).  These 
results were also confirmed when two separate studies showed that 88% of 27 STEC 
(O111, O26 and O157) strains tested, and 100% of 67 (O157, O26, O111 and O145) 
strains, contained the astA gene (Paiva de Sousa and Dubreuil 2001). However, the 
sequence of EAST1 toxin in STEC strains differs from the hallmark sequence of the 
Enteroaggregative E. coli (EAEC) EAST1 toxin found on the EAEC strain O42, by 
possessing several mutations throughout the gene (Yamamoto, Wakisaka et al. 1997; 
Yamamoto and Taneike 2000).  
A new subtilase cytotoxin has been recently identified in the STEC O113 serotype 
responsible for HUS outbreaks. This toxin is a member of a new family of AB toxins, 
where the A subunit has subtilase-like serine protease properties, and a homology to 
Bacillus anthracis (Paton, Srimanote et al. 2004).  The injection of this toxin into mice 
caused extensive thrombosis, kidney, brain and liver damage resulting in death. 
 
1.2.4 Fimbrial adhesins 
The genome of STEC O157 possesses at least 16 fimbrial gene clusters (Low, 
Holden et al. 2006). However, under in vitro conditions, many of these genes are not 
functionally expressed. Of the small number of STEC clusters that are expressed, they 
produce multiple fimbrial adhesins believed to influence adherence and microcolony 
formation. Two adhesins closely related to the long polar fimbria operon (lpf) of 
Salmonella enterica subspecies enterica serovar Typhimurium (S. Typhimurium), are 
lpf1 and lpf2 (Torres, Giron et al. 2002; Torres, Kanack et al. 2004).  The lpf1 operon 
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expresses long polar fimbriae, where an E. coli O157:H7 lpf mutant demonstrated a 
reduction in adherence and microcolony formation. The lpf2 operon expresses thin 
fibrillae-like structures, and an isogenic mutant demonstrated a significant reduction in 
early stages of STEC adhesion. Both of these long polar fimbriae are located on the OI-
141 and OI-154 chomosomal region of STEC O157, where at least four different variants 
of the lpf gene exist throughout STEC serotypes (Toma, Martinez Espinosa et al. 2004; 
Toma, Higa et al. 2006). It was recently described that fimbriae-encoding genomic 
islands such as OI-1, OI-47, OI-141 and OI-154 are distributed almost entirely in 
serotypes O157:H7 and O157:NM, which correlates with their ability to cause serious 
disease more frequently than other serotypes (Shen, Mascarenhas et al. 2005). Several 
other long polar fimbriae genes with homology to sfaA and stcA of S. Typhimurium have 
been identified, however further studies are required to fully understand their role in 
colonization (Spears, Roe et al. 2006). 
Several pili have been identified in STEC serotypes, and are thought to play a role 
in the colonization of a host. A number of STEC O157 strains encode the pilus-forming 
sfp gene cluster found in sorbitol-fermenting strains (Friedrich, Nierhoff et al. 2004). This 
cluster is not found in non-sorbitol-fermenting STEC strains, or in E. coli O55:H7, an 
ancestor of STEC O157. Recently, a hemorrhagic E. coli pilus (type IV pilus) encoded by 
the chromosomal hcpA gene was discovered in STEC O157. This pilus bridges the 
bacterial cell to the host cells, and an hcpA mutant exhibited reduced adherence in human 
and bovine epithelial cells (Xicohtencatl-Cortes, Monteiro-Neto et al. 2007). Sera from 
HUS patients were also shown to react with the HcpA protein, confirming its expression 
during colonization. An additional pilus called the E. coli common pilus expressed from 
the yagZ gene, was identified in all E. coli genomes sequenced to date (Rendon, Saldana 
et al. 2007). This pilus is thought to bridge the bacterium and the epithelial cell, and a 
significant reduction in adherence was reported with a yagZ mutant. 
 
1.2.5 Nonfimbrial adhesins 
Shiga toxin-producing E. coli possess a number of nonfimbrial adhesins involved 
in pathogenesis. The outer membrane protein A (OmpA), which has been extensively 
studied in other E. coli strains and revealed to have adhesive properties, was shown to be 
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involved in the adherence of STEC O157 to HeLa and Caco-2 human cells (Torres and 
Kaper 2003). However, the host receptor to which this porin binds is unclear. The STEC 
protein called the factor for adherence (Efa1) is also important in adherence (Nicholls, 
Grant et al. 2000). An efa1 STEC O111 mutant showed a reduction in cell 
autoaggregation, cell adherence and human RBC agglutination. These results were 
confirmed when STEC O111 and O5 efa1 mutant were tested in calves, and demonstrated 
reduced shedding and a dramatic reduction in association with the intestinal epithelium 
(Stevens, van Diemen et al. 2002). Interestingly, these mutants also had reduced 
expression of the locus of enterocyte effacement (LEE) genes. A plasmid encoded gene 
called toxB, with similarities to toxins A and B found in Clostridium difficile, was found 
in a large number of STEC serotypes. The ToxB protein is believed to be involved in the 
adherence of STEC to epithelial cells by promoting the production of T3SPs (Tatsuno, 
Horie et al. 2001). In addition, with 47% homology to the efa1 gene, toxB is believed to 
be a plasmid-encoded efa1 homologue (Toma, Martinez Espinosa et al. 2004).  
Several less-known adhesins are found throughout STEC strains. An auto-
agglutinating adhesin called Saa (STEC autoagglutinating adhesin) was reported in LEE-
negative strains responsible for HUS outbreaks (Paton, Srimanote et al. 2001). The 
transfer of saa on a plasmid to a non-pathogenic E. coli strain resulted in an increase in 
adherence nearly 10 fold that of the wildtype, while a STEC O103 saa mutant had a 
significant reduction in adherence. A study found that the saa gene was most commonly 
found in bovine and human STEC strains, suggesting a role in the colonization of cattle 
(Jenkins, Perry et al. 2003). The chromosomal iha gene found in a large population of 
STEC strains has also been reported to be involved in the adherence to epithelial cells 
(Tarr, Bilge et al. 2000; Toma, Martinez Espinosa et al. 2004). This gene is similar to the 
iron-regulated gene A (irgA) found in Vibrio cholerae. 
 
1.2.6 Secreted proteases 
A protease is an enzyme capable of cleaving a protein. Shiga toxin-producing E. 
coli possesses several plasmid-encoded proteases that facilitate the colonization of a host. 
An important serine protease found in STEC O157 and STEC O26 serotypes is the 
secreted EspP protein (Brunder, Schmidt et al. 1997).  This protein is a member of the 
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autotransporter protein family, where homology is observed within Neisseria, 
Haemophilus influenzae and EPEC proteases. The EspP protein is capable of cleaving 
pepsin A and the human coagulation factor V, which contributes to mucosal hemorrhage. 
Another important protease is the metalloprotease StcE, found on the plasmid pO157 
(Grys, Siegel et al. 2005). This protease cleaves the C1-esterase inhibitor that controls 
multiple inflammation pathways. Interestingly, the StcE protein is regulated by the LEE-
encoded Ler protein and is believed to contribute to adherence and the destruction of 
glycoproteins. 
 Another protease which has been extensively studied is NleA (also known as 
EspI). This protein, which is prophage-encoded, has serine protease activity against 
pepsin A and human apolipoprotein A-I (Schmidt, Zhang et al. 2001). NleA is also 
regulated by the LEE-encoded Ler protein, and is present in 86% of LEE-positive STEC 
strains (Mundy, Jenkins et al. 2004; Roe, Tysall et al. 2007). Once NleA is secreted 
through the T3SS, it is localized to the Golgi apparatus, where it compromises COPII-
dependent protein trafficking and secretion from the ER (Kim, Thanabalasuriar et al. 
2007; Lee, Kelly et al. 2008). 
 Two lesser-known proteases have been discovered in STEC strains.  A serine 
protease called EpeA, with both mucinase and protease activity, was found in the pO157 
plasmid in the majority of LEE-negative STEC strains tested (Leyton, Sloan et al. 2003). 
Another protease called KatP is present on the pO157 plasmid, and is transported through 
the cytoplasmic membrane where it appears to have catalase-peroxidase activity 
(Brunder, Schmidt et al. 1996). Catalases are considered part of a bacterial defense 
mechanism against oxidative stress (Farr and Kogoma 1991). 
 
1.2.7 Other 
 Shiga toxin-producing E. coli contains a number of other virulence elements 
which are important in host colonization. A gene cluster (etp genes) has been reported 
with homology to a Type II secretion pathway (Schmidt, Henkel et al. 1997). This cluster 
was identified in all STEC O157 serotypes, and in 60% of non-O157 serotypes tested. 
Several strains also carry the urease ureC gene found amongst eae-positive STEC isolates 
(Friedrich, Lukas et al. 2006). This gene is present amongst O111 and O145 serotypes, 
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but few strains actually express the gene. Urease expression by STEC serotypes may be 
involved in acid tolerance (Heimer, Welch et al. 2002). 
 The flagella produced by STEC can play an important role in pathogenesis. A 
study showed that H7 and H6 flagellin have adhesive properties that bind mucins I and II, 
and contribute to the colonization of cattle (Erdem, Avelino et al. 2007). These results 
were confirmed using a H7 fliC mutant with reduced capacity to adhere to a bovine 
terminal rectal epithelial cell line, but adherence was restored through complementation 
(Mahajan, Currie et al. 2008). However, complementation with the heterologous fliC 
from H6 was unable to restore H7 adherence properties. The ability of the wildtype to 
adhere was also reduced by the addition of H7-specific antibodies. The bacterial flagella 
can also play a role in the induction of inflammatory pathways, where the H7 from STEC 
O157 triggered intracellular signalling pathways and epithelial cell pro-inflammatory 
responses via TLR5 (Berin, Darfeuille-Michaud et al. 2002). This activation takes place 
by signalling the epithelial cell mitogen-activated protein (MAP) kinase and nuclear 
factor-kappa B (NF-κB) pathways, which results in Interleukin (IL)-8 secretion. 
 The lipopolysaccharide (LPS) produced by STEC, which is commonly released 
into the blood stream, plays a role in the establishment of HUS (Bitzan, Moebius et al. 
1991; Azim, Qadri et al. 1996). Bacterial LPS is a strong activator of immune and non-
immune cells, where the induction of signalling cascades, such as that via Toll-like 
receptor 4 (TLR4), result in the expression of chemokines such as IL-8 (Faure, Equils et 
al. 2000). Lipopolysaccharide and Stx, individually or in combination, cause THP-1 and 
human monocytes to release large amounts of IL-8 and other chemokines, such as IL-1β,  
tumor necrosis factor (TNF)-α, IL-8, GRO-β,  macrophage inflammatory protein (MIP)-
1α and MIP-1β, resulting in extensive platelet aggregation (Guessous, Marcinkiewicz et 
al. 2005). While exposure to Stx resulted in a 17 to 80 fold increase of chemokines, the 
addition of LPS combined with Stx, resulted in a 300 to 2000 fold increase. It is 
suggested that the development of HUS may in part be due to the combination of Stx and 
LPS, which causes the activation and release of chemokines by macrophages, resulting in 
tissue damage by leukocyte recruitment and activation.  
1.3 Type III Secretion System 
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1.3.1 Overview 
 In 1994, Rosqvist and colleagues proposed a model for the secretion of Yop 
proteins by Yersinia into a host target cell (Rosqvist, Magnusson et al. 1994). This study 
led to the discovery of the Type III Secretion System (T3SS). This system is unique in 
function and structure in that it crosses not only the bacterial outer and inner membranes, 
but also the host epithelial cell membrane. The T3SS is a bacterial syringe-like structure, 
permitting the secretion of effector proteins into a host cell and allowing a pathogen to 
manipulate host cell pathways and functions.   
A large number of Gram-negative pathogens possess T3SSs as a tool to colonize 
and infect a host. This system has been described in terms of colonization of a variety of 
hosts ranging from mammals to insects to plants (Troisfontaines and Cornelis 2005). The 
genes coding for the T3SS of many important enteric pathogens are located on either a 
plasmid or a pathogenicity island. The initial infection by Salmonella serovars is 
mediated by two T3SSs encoded by pathogenicity islands called Salmonella 
pathogenicity islands 1 and 2 (SPI-1) and (SPI-2). These systems mediate the secretion of 
effectors into the host cell cytoplasm which in turn manipulate host cell function and 
allow colonization, internalization and survival (Haraga, Ohlson et al. 2008). Other 
important enteric pathogens such as Shigella flexneri, uses a “trigger mechanism of 
entry” involving the formation of a macropinocytic pocket similar to S. typhimurium, 
where a plasmid-encoded T3SS secretes a number of effectors into IECs, which mediates 
invasion (Jensen, Harty et al. 1998). Although Yersinia spp, S. typhimurium and S. 
flexneri invade Microfold cells (M cells), Y. enterocolitica differs in the mechanism used 
to rearrange the actin cytoskeleton for bacterial uptake. While S. typhimurium and S. 
flexneri both use a T3SS to secrete effectors into host cells causing ruffling and 
engulfment (Grassl, Bohn et al. 2003), entry into M cells by Y. enterocolitica is 
dependent on adhesins to adhere to the host cell (Bliska, Copass et al. 1993; Clark, Hirst 
et al. 1998). This pathogen then uses its plasmid-encoded T3SS to mediate 
antiphagocytosis by secreting effectors into phagocytic cells (Cornelis, Boland et al. 
1998). 
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1.3.2 Locus of Enterocyte Effacement 
 
1.3.2.1 Shiga toxin-producing E. coli 
The ability of STEC serotypes to effectively colonize intestinal eukaryotic cells 
and form the hallmark attaching and effacing (A/E) lesions, is a result of a chromosomal 
genetic element called LEE. An A/E lesion is characterized by the localized destruction 
of the brush border microvilli, and the intimate attachment of the bacterium to the host 
cell apical membrane, resulting in the formation of a pedestal-like structure underneath 
the bacteria (Frankel, Phillips et al. 1998). This 43 kb pathogenicity island, contains the 
genes involved in the formation of a T3SS (McDaniel, Jarvis et al. 1995; Perna, Mayhew 
et al. 1998). The STEC O157 LEE Island is integrated on one end with a 7.5 kb cryptic 
P4 prophage, which together, is inserted within the selC tRNA locus (Wieler, McDaniel 
et al. 1997; Perna, Mayhew et al. 1998). The LEE island contains 41 ORFs organized in 
five polycistronic operons called LEE1 through LEE5 (Wieler, McDaniel et al. 1997). 
The operons LEE1, LEE2 and LEE3 contain 22 ORFs that encode proteins required for 
the basal Type III Secretion apparatus, spanning the inner and outer membranes (Elliott, 
Wainwright et al. 1998; Perna, Mayhew et al. 1998; Roe, Hoey et al. 2003). These 
operons also include EscN, the ATPase of the secretion system, and the outer membrane 
porin EscC. The LEE 4 operon encodes the needle escF gene, the Esp (E. coli secreted 
proteins) group of genes, including the monomer espA filament, espB, espD and espF 
(Ebel, Podzadel et al. 1998; Kresse, Rohde et al. 1999; Wachter, Beinke et al. 1999; Ide, 
Laarmann et al. 2001; Shaw, Daniell et al. 2001; Wilson, Shaw et al. 2001; Roe, Hoey et 
al. 2003). These genes (excluding espF) permit the configuration of a needle-like 
structure, known as a translocon, and a pore to be formed, which allows effector proteins 
to be secreted directly into the host cell. The last operon contains the ligand intimin, the 
translocated intimin receptor (Tir), and its chaperone CesT (Kenny, DeVinney et al. 
1997; Dean-Nystrom, Bosworth et al. 1998; Abe, de Grado et al. 1999; Elliott, Hutcheson 
et al. 1999; Cornick, Booher et al. 2002; Roe, Hoey et al. 2003). 
However, the LEE pathogenicity island has been found to be inserted in other 
locations, aside from the tRNA locus, for a number of non-O157 serotypes. The STEC 
O26 bovine strain 413/89-1 is located in the pheU tRNA gene, while the STEC O103 
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bovine strain RW1374 had the LEE Island inserted in the pheV tRNA gene (Jores, Rumer 
et al. 2004). While the core region of these non-O157 LEE islands is conserved, the 
flanking regions differ where a number of unknown genes are present. 
  
1.3.2.2 Enteropathogenic Escherichia coli and Citrobacter rodentium 
Enteric pathogens other than STEC also contain the LEE pathogenicity island. In 
fact, the LEE Island was originally identified and sequenced in enteropathogenic 
Escherichia coli (EPEC) (Elliott, Wainwright et al. 1998). This pathogen is the leading 
cause of watery diarrhea in infants in developing countries, where mortality ranges from 
10% to 40% (Levine 1987; Nataro and Kaper 1998; Chen and Frankel 2005). Unlike 
STEC, EPEC does not cause bloody diarrhea or HUS due to a lack of Stxs. However, 
while STEC is mostly asymptomatic in animals, EPEC is responsible for ruminant 
disease because of numerous features such as virulence factors such as bundle-forming 
pili (Fischer, Maddox et al. 1994; Cid, Ruiz-Santa-Quiteria et al. 2001; Jores, Rumer et 
al. 2004).   
The EPEC LEE Island is smaller than that found in STEC, with a size of 35.5 kb, 
as it does not contain the 7.5 kb cryptic P4 prophage found on one end of the STEC LEE 
Island (Perna, Mayhew et al. 1998; Jores, Rumer et al. 2004). However, the LEE Island is 
still inserted within the selC tRNA locus, and contains all 41 ORFs organized into 
operons LEE1-LEE5.  A high level of sequence homology within the 41 ORFs of STEC 
and EPEC is observed, where the majority average over 95% homology (Perna, Mayhew 
et al. 1998). However, a number of genes (eae, espA, espB, espD and tir) which express 
proteins that are exposed on the outer surface of the bacterium have a sequence difference 
of over 15%.  The variability among these genes could be a result of the interaction with 
the host, causing an increase in selective pressure (Frankel, Phillips et al. 1998). 
Another bacterial pathogen which contains the LEE island within its chromosome 
is Citrobacter rodentium. Unlike STEC and EPEC, this pathogen infects rodents and 
causes transmissible murine colonic hyperplasia in mouse breeding colonies (Schauer and 
Falkow 1993). The C. rodentium LEE Island is flanked by a ABC transport system 
operon and an IS element on one side, and a sequence homologous to the pO157 plasmid 
on the other side (Deng, Li et al. 2001).  The presence of plasmid sequences flanking the 
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LEE island insinuates that horizontal plasmid transfer might be responsible for the A/E 
phenotype in C. rodentium. 
  The C. rodentium LEE Island contains all 41 ORFs, but differs in the 
organization of the rorf1 and espG genes (Deng, Li et al. 2001). However, a conserved 
role in pathogenesis and disease has been described, where the intimin protein from 
EPEC restored virulence of a C. rodentium intimin mutant, while the Tir protein from 
STEC O157 restored virulence of a C. rodentium tir mutant (Deng et al. unpublished 
data) (Frankel, Phillips et al. 1996). Since this organism produces A/E lesions when 
colonizing the gastrointestinal tract, it has provided an excellent in vivo model to 
investigate the interaction between pathogen and host. In fact,  many of the early studies 
exploring the role of Intimin and the LEE islands in virulence as well as the present 
studies on the role of LEE and non-LEE effectors  have been investigated using the C. 
rodentium mouse model (Schauer and Falkow 1993).  
  
1.3.3 Other pathogenicity islands 
 Apart from the LEE pathogenicity island, STEC serotypes possess other 
pathogenicity islands associated with virulence and disease. The sequencing of the STEC 
O157 genome confirmed the existence of multiple O islands (OI) such as OI-1, OI-43, 
OI-48, OI-115, OI-122, OI-140, OI-141 and OI-154 (Perna, Plunkett et al. 2001). 
Pathogenicity Islands such as LEE, and their role in virulence have been well-
characterized. However, the elucidation of the role of these OIs in the virulence of STEC 
is still in its early stages. One exception is the well-characterized OI-122.  
The OI-122 is a 23 kb pathogenicity island composed of 26 ORFs, harboring a 
number of virulence genes (Perna, Plunkett et al. 2001). These genes are divided into 
three modules, the first includes a gene with homology to the S. Typhimurium pagC gene 
involved in survival within macrophage, the second module contains the nleB and nleE 
secreted effectors and the sen gene resembling a Shigella enterotoxin, while the third 
contains the efa1 and efa2 genes used for adherence (Nicholls, Grant et al. 2000; 
Karmali, Mascarenhas et al. 2003; Nishio, Okada et al. 2005; Konczy, Ziebell et al. 
2008). Interestingly, not all of these genes are found in every STEC serotype. Each 
module is believed to have been acquired or lost as a tranposon-like independent mobile 
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element. This is confirmed by the variable regions on the genome, where OI-122 is 
incorporated. For example, in STEC O157, OI-122 is adjacent to the pheV tRNA locus 
and is located 7 kb upstream of LEE island, while in STEC O26:NM, which contains 
module 2 and 3, the OI-122 is attached to LEE, resulting in a large 59.4 kbp 
pathogenicity island called LEE O26 (Karmali, Mascarenhas et al. 2003; Muniesa, 
Schembri et al. 2006). In STEC O103 serotypes, the OI-122 with module 2 and 3 is 43 kb 
upstream of LEE forming a large 111 kb island, while in STEC O113:H21, the one 
module containing OI-122 is entrenched in OI-48 (Shen, Mascarenhas et al. 2004; Jores, 
Wagner et al. 2005). The LEE and the OI-122 islands are functionally related where nleB 
and nleE genes transcribe effectors that are secreted through the T3SS found on the LEE 
Island (Kelly, Hart et al. 2006).  
In 2003, Karmali and colleagues devised a method to classify STEC serotypes 
into five seropathotypes A through E, based on the distribution of the OI-122 
Pathogenicity island modules (summarized in Table 1.2) (Karmali, Mascarenhas et al. 
2003; Wickham, Lupp et al. 2006). The OI-122 was selected given that its presence in 
STEC correlates with a strain’s ability to cause HUS and trigger outbreaks. These 
seropathotypes were divided as follows (Karmali, Mascarenhas et al. 2003): 
Seropathotype A consisting of STEC O157:H7 and O157:NM is affiliated with human 
disease involving outbreaks and HUS cases. Seropathotype B consisting of serotypes 
O26:H11, O103:H2, O111:NM, 121:H19 and O145:NM are associated with outbreaks of  
HUS but are less common than serotype O157:H7. Seropathotype C consists of serotype 
O91:H21, O104:H21 and O113:H21, and are associated with sporadic cases of HUS, but 
not involving outbreaks. Seropathotype D involves serotypes associated with diarrhea but 
not with HUS cases, while seropathotype E consist of serotypes not implicated in human 
disease.  
A number of genes (pagC, nleB, nleE, ent and efa1) located on the OI-122 Island 
play a critical role in the ability of a pathogen to colonize, and cause outbreaks involving 
HUS (Wickham, Lupp et al. 2006; Wickham, Lupp et al. 2007). A C. rodentium nleB 
mutant required an infectious dose 285-fold higher than the wildtype strain (Wickham, 
Lupp et al. 2006). Since the nleB gene is found in 100% of STEC O157:H7 and 69% of 
non-O157 strains implicated in outbreaks with HUS, and that a low infectious dose plays 
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Table 1.2 Classification of STEC serotypes into seropathotypes. * Represents HUS 
and hemorrhagic colitis. Diagram adapted and modified from (Karmali, Mascarenhas et 
al. 2003) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 37 
a significant part in outbreaks; this protein could be a vital to STEC pathogenesis. In fact, 
genes such as nleB and efa1 are used in a clinical setting for molecular serotype typing to 
identify pathogenic serotypes, apart from Mackonkey sorbitol plating and other 
commonly used STEC identification methods. 
Although less-characterized, other pathogenicity islands found within the STEC 
genome also contain important virulence factors. The lpf1 operon and the lpf2 operon 
which express long polar fimbriae and thin fibrillae-like structures, respectively, are 
involved in adherence and microcolony formation. Both of these long polar fimbriae are 
located on the OI-141 and OI-154 chromosomal region of STEC O157, where at least 
four variants of lpf exist throughout STEC strains (Toma, Martinez Espinosa et al. 2004; 
Toma, Higa et al. 2006). As noted, fimbriae-encoding genomic islands such as OI-1, OI-
47, OI-141 and OI-154 are distributed almost entirely in serotypes O157:H7 and 
O157:NM, indicative of their ability to cause serious disease more frequently than other 
serotypes (Shen, Mascarenhas et al. 2005).  
The Iha is an adherence-conferring protein produced by STEC O157 (Tarr, Bilge 
et al. 2000). This protein, which is not fully understood, is adjacent to the tellurite 
resistance loci, has a conserved structure, and has duplicate genes located on OI-43 and 
OI-48 (Tarr, Bilge et al. 2000; Toma, Martinez Espinosa et al. 2004). Both of these 
islands are identical and contain over 100 ORFs. The uncharacterized Z1640 gene located 
in the middle portion of the OI-48 has also recently been tested and suggested to play a 
role in virulence (Shen, Mascarenhas et al. 2004). Using PCR, 36 STEC strains were 
sampled, and the intact gene Z1640 was only located in serotypes such as O157:H7, 
O26:H11, O103:H2, O111:NM, and O145:NM, commonly associated with HUS and 
worldwide outbreaks. On the other hand, in STEC strains that do not cause human 
infection, such as O91:H21 and O113:H21, the Z1640 gene was found only in 
fragmented forms. 
 
1.3.4 Structural components and assembly of secretion apparatus  
The Type III Secretion apparatus is made up of two interconnected rings, 
spanning both the inner and the outer membranes. A translocon is then extended from the  
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Figure 1.4 Representation of the Type III Secretion Sytem (T3SS). The EscC protein 
is the main component of the outer membrane ring. This ring uses the EscJ protein to 
form a periplasmic ring that connects the outer membrane ring to the inner membrane. 
The inner membrane rings, are made up of a group of proteins called EscV, EscR, EscS, 
EscU and EscT. The EscF protein forms the needle structure connecting the EscC outer 
membrane rings to the extracellular space. A filament then extends from the needle made 
up EspA protein subunits. Two other proteins called EspD and EspB form a pore on the 
surface of the host cell, and connect the filament to the eukaryotic cell. The EscN protein 
is an ATPase which provides the energy for the transportation of effectors through the 
channel. SepL and SepD are cytoplasmic components of the T3SS. Diagram was adapted 
from (Garmendia, Frankel et al. 2005). 
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bacterial outer membrane, allowing the secretion of proteins into a host cell (summarized 
in Figure 1.4) (Roe, Hoey et al. 2003). The initial formation of the membrane structure, 
involves proteins with a sec-dependent signal sequence, which allows them to be 
transported and positioned on the membranes through the sec- pathway. Several cytosolic 
proteins are then added to the basal end of the structure. The next portion of the apparatus 
assembles in a sec-independent method, where proteins are exported through the channel 
formed by the interconnecting membrane structure.  
The EscC protein is the main component used for the outer membrane rings 
(Ogino, Ohno et al. 2006). This protein belongs to the secretin super family of outer 
membrane proteins, which uses multiple subunits to form a two ring-shaped 
homomultimeric complex on the outer membrane (Koster, Bitter et al. 1997; Garmendia, 
Frankel et al. 2005). The inner membrane rings are made up of a group of proteins called 
EscV, EscR, EscS, EscU and EscT (Garmendia, Frankel et al. 2005). At this point, little 
is known about their interactions and their roles with respect to one another. However, 
the EscV protein, which possesses seven transmembrane domains, is the principal protein 
in the formation of the inner membrane rings. This was confirmed when an escV mutant 
lost the ability to form the apparatus, causing the accumulation of the EscC protein in the 
periplasm (Gauthier, Puente et al. 2003; Garmendia, Frankel et al. 2005).  
The STEC EscJ protein makes up the large 24-subunit periplasmic ring that 
connects the outer with the inner membrane structure (Yip, Kimbrough et al. 2005). This 
protein is required for the transportation of numerous proteins, where an escJ mutant 
failed to secrete or form a functional T3SS (Garmendia, Frankel et al. 2005). Using 
nuclear magnetic resonance spectroscopy, the EscJ protein was found to possess two 
domains connected by a linker, which fit perfectly into the width of the periplasmic 
region of Gram negative bacteria (Crepin, Prasannan et al. 2005). The EscJ protein spans 
both membranes, but appears to mostly interact with the outer membrane structure and 
with the EscF needle protein (Ogino, Ohno et al. 2006). This interaction may be required 
to directly connect the channel to the needle structure. Interestingly, a homologue of EscJ 
has been discovered in Salmonella spp, called PrgK that with the assistance of another 
protein, is  required for the formation of the inner membrane rings, and may be involved 
in bringing together the periplasmic channel protein with the inner membrane rings 
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(Kimbrough and Miller 2000; Yip, Kimbrough et al. 2005).  All three of the structural 
membrane proteins discussed ( EscC, EscV and EscJ ), have sec-dependent sequence 
signals, and have structural homologues found in other T3SSs  possessing bacteria such 
as Salmonella, Shigella and Yersinia spp. (Schuch and Maurelli 1999; Galan 2001; Ghosh 
2004; Kostakioti, Newman et al. 2005; Spreter, Yip et al. 2009).  
For proteins to be secreted through the recently formed membrane apparatus, an 
energy source is required. The EscN protein is a unique ATPase which provides the 
necessary energy for the transportation of effectors (Gauthier and Finlay 2003). This 
protein also acts as an inner-membrane gate operator by interacting with chaperone-
effector complexes through a docking site on its C-terminal domain. Through ATP 
hydrolysis, the conformational change of the domain may disrupt the chaperone binding 
site, allowing the effector to dissociate and be secreted through the T3SS (Woestyn, 
Allaoui et al. 1994; Akeda and Galan 2004; Zarivach, Vuckovic et al. 2007). This 
ATPase shares homology with the β subunit of the F0F1ATPase complex, which breaks 
down ATP in the membranes of both prokaryotes and eukaryotes (Zarivach, Vuckovic et 
al. 2007) . The EscN protein has also been found to interact with several proteins on the 
T3SS apparatus. 
The single protein needle structure which connects the EscC outer membrane 
rings to the extracellular space is made up of an EscF protein (Wilson, Shaw et al. 2001). 
An escF mutant completely abolished the secretion by the T3SS, which was fully 
restored once the escF gene was re-introduced (Wilson, Shaw et al. 2001). These results 
demonstrated that without the EscF protein, the channel within the inner and outer 
membrane is inactivated or blocked. This protein shares a homology with the PrgI needle 
produced by Salmonella, where both needles protrude roughly 40 to 50 nm from the 
bacterial surface (Daniell, Takahashi et al. 2001; Marlovits, Kubori et al. 2004). In 
addition, like Salmonella and Shigella, the needle length is believed to be strictly 
regulated (Marlovits, Kubori et al. 2004; Kenjale, Wilson et al. 2005; Marlovits, Kubori 
et al. 2006). However, the regulatory protein which controls the STEC EscF length has 
not yet been discovered. 
A trait which separates the STEC T3SS from the rest of the Gram negative 
T3SSs, is the production of an extended filament that binds directly to the EscF needle 
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structure (Knutton, Rosenshine et al. 1998; Delahay, Knutton et al. 1999; Wilson, Shaw 
et al. 2001; Daniell, Kocsis et al. 2003). This filament is made up of a polymer of 
multiple coiled-coil interactions between EspA protein subunits (Delahay, Knutton et al. 
1999). The EspA subunits are added to the growing tip of the filament as they are 
secreted through the membrane-spanning channel (Crepin, Shaw et al. 2005). These 
subunits co-polymerize to form a hollow tube, which allows effector proteins to be 
secreted. This function was recently verified where the translocated intimin receptor (Tir) 
was secreted through the filament tip into the extracellular environment (Crepin, Shaw et 
al. 2005). Through close analysis of the crystal structure, the hollow tube is made up of 
roughly 28 subunits, with an inner diameter of 25 angstrom, an outer diameter of 120 
angstrom, where each subunit gives a rise of 4.6 angstrom (Daniell, Kocsis et al. 2003). 
Just like the EscF protein, the extension of the EspA filament is also believed to be 
tightly regulated by controlling the amount of monomeric EspA available in the 
cytoplasm. This was confirmed where an increase in the concentration of intracellular 
EspA subunits resulted in an extended filament structure (Crepin, Shaw et al. 2005).  
Once the translocon structure is complete, the filament, with the assistance of the 
EspB and EspD proteins, is inserted into IECs, where LEE and non-LEE effectors are 
secreted much like fluid through a syringe (Knutton, Rosenshine et al. 1998; Daniell, 
Delahay et al. 2001). Once effector genes are expressed and begin to be transported into a 
host cell, the transcription of espA is down-regulated (Dahan, Knutton et al. 2004). The 
EspB and EspD proteins are important in the secretion process because of their ability to 
form a pore on the surface of IECs (Fivaz and van der Goot 1999; Warawa, Finlay et al. 
1999). Both proteins have been purified from eukaryotic cells, and demonstrate 
hemolytic properties on RBCs (Wachter, Beinke et al. 1999; Daniell, Delahay et al. 2001; 
Shaw, Daniell et al. 2001). The observed hemolysis was dependent on a working 
secretion system and the EspD protein. However, an espB mutant was still able to cause 
hemolysis, but levels were significantly reduced. These results show that EspD is 
essential for the production of the pore, and that EspB binding to EspD allows the pore to 
be fully formed. Interestingly, an espD mutant secreted low levels of the EspA filament 
and displayed reduced attachment to IECs when compared to the wildtype (Knutton, 
Rosenshine et al. 1998; Daniell, Delahay et al. 2001). It is believed that EspD plays a role 
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in attaching the filament to the IEC membrane, and could be involved in the capping of 
the EspA filament (Delahay, Knutton et al. 1999; Fivaz and van der Goot 1999). 
 
1.3.5 Regulation of secretion by the Type III Secretion System 
 Pathogenic bacteria must be able to respond accordingly to any type of 
environment. This responsiveness becomes critical for the expression of virulence factors 
once the bacteria have reached a potential host. The regulation of the formation of A/E 
lesions is a complex system involving numerous direct and indirect regulatory factors 
(Figure 1.5). The T3SS found on the LEE Island is responsible for the secretion of 
proteins into host epithelial cells, which initiates the formation of A/E lesions. These 
lesions can be mimicked in vitro during early exponential growth phase by stimulating 
the bacteria to 37ºC, which allows lesion formation on HeLa cells (Rosenshine, 
Ruschkowski et al. 1996). However, this event does not occur if the bacteria are initially 
incubated at 27ºC. 
 Under non-host conditions such as the external environment, or during the initial 
time of ingestion, the expression of the LEE Island is suppressed by H-NS (Histone-like 
nucleoid structuring protein) (Umanski, Rosenshine et al. 2002). The H-NS is a negative 
regulator that responds to numerous regulatory proteins and environmental signals 
(Atlung and Ingmer 1997). This protein binds and represses Ler (LEE-encoded 
regulator), and the expression of LEE1, LEE2, LEE3, LEE4 and LEE5 operons at 27ºC 
(outside environment). This effect involves the binding of silencer regulatory sequences 1 
and 2 (SRS1 & SRS2) that flank the LEE operon promoters (Bustamante, Santana et al. 
2001). This binding results in the formation of a repressor nucleoprotein complex, which 
is stabilized by the H-NS-H-NS bridging interaction (Bustamante, Santana et al. 2001).  
Once the temperature is switched from 27ºC to 37ºC (gastrointestinal environment), Ler 
activates the LEE operons through the release of the H-NS mediated repression, by acting 
as a anti-H-NS factor (Umanski, Rosenshine et al. 2002).  The Ler protein binds to the 
same H-NS region on LEE2 and LEE5, resulting in silencing through disruption of 
binding (Haack, Robinson et al. 2003; Torres, Lopez-Sanchez et al. 2007). The binding of 
Ler to the SRS1 weaken the H-NS nucleoprotein complex which allows the expression of  
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Figure 1.5 Transcriptional regulation of the locus of enterocyte effacement (LEE). 
Solid arrows represent activators, while crossbars represent repressors. For further 
explanation of LEE repressors or activators please see text.  H-NS (Histone-like nucleoid 
structuring protein), Ler (LEE-encoded regulator), IHF (integration host factor), QS 
(quorum sensing), NE (norepinephrine).  Diagram adapted and modified from (Zhang, 
Chaudhuri et al. 2004). 
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the LEE operons (Bustamante, Santana et al. 2001; Barba, Bustamante et al. 2005; 
Torres, Lopez-Sanchez et al. 2007).   
The Ler protein, which is encoded on the LEE1 operon, is the central regulator of 
the LEE Island. A study has shown that the deletion of the ler gene limits production of 
the hallmark A/E lesions, and strongly attenuates virulence, making it a global regulator 
(Elliott, Sperandio et al. 2000). Using a HEp-2 cell in vitro model, a study has shown that 
the transcription of ler only appears to be required during the early stages of infection 
(Leverton and Kaper 2005). The transcription of LEE3, LEE4 and LEE5 was maximal at 
the 3 hour point and remained constant throughout the 5 hour infection. On the other 
hand, the LEE1 operon that contains the ler gene began decreasing at the 3 hour time 
point. These results show that the Ler activity is less important once the infection has 
been established, but is crucial in the early stages to remove H-NS repression and to 
activate the LEE operons. This protein has also been found to have a DNA binding C-
terminus homology to the H-NS family of DNA binding proteins.  
 The Ler protein can be regulated by a large number of factors. Two Ler-
regulatory proteins encoded on LEE Island are called GrlA and GrlR act to optimize the 
LEE1 promoter. A positive regulatory loop formed by GrlA and the Ler protein has been 
identified, since each activates the expression of the other (Barba, Bustamante et al. 
2005).  This was confirmed when a grlA mutant caused a significant reduction of the 
expression of the ler gene. However, this expression was restored when GlrA was re-
introduced. The same results were observed when a ler mutant strongly reduced the 
expression of the grlA, but was restored by the introduction of the Ler protein. The GrlR 
which is expressed from the same operon as GrlA, acts as negative regulator of ler 
expression (Barba, Bustamante et al. 2005; Jobichen, Li et al. 2007).  GrlR is involved in 
down-regulating the GrlA and Ler regulatory loop by binding to GrlA once the Ler 
protein has reached a threshold, which prevents the  accumulation of Ler (Jobichen, Li et 
al. 2007).  
 Other proteins can also influence the regulation of the LEE island. The Fis and the 
integration host factor (IHF), which bind upstream of Ler, are positive regulators of the 
Ler encoded LEE1 operon (Friedberg, Umanski et al. 1999; Goldberg, Johnson et al. 
2001). Interestingly, the IHF did not bind to the LEE2 operon, which verifies that the Ler 
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protein is the main regulator of the LEE2 to LEE5 operons. A member of the ribosome 
binding GTPase family called BipA also indirectly regulates the transcription of the LEE 
Island through Ler (Grant, Farris et al. 2003). A bipA mutant demonstrated decreased 
transcription of the LEE operons including the ler gene. The transcription levels could be 
normalized following introduction of the gene on a plasmid. The Hha protein which 
regulates the α-hemolysin is also a repressor of the ler gene. A hha mutant in STEC 
resulted in a 10-fold increase in the expression of Ler, followed by an increase of LEE1, 
LEE2, LEE3 and LEE5 expression, and an increase in adherence to HEp-2 cells (Sharma, 
Carlson et al. 2005). The effect of Hha is believed to be direct, where the repression of ler 
takes place by binding to the ler promoter. Two other regulatory pathways called the 
RcsDCB and the GrvA regulator play a positive role in the expression of Ler (Tobe, 
Ando et al. 2005).  
 Regulators of LEE expression can be found on mobile genetic elements. One 
example is the cluster of genes that possess a second T3SS called T3SS2, found 
throughout STEC serotypes (Zhang, Chaudhuri et al. 2004). However, the T3SS2 
apparatus is not functional, as a result of frameshift mutations occurring over time. This 
system also bears a resemblance to the S. Typhimirum T3SS present on SPI-1 (Lostroh 
and Lee 2001). Using a microarray, the etrA and eivF genes located on T3SS2 were 
found to function as repressors of the transcription of LEE genes (Zhang, Chaudhuri et al. 
2004). In addition, etrA and eivF mutants led to an increase in the expression of LEE 
genes and the adherence to IECs. This negative effect on the LEE T3SS could result from 
cross-talk, where the regulators ensure that only one T3SS is being expressed at any 
given time to avoid the excess use of energy. 
 Quorum sensing is a cell-to-cell communication mechanism used by bacteria to 
sense environmental change, and allows them to respond accordingly. Quorum sensing 
also controls the ability of the bacteria to activate transcription of virulence factors such 
as the LEE-encoded T3SS (Anand and Griffiths 2003). In the presence of high numbers 
of pathogenic bacteria, such as microcolonies of STEC on IECs, LEE genes are 
expressed. This allows bacteria to mount an assault when large numbers are present, 
overwhelming the host. The quorum sensing luxS gene is responsible for the activation of 
the LEE operons through the regulation of Ler and in the production of the autoinducer 3 
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(AI-3) (Gasser, Gautier et al. 1955; Barnard and Kibel 1965; Kaplan, Chesney et al. 
1975; Walters and Sperandio 2006). A luxS mutant caused a reduction of the LEE gene 
transcription, secretion of effectors and the disruption of A/E lesions. Epinephrine and 
norepinephrine also play a role in the activation of LEE where the addition of epinephrine 
enhanced the expression of LEE genes. However, the expression of LEE genes can also 
be turned on when a low population of bacteria are present (Anand and Griffiths 2003). 
This effect is due to quorum sensing signals received by non-pathogenic E. coli present in 
the gut. 
 The regulation of the expression of structural proteins, followed by the expression 
of the effectors, must also be strictly controlled. A recent study by Deng and colleagues 
reported that two regulatory proteins SepD and SepL, act as “gatekeepers” to control the 
switch between the expression of translocon proteins and the expression of effectors 
(Deng, Li et al. 2005). The mutation of sepL and sepD genes resulted in the elimination 
of the secretion of translocators and an increase in the secretion of effectors. Both 
proteins also appear to interact with one another, and associate with the bacterial 
membranes. This was noted when a single mutation, or a double mutation, had the same 
effect [33, 42-44]. Calcium also plays an important role in the switch between translocon 
proteins and effectors (Deng, Li et al. 2005). In a high calcium environment, such as in 
the extracellular fluid, translocon proteins are expressed and the translocon is assembled. 
However, once a pore is formed, the influx of a low calcium concentration switches the 
production of translocon protein into effector proteins, with the help of SepL and SepD, 
which can now be secreted into the host cell.  
 
1.3.6 Effectors 
 
1.3.6.1 LEE effectors 
Secreted effectors play an important role in the colonization process of enteric 
pathogens by manipulating host cell pathways and function. The LEE Island which is 
generally found in the majority of STEC serotypes contains seven (Tir, Map, EspB, EspF, 
EspH, SepZ and EspG) T3SS secreted effectors (Table 1.3). 
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Table 1.3 List of Shiga toxin-producing E. coli (STEC) effector proteins. 
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1.3.6.1.1 Tir  
 One of the most important and best-studied LEE effectors is the translocated 
intimin receptor, Tir. The study of Tir began with the identification of the STEC outer 
membrane adhesin called intimin (Jerse, Yu et al. 1990). Initially, it was assumed that  
intimin bound to a host 90 kDa host protein called Hp90. However, Kenny and 
colleagues discovered that the Hp90 was actually a LEE encoded T3SS effector protein, 
eventually re-named Tir (Kenny, DeVinney et al. 1997). This surprising ability of a 
bacterial pathogen to carry its own receptor is a trait only observed in A/E pathogens.  
Once Tir is translocated through the T3SS, it localizes in the plasma membrane of 
the eukaryotic cell (Kenny, DeVinney et al. 1997; Deibel, Kramer et al. 1998). This 
protein contains two trans-membrane domains, which form a surface-exposed 
extracellular loop responsible for binding intimin, while the N and C termini are buried 
within the eukaryotic cell (de Grado, Abe et al. 1999; Hartland, Batchelor et al. 1999; 
Kenny 1999). This extracellular loop is 104 amino acids long and is critical for intimin 
binding and pedestal formation (de Grado, Abe et al. 1999). Both Tir and intimin proteins 
are dimers, allowing each intimin monomer to bind to a monomer of the Tir protein, 
resulting in an intimate interaction between the bacterium and the host cell (Luo, Frey et 
al. 2000). The intracellular N and C termini of the Tir protein can recruit and interact with 
a number of intracellular host and bacterial proteins. These interactions result in actin 
polymerization and pedestal formation observed with a typical STEC infection.  
The actin polymerization involved in the formation of the pedestal is dependent 
on the C terminus of Tir protein (Campellone, Rankin et al. 2004). Although the N 
terminus interacts with a number of host proteins, the deletion of this terminus still allows  
formation of A/E lesions (Campellone, Rankin et al. 2004). Following attachment of Tir 
to intimin, actin polymerization is triggered by the bacterial T3SS secreted protein called 
TccP, also referred to as EspFU (Garmendia, Frankel et al. 2005; Frankel and Phillips 
2008). This protein is capable of recruiting and activating the Neural Wiskott-Aldrich 
syndrome protein (N-WASP), which in turn triggers the actin-nucleating Arp2/3 
complex, resulting in actin polymerization (Figure 1.6). A number of other host proteins 
such as cortactin and Gbr2 are also recruited to assist with the  
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Figure 1.6 Model for protein interaction during the formation of STEC pedestal. 
During the early stages of pedestal formation STEC attaches to the host cell through the 
Tir-intimin interaction. The tyrosine phosphorylated host protein cortactin binds Tir and 
TccP which accumulates around the attached bacterium. Cortactin may also interact with 
both proteins at the same time. During the later stages, cortactin dephosphorylation 
releases cortactin and TccP from Tir. The TccP protein then recruits and activates the 
neurol Wiskott-Aldrich syndrome protein (N-WASP), which in turn triggers the actin 
nucleating Arp2/3 complex, resulting in actin polymerization. STEC can be referred as 
Enterohemorrgic E .coli (EHEC). TccP is also referred to as EspFU. Diagram adapted and 
modified from (Cantarelli, Kodama et al. 2007). 
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amplification of the signal (Goosney, DeVinney et al. 2001; Cantarelli, Takahashi et al. 
2002). The cortactin protein directly binds to Tir and the TccP protein, where it links the 
bacterial proteins to the actin polymerization, and helps guide pedestal formation through 
closely controlled tyrosine phosphorylation and dephosphorylation of cortactin proline-
rich domains (Figure 1.6) (Cantarelli, Kodama et al. 2007). Several other Tir-independent 
host proteins such as calpactin, CD44, ezrin, talin, gelsolin and tropomyosin localize to 
the site of bacterial attachment (Goosney, DeVinney et al. 2001). The role of Tir within 
EPEC and STEC is almost identical, where the main difference is observed were STEC 
uses TccP to activate N-WASP, while EPEC recruits the host Nck protein to employ the 
N-WASP/Arp2/3 complex (Gruenheid, DeVinney et al. 2001). However, recently, in vivo 
studies have identified a common actin polymerization pathway used by both STEC and 
EPEC strains. A number of non-O157 STEC serotypes, sorbitol-fermenting STEC O157, 
as well as EPEC strains, possess a gene that expressed a protein with a 69% homology to 
the STEC TccP protein, called TccP2 (Ogura, Ooka et al. 2007). Over 95% of non-O157 
STEC serotypes that possess the tccP2 gene, 90% also contain a Tir protein that can be 
tyrosine phosphorylated and trigger the Nck actin polymerization pathway.  Interestingly, 
this protein functionally complements a STEC O157 tccP mutant, when the gene is 
introduced on a plasmid. 
 
1.3.6.1.2 Map 
 The Mitochondrial associated protein (Map) was given its name because of its 
ability to target and disrupt the mitochondria via its N-terminal signal sequence (Kenny 
and Jepson 2000). This disruption occurs by interfering with the ability of the 
mitochondria to maintain membrane potential, which causes mitochondrial swelling, the 
formation of distorted mitochondria and eventual organelle damage (Kenny and Jepson 
2000; Kenny 2002). The Map protein is a multifunctional effector that can play a number 
of roles during STEC infection, such as the disruption of barrier function and tight 
junction structure (Dean and Kenny 2004). This protein is also involved in cytoskeletal 
rearrangement by inducing Cdc42-dependent filopodium-like structures, which is not 
dependent on mitochondrial targeting (Kenny, Ellis et al. 2002).  
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 Using the C. rodentium mouse model, a map mutant induced lower levels of 
hyperplasia while efficiently colonizing the mouse (Mundy, Petrovska et al. 2004). In a 
competition infection between the mutant and the wildtype strain, the mutant initially 
colonized the host at low doses, but was outcompeted by the wildtype strain by day 9. 
These results confirm that the Map protein gives STEC the ability to outcompete a Map-
negative strain in a competitive environment. In addition Map may also play a role in 
altering immunological responses. 
 Interestingly, both Tir and Map proteins interact with a 15 kDa cytoplasmic 
protein called the chaperone for E. coli secretion of Tir (CesT) (Elliott, Hutcheson et al. 
1999; Delahay, Shaw et al. 2002; Creasey, Delahay et al. 2003). This interaction which 
occurs at the amino acid terminus, is not absolutely necessary for secretion, where both 
proteins, although nearly abolished, could still be secreted. However, a cesT mutant was 
unable to form A/E lesions (Elliott, Hutcheson et al. 1999). These results demonstrate 
that CesT is a chaperone required for the translocation of both Map and Tir secreted 
proteins. 
 
1.3.6.1.3 EspF 
  The EspF protein is involved in the disruption of barrier function and tight 
junction structure, as well as in the increase of membrane permeability and the 
distribution of the tight junction protein called occludin (McNamara, Koutsouris et al. 
2001; Dean and Kenny 2004). The disturbance of the barrier function involves the 
coordinated action of both Map and EspF, where individually map or espF mutants 
showed reduced disruption compared to the wildtype (McNamara, Koutsouris et al. 
2001). Surprisingly, an intimin mutant was unable to disrupt barrier function, implying 
that the EspF and Map affect may be dependent on the intimin protein or on attachment. 
 The EspF protein is transported to the mitochondria, where it releases the 
mitochondrial cytochrome C protein, and helps in the cleavage of caspases 9 and 3, both 
implicated in cell death (Nougayrede and Donnenberg 2004; Nagai, Abe et al. 2005). The 
EspF protein has also been suggested to play a role in other virulence aspects such as 
apoptosis and the inhibition of the uptake by macrophages (Crane, McNamara et al. 
2001; Marches, Covarelli et al. 2008). In addition, in vitro experiments using organ 
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cultures demonstrated that an espF mutant displayed A/E lesions with non-effaced 
microvilli still uniform in length. This implies that EspF could play a role in the re-
modeling of the brush border microvilli (Shaw, Cleary et al. 2005).  
When an espF mutant was tested in an C. rodentium mouse model, a significant 
decrease in virulence was observed, with a reduction in mortality, colon weight and 
intestinal mucosal layer thickness (Nagai, Abe et al. 2005). These results demonstrate 
that the abilityv of EspF to be transported to the mitochondria plays an important role in 
the colonization of the gastrointestinal area. 
 
1.3.6.1.4 EspG 
 The LEE-encoded EspG protein is involved in triggering actin stress fiber 
formation and the destruction of the microtubule networks underneath adherent bacteria, 
resulting in an increase in paracellular permeability (Matsuzawa, Kuwae et al. 2004). 
Using Swiss 3T3 mouse cells in in vitro experiments, EspG was shown to interact with 
tubulins causing destabilization of microtubules. Similar results were confirmed with 
Caco-2 cells, were the cytoskeleton was disrupted through microtubule depletion due to 
tubulin binding (Shaw, Smollett et al. 2005). This microtubule destabilization involves 
the release of the attached microtubule GEF-H1 protein, followed by the activation of the 
RhoA-ROCK signalling pathway (Matsuzawa, Kuwae et al. 2004). A sequence 
homology exists between EspG and the VirA effector of S. flexneri, which is also 
involved in the interaction of tubules causing microtubule instability (Yoshida, Katayama 
et al. 2002). Using the C. rodentium mouse model, infection with an EspG mutant 
resulted in a significant reduction in the ability of STEC to colonize the gastrointestinal 
tract, and to cause colonic hyperplasia (Hardwidge, Deng et al. 2005). 
 
1.3.6.1.5 EspB 
 The EspB protein contributes to the formation and secretion of the T3SS 
translocon by assisting in the development of a surface pore on IECs (Fivaz and van der 
Goot 1999; Warawa, Finlay et al. 1999). However, EspB also plays a role as a bacterial 
effector. This protein can be transported to the host cell cytoplasm, where it localizes at 
the site of bacterial attachment and participates in the re-organization of actin structures 
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(Taylor, O'Connell et al. 1998; Taylor, Luther et al. 1999). Epithelial cells transfected 
with EspB displayed altered morphology where the number of stress fibers was reduced 
(Taylor, Luther et al. 1999). It is proposed that EspB functions as a cytoskeleton toxin by 
releasing monomeric actin for the re-organization of the filamentous actin under 
pedestals. This was suggested since transfected cells were able to concentrate high 
amounts of actin underneath bacteria, without stress fibers. The role of EspB in the 
modulation of the actin cytoskeleton was further confirmed when Kodoma and 
colleagues identified that EspB was capable of recruiting and interacting with the 
cytoskeleton associated protein called α-catenin, essential for A/E lesion formation 
(Kodama, Akeda et al. 2002).  
 
1.3.6.1.6 EspZ 
 The EspZ protein localizes underneath the bacterial attachment site, around the 
Tir protein (Kanack, Crawford et al. 2005). Using the C. rodentium mouse model, EspZ 
was shown to be required for full virulence and pathogenesis during infection, where an 
espZ mutant did not cause development of the characteristic colonic hyperplasia. A 
significant reduction in mortality was also observed. However, the precise role and 
function of the EspZ effector is yet to be determined. 
 
1.3.6.1.7 EspH  
The LEE-encoded EspH protein is translocated through the T3SS, where it 
localizes at the pedestal structure underneath the adherent bacterium (Tu, Nisan et al. 
2003; Deng, Puente et al. 2004). This protein represses filopodium formation, and is 
involved in controlling pedestal length, where the over-expression of EspH led to the 
elongation of flat pedestals. EspH also disrupted COS cells actin polymerization by  
acting as Rho, Rac and Cdc42 inhibitors (Ben-Ami, Ozeri et al. 1998). However, when an 
espH mutant was tested for virulence in the C. rodentium mouse model, the strain was 
only slightly attenuated (Deng, Puente et al. 2004). Overall, the EspH protein is involved 
in the repression of infected host cells and appears to play a role as a modulator of the 
actin cytoskeleton (Tu, Nisan et al. 2003). 
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1.3.6.2 Non-LEE effectors 
  
1.3.6.2.1 NleA 
In 2004, through the use of proteomics, the first non-LEE encoded (NLE) effector 
called NleA was identified (Table 1.3). The CP-933P prophage-encoded NleA effector, 
also known as EspI, is secreted through the T3SS and is transported to the Golgi 
apparatus (Gruenheid, Sekirov et al. 2004). Once it reaches the Golgi, it co-localizes with 
the mannoside II and Golgin-97 host proteins. NleA was also found to bind a number of 
host proteins through a PDZ binding motif. Using a yeast two-hybrid system, and a PDZ-
domain protein array overlay, NleA interacted with a total of 15 host proteins (Lee, Kelly 
et al. 2008). These proteins are involved in the formation of tight junctions, membrane 
integrity, ion channels, and protein signalling to the host cell membrane (Albrecht and 
Froehner 2002; Lee, Kelly et al. 2008). 
When a C. rodentium nleA mutant was tested in the mouse model, it was found to 
be non-lethal and the mice did not develop the typical colonic hyperplasia (Gruenheid, 
Sekirov et al. 2004; Kelly, Hart et al. 2006). Although NleA plays a role in colonization, 
it is not required for the formation of A/E lesions. A recent study identified that 86% of 
disease-causing STEC strains contained the nleA gene (Mundy, Jenkins et al. 2004). In 
addition, using statistical analysis, nleA was also found to be present in STEC strains 
most commonly associated with severe human disease. 
 
1.3.6.2.2 NleB-NleH 
 Apart from NleA, a number of other effectors from the Nle group have been 
identified (Table 1.3) (Roe, Tysall et al. 2007). However, their roles and functions are not 
yet fully understood. The OI-122 nleB gene, and the immediate upstream nleE gene, are 
secreted through the T3SS and are involved in colonization and disease as described 
(Tobe, Beatson et al. 2006; Wickham, Lupp et al. 2006; Wickham, Lupp et al. 2007). The 
nleB gene is present in 100% of STEC O157:H7 and 69% of non-O157 disease causing 
strains. In addition, when a C. rodentium nleB mutant was tested in vivo, it required an 
infectious dose 285-fold higher than the wildtype strain, while demonstrating a reduction 
in colonization and in colonic hyperplasia of mice. These results have established that the 
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NleB protein is a vital component of STEC pathogenesis (Kelly, Hart et al. 2006; 
Wickham, Lupp et al. 2006). The NleE protein has also been shown to be essential for the 
full virulence of STEC (Wickham, Lupp et al. 2007). Non-O157 strains that possess the 
nleE gene are 28 times more likely to be involved in outbreaks, and four times more 
probable to cause HUS (Wickham, Lupp et al. 2006). When tested in the mouse C. 
rodentium model, the nleE gene was required for full colonization and introduction of 
disease. 
 Although NleC and NleD are transported by the LEE-encoded T3SS, deletion 
mutants are still able to infect both calves and lambs and cause A/E lesions (Marches, 
Wiles et al. 2005; Tobe, Beatson et al. 2006). These results suggest that neither protein is 
required for STEC colonization, but further studies are necessary to fully understand their 
role in STEC infection. The NleF protein, which is found on OI-71, is also secreted 
through the T3SS into the host cytoplasm (Tobe, Beatson et al. 2006; Echtenkamp, Deng 
et al. 2008). This protein is believed to interact with other effectors in order to decrease 
the host response to infection. Although, no role was observed in bacterial adherence, 
cytoskeleton rearrangement, or host protein interaction, a competitive co-infection of 
mice demonstrated that a C. rodentium nleF mutant had reduced levels of colonization. 
An infection study of the terminal rectum and piglet colon with an nleF mutant also 
demonstrated reduced colonization compared to the wildtype (Echtenkamp, Deng et al. 
2008). Interestingly, seropathotype classifications completed on STEC strains have 
shown that NleF is affiliated with seropathotype A, which is the group most likely to 
cause severe human disease.  
A family of 14 effectors belonging to the NleG family were recently identified in 
STEC O157 (Tobe, Beatson et al. 2006). These effectors were discovered through a short 
sequence peptide which, after a TBLASTN search, revealed several NleG homologs. The 
majority of these proteins have also been shown to be secreted through the T3SS. 
Although their role in STEC infection is unknown, the presence of conserved sequence 
patches of histidine, cysteine and aspartate amino acid residues, suggest that they may 
have conserved enzymatic activity (Mukherjee, Keitany et al. 2006; Tobe, Beatson et al. 
2006). 
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 Another important non-LEE effector, which appears to have a host specific 
response, is NleH (Garcia-Angulo, Deng et al. 2008). Shiga toxin-producing E. coli 
serotypes have two nearly identical copies of the nleH gene (nleH1 and nleH2), while C. 
rodentium only contains one (Tobe, Beatson et al. 2006; Garcia-Angulo, Deng et al. 
2008). Infection of lambs or calves with an nleH mutant showed varying results 
(Hemrajani, Marches et al. 2008). In an oral challenge of lambs, a ∆nleH1∆nleH2 mutant 
out-competed a wildtype strain, while oral challenge of calves resulted in a reduction of 
shedding by the mutant. In a mouse model, the level of activation of NF-κB and TNF-α 
were significantly reduced compared with the wildtype (Hemrajani, Marches et al. 2008). 
These results suggest that NleH protein plays a role in the activation of NF-κB, which is 
responsible for an increase of inflammatory cytokines. However, to fully understand its 
functional properties, further studies must be completed. 
 
1.3.6.2.3 Other non-LEE encoded secreted proteins 
The first STEC prophage effector to be identified was the cycle inhibiting factor 
(Cif) (Table 1.3). This effector, which is located on a lamboid prophage, is secreted 
through the T3SS, and is a member of the cyclomodulin family of proteins that target the 
host cell cycle (Marches, Ledger et al. 2003). Using HeLa cells, the Cif protein was 
shown to have irreversible cytopathic effect involving the recruitment of focal adhesins, 
congregation of stress fibers, and the arrest of the cell cycle G2/M phase transition 
through the accumulation of the inactive Cdk1 protein (Marches, Ledger et al. 2003; 
Samba-Louaka, Nougayrede et al. 2008). The Cif protein can also block the G1/S phase 
transition by stabilizing and allowing the accumulation of the cyclin dependent kinase 
inhibitors p21
waf1
 and p27
kip1
 (Samba-Louaka, Nougayrede et al. 2008). In addition, the 
infection of HeLa cells with cif mutant was unable to block mitosis but did affect the 
formation of A/E lesions (Marches, Ledger et al. 2003). 
Another important effector located on a CP-933U prophage is the espJ gene 
directly upstream of tccP (Table 1.3). The infection of mice with an espJ mutant resulted 
in prolonged colonization and the inability of mice to clear the infection (Dahan, Wiles et 
al. 2005). Similar results were observed with lambs when challenged with both the 
wildtype and the mutant strain. Although colonization levels were identical, the mutant 
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strain persisted longer for a period of 18 days. Surprisingly, this effector appears to be 
involved in pathogen clearance from the host gastrointestinal tract.  Recent studies have 
also shown that EspJ is involved in the inhibition of phagocytosis by blocking both FcγR-
and CR2-mediated phagocytosis, by possibly interacting with a host complex 
downstream (Marches, Covarelli et al. 2008). 
The TccP effector is present on the CP-933U prophage (Table 1.3). As described 
earlier, this protein is involved in the binding of Tir and host cortactin protein where it 
activates the N-WASP protein that recruits and binds the Arp2/3 complex allowing actin 
polymerization (Figure 1.6) (Garmendia, Frankel et al. 2005; Cantarelli, Kodama et al. 
2007; Frankel and Phillips 2008). Recently, a second T3SS secreted effector called Tccp2 
was identified and is involved in triggering the Nck actin polymerization pathway 
(Ogura, Ooka et al. 2007). 
 With the identification of the first non-LEE effector NleA, the study of STEC 
pathogenesis began to focus on other possible secreted effectors positioned outside of the 
LEE Island. Using bioinformatics and other experimental approaches, an important study 
in 2006 by Tobe and colleagues identified a new set of 28 non-LEE effectors, which are 
secreted through the T3SS, and are located in various lamboid prophages and 
pathogenicity islands (Tobe, Beatson et al. 2006).  Until this point only a small group of 
proven non-LEE effectors had been discovered in C. rodentium (Deng, Puente et al. 
2004; Gruenheid, Sekirov et al. 2004; Marches, Wiles et al. 2005). However, at present, 
the role of the majority of these newly identified non-LEE effectors remains unknown.  
 
1.4 Host response  
 
1.4.1 Host response to enteric pathogens 
Intestinal mucosal surfaces are constantly exposed to large amounts of both 
commensal and pathogenic bacteria. It is estimated that the human colon contains 
approximately 10
14
 bacteria (Hooper, Midtvedt et al. 2002) representing over 1000 
different bacterial species. These bacteria include both resident microflora as well as 
pathogenic bacteria that are in transit throughout the bowel. Early recognition and 
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subsequent neutralization of these bacteria is therefore crucial for prevention of 
gastrointestinal diseases. 
 The gastrointestinal-associated lymphoid tissues (GALT) represent the largest 
immune compartment within the body. The GALT recognize and prevent pathogens from 
invading the mucosal tissues and tolerate commensal organisms that are required for 
effective food digestion and processing (Figure 1.7). To this end, the mucosal surfaces 
are equipped with an effective surveillance system that relies on both innate and acquired 
immune mechanisms involving a variety of effector molecules and immune cells 
(Athman and Philpott 2004). The main function of the GALT is to distinguish between 
commensal and pathogenic flora resulting in either oral tolerance or active immune 
responses. The GALT are equipped with a variety of receptors and effector molecules 
that enable recognition of conserved pathogen-associated molecular patterns (PAMPs). 
Pattern recognition receptors (PRRs), located primarily on IECs, include TLRs, NOD 
proteins, mannose receptors, and C-type lectins (Figure 1.7). Stimulation of PRRs with 
bacterial products, such as LPS or pro-inflammatory cytokines, such as IL-1  and TNF-
, trigger signalling cascades that lead to inducible nitric oxide synthase (iNOS) 
transcription. This pathway results in the activation of p38 mitogen-activated protein 
kinase (MAPK), NF- B and Janus-activated kinase–signal transducer and activator of 
transcription–interferon regulatory factor 1 (JAK–STAT–IRF1) pathways (Kamijo, 
Harada et al. 1994; Xie, Kashiwabara et al. 1994). In addition, upregulation of phagocytic 
co-stimulatory molecules leads to T cell activation.  
Intestinal epithelial cells possess TLRs such as TLR 2, 3, 4, 5, 7/8 and 9 (Lundin, 
Bok et al. 2008) that contain three major domains. The amino-terminal domain consists 
of a series of leucine rich repeat (LRRs) motifs followed by a transmembrane domain and 
a C-terminal Toll/IL-1 receptor (TIR) domain. The LRR domains of TLR2 and TLR5 
have been shown to bind peptidoglycan (PG) and flagellin (Iwaki, Mitsuzawa et al. 
2002), respectively. Following ligand recognition and binding by the LRR domain, a 
signal is transduced across the membrane to the TIR domain, which activates associated 
adaptor proteins and subsequent signal transduction cascades. TLR2 is functionally 
associated with TLR1 and/or TLR6. The TLR2/TLR1 heterodimer recognizes triacylated 
lipopeptides, whereas the TLR2/TLR6 recognizes lipoproteins and lipoteichoic acid  
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Figure 1.7 Inductive and effector sites in intestinal mucosa. The intestinal mucosa 
includes the epithelial layer, associated brush border, tight junctions, and mucosa. (1) 
Paneth cells at the intestinal crypts secrete host defense peptides (HDPs), which 
contribute to local immunity. (2) Dendritic cells extend processes into the lumen to 
sample antigen. (3) An M cell, a gateway for bacterial entry, within the Peyer’s patch is 
shown. (4) The inset Figure shows components involved in host recognition of pathogen-
associated molecular patterns (PAMPs) via TLR4 (apical), TLR5 (basal) or intracellular 
NOD, TLR3 and TLR9. Ligand binding culminates in MyD88-dependent activation of 
NF- B and expression of pro-inflammatory mediators such as tumor necrosis factor-  
(TNF- ) and IL-8.  
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(LTA), found in the PG layer of Gram-positive bacteria (Schwandner, Dziarski et al. 
1999; Yoshimura, Lien et al. 1999). Binding of LPS to TLR4 and CD14 results in the 
recruitment of MyD88 (myeloid differentiation primary response gene 88) through the 
interaction of TIR-homology domains in TLR4 and MyD88, whereas the amino-terminal 
death domain of MyD88 interacts with IL-1-receptor-associated kinase (IRAK) 
(Silverman and Maniatis 2001). Subsequent to the activation of IRAK, another adaptor 
protein, TNF-receptor-associated factor 6 (TRAF6) is phosphorylated and recruited to 
IRAK to activate the NF-κB pathway. Flagellin, a bacterial virulence factor, is 
recognized by TLR5 present on the basolateral side of the epithelial cell (Hayashi, Smith 
et al. 2001) whereas TLR9 is present in the endosome and recognizes unmethylated 
bacterial cytosine–phosphate–guanosine (CpG) motifs (Hemmi, Takeuchi et al. 2000). 
Another type of important PRR is NOD. NOD1 and NOD2 are intracellular receptors for 
PGN (Girardin, Boneca et al. 2003; Girardin, Boneca et al. 2003), whereby NOD1 detects 
PGN from Gram-negative bacteria, and NOD2 detects PGN from both Gram-negative 
and Gram-positive bacteria (Inohara, Koseki et al. 1999; Girardin, Boneca et al. 2003). 
In response to stimulation, IECs secrete effector molecules including 
antimicrobial peptides, cytokines, and chemokines that recruit polymorphonuclear cells, 
macrophages, dendritic cells (DCs), and lymphocytes which are capable of immune 
modulation and killing pathogens. Local cytokine expression also results in the activation 
and maturation of these cells. For example, granulocyte macrophage-colony stimulating 
factor (GM-CSF), IL-6, and TNF-  promote macrophage activation, proliferation, and 
additional cytokine secretion, resulting in the engulfment and destruction of pathogens 
(Eckmann and Kagnoff 2001). Secretion of TNF- , IFN-γ, IL-1 , IL-12, IL-18 and IL-15 
further enhances the pro-inflammatory response, which alternatively can be suppressed 
by IL-4 and IL-10 (Eckmann and Kagnoff 2001). Recruitment of immune cells into the 
subepithelial region is dependent on the recognition of PAMPs such as flagellin or PGN 
by infected IECs (Mrsny, Gewirtz et al. 2004). 
Although IECs respond poorly to resident microflora (Otte, Cario et al. 2004), 
they influence the responsiveness of DCs towards the microflora. The local 
microenvironment manipulates the priming ability of DCs to different subsets of T cells, 
including T helper 2 (TH2) cells (Iwasaki and Kelsall 1999) and T regulatory (Treg) cells 
 61 
(Kelsall and Leon 2005). Recently, thymic stromal lymphopoietin (TSLP) has been 
shown to be constitutively released by IECs and needed for IEC-DC crosstalk (Zeuthen, 
Fink et al. 2008). How aspects of the microflora influence the production of IEC-derived 
factors is unknown, but it is possible that the microflora influences the underlying DC 
through the IECs. IEC-DC crosstalk represents an important ability of the immune 
system to respond to alterations in gut homeostasis. By priming antigen-specific naïve 
CD4+ and CD8+ T cells, DCs are critical for initiating adaptive immunity in response to 
infection by pathogenic bacteria (Rescigno 2002). Dendritic cells residing in the intestinal 
mucosa sense bacterial PAMPs, mature, and migrate into the mediastinal lymph node 
(MLN), where antigens are presented to T and B lymphocytes. B cells undergo 
differentiation, migrate to the lamina propria (LP), and secrete IgA locally (Means, 
Hayashi et al. 2003). 
The innate defense against enteric pathogens includes host defense peptides 
(HDPs), lysozyme, phospholipase A2, and 1-antitrypsin (Lehrer and Ganz 2002). Host 
defense peptides are small cationic polypeptides that mediate host defense in mammals, 
plants and insects (Boman 2003) and have direct, broad-spectrum antimicrobial
 
activity 
through direct killing of bacteria by membrane permeabilization (Yeaman and Yount 
2003). Immunostimulatory functions include induction of chemotaxis of immature 
dendritic cells and T cells, activation
 
of antigen-presenting cells (APC), increased 
glucocorticoid
 
production, macrophage phagocytosis, mast cell degranulation,
 
complement activation, and IL-8 production by
 
epithelial cells (Biragyn, Belyakov et al. 
2002).  
One class of HDPs are defensins, which are divided into α-, β- and θ-defensins, 
based on structural features (Lehrer and Ganz 1999). Livestock have been shown to 
express a wide variety of -defensins (Selsted, Tang et al. 1996) and porcine defensins 
have been shown to be microbicial against intestinal pathogens (Veldhuizen, Rijnders et 
al. 2007). Cathelicidins are another class of HDPs which possess broad-spectrum activity 
against bacteria and fungi, including clinical isolates resistant
 
to antibiotics (Gennaro and 
Zanetti 2000). The peptides have been demonstrated to bind to LPS and provide 
protection in animal models of endotoxemia (Larrick, Hirata et al. 1994) and bacterial 
infection (Brogden, Kalfa et al. 2001).   
 62 
Invading pathogens must also overcome the mucus produced by goblet cells. 
Intestinal goblet cells are highly polarized secretory cells present throughout the intestinal 
tract which increase in number from the esophagus to the rectum (Specian and Oliver 
1991). Mucus, the gel layer overlying epithelial cells, is required for the lubrication of the 
intestinal surface. This layer limits the passage of luminal molecules into the mucosa, 
acts as a defensive barrier against enteric pathogens (Deplancke and Gaskins 2001), and 
as a substrate for colonization of commensal flora (Sonnenburg, Xu et al. 2005) (Figure 
1.7). Goblet cells synthesize mucins, such as MUC2, a glycoprotein present in the mucus 
(Moncada, Kammanadiminti et al. 2003), which inhibit the adherence of enteric 
pathogens. 
Intestinal macrophages (IM) which also play an important role against enteric 
pathogens, are located in the sub-epithelial dome region of PP, with the small intestine 
containing fewer mucosal macrophages than the colon (Lee, Starkey et al. 1985). 
Intestinal macrophages interact with luminal bacteria and detect microbes and microbial 
products that cross the epithelium and clear local pathogens without prior activation 
(Macpherson and Uhr 2004). In addition to lacking TLRs, IMs fail to express receptors 
present on other macrophage populations needed to detect and respond to bacteria. One 
example is the IgA-specific Fc high affinity receptor (FcαR), which interacts with IgA 
(Smith, Smythies et al. 2001). IgA is the most abundant antibody isotype in the GALT 
and IgA-mediated phagocytosis can induce a respiratory burst in IMs (Babior 1984). 
Intestinal macrophages also lack the FcγR1 and FcγRIII receptors for IgG, as well as the 
CR3 and CR4 complement receptors (Smythies, Sellers et al. 2005). The absence of these 
receptors may contribute to their lack of pro-inflammatory responses.  
 
1.4.2 Host response to STEC 
 
1.4.2.1 Innate response 
The innate response plays an important role in the rapid defence against STEC 
infections. This initial response is non-specific, and protects the host until it is capable of 
developing the more specialized adaptive response. The initial line of defense is the 
presence of the mucus barrier. Goblet cells synthesize mucins such as MUC2, a 
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glycoprotein (Moncada, Kammanadiminti et al. 2003) which inhibits the adherence of 
enteric pathogens, such as STEC (Mack and Sherman 1991). The normal flora found 
within the gut can also help reduce STEC O157 infection by priming the immune system. 
The activation of MUC2 and IECs by probiotic bacteria such as Lactobacillus 
acidophilus was found to protect against STEC infection (Kim, Kim et al. 2008). An in 
vitro study using L. acidophilus bacteria and cell extracts, resulted in the production of 
MUC2 and increased mRNA levels of IL-1β, TNF-α and IL-8 (Kim, Kim et al. 2008). 
This increase resulted in the inhibition of attachment of STEC O157 to the epithelial cell 
layer.  
Phagocytosis along with macrophage signalling are common methods used by the 
host to combat invading enteric pathogens. Phagocytosis involves the uptake of large 
foreign material by neutrophils, macrophages and dendritic cells. However, STEC with a 
functional Type III apparatus can limit its uptake by inhibiting the phosphatidylinositol 3-
kinase (PI3K)-dependent F-actin rearrangements required for uptake (Celli, Olivier et al. 
2001). The ability of STEC and EPEC to control this uptake by phagocytes is due to 
effectors EspF and EspJ, which are responsible for the inhibition of FcγR- and CR3 
mediated phagocytosis (Marches, Covarelli et al. 2008). 
Initial contact between a host and an enteric pathogen leads to induction of 
inflammation through TLRs as described. A single bacterium is able to activate multiple 
TLRs such as TLR4 by LPS, TLR5 by flagellin, or TLR2 which recognizes PG (Lundin, 
Bok et al. 2008). Signalling via MyD88 is necessary for the recruitment of macrophages 
for bacterial phagocytosis and the re-establishment of the epithelial layer. A study using 
MyD88-/- mice reported that infection with STEC O157 led to substantially more disease 
and increased shedding compared to the wildtype (Calderon Toledo, Rogers et al. 2008). 
Numerous studies have also been completed on A/E pathogens using the C. rodentium 
model. A separate study using MyD88-/- mice infected with C. rodentium demonstrated 
similar results with increased shedding and severe colonic pathology (Lebeis, Bommarius 
et al. 2007). However, these mice also had delayed neutrophil recruitment and mortality. 
The increase in pathological and haematological changes with MyD88-/- mice, imply that 
the exclusion of the innate response during STEC infection leads to an increase in 
disease.  
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Mast cells are implicated in the host inflammatory response by secreting IFN-α 
and by recruiting neutrophils, which are involved in bacterial clearance (Malaviya, Ikeda 
et al. 1996). Surprisingly, the use of mast cell deficient mice infected with C. rodentium, 
resulted in severe inflammation, increased cytokine production, tissue damage, 
bacteraemia and increased mortality compared to wildtype (Wei, Hilliard et al. 2005). 
These results show that mast cells play a protective role by preventing bacteraemia and 
sepsis, by facilitating the repair of IECs used for bacterial entry, and by destroying 
pathogens (such as C. rodentium) with the release of antimicrobial factors. 
A consequence of STEC infection is the initial up-regulation of signalling via NF-
κB, p38 and ERK MAP kinases, resulting in the increase of IL-8 expression and 
neutrophil migration (Savkovic, Koutsouris et al. 1997). However, after prolonged 
infection, STEC suppress this activation, likely via the secreted EspB effector (Hauf and 
Chakraborty 2003). The delayed suppression is consistent with the sequence of events, 
where initially the bacterium adheres to the host cell, followed by the assembly of the 
secretion apparatus, which triggers the secretion of effectors. STEC can also down-
regulate the expression of iNOS (Maresca, Miller et al. 2005), which occurs through the 
decrease of STAT-1 activation (Vareille, Rannou et al. 2008). Interestingly, the nitric 
oxide (NO) response has been shown to reduce the Stx synthesis and its release in the gut 
(Vareille, de Sablet et al. 2007).  
  The clearance of A/E pathogens such as STEC involves a combination of 
protective and destructive elements of the innate immune system (Lebeis, Sherman et al. 
2008).  The infection of mice with C. rodentium is thought to induce a strong mucosal 
Th1 response by macrophages and T cells in the area, which induce the production of IL-
12, IFN-γ and TNF-α. This induction is partly responsible for the crypt hyperplasia and 
acute colitis seen in these animals (Higgins, Frankel et al. 1999; Higgins, Frankel et al. 
1999). However, crypt hyperplasia, which is also observed with STEC and EPEC, could 
benefit the host. The amount of carefully controlled epithelial cells produced by the 
colonic crypts is disrupted by C. rodentium, which results in an increase in crypt height. 
This increase causes the rapid sloughing of IEC into the lumen while the bacteria are still 
attached, which could help with the clearance of the bacterial infection (Vallance, Deng 
et al. 2002).  
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Interleukin-1 receptor (IL-1R) is also important in resolving C. rodentium 
infection in mice (Lebeis, Powell et al. 2009). Infected IL-1R-/- mice had reduced levels 
of IL-6 and IFN-γ, and increased intestinal damage, including gangrenous mucosal 
necrosis, colonic bleeding and mortality. The IL-1R is involved in inducing IL-6 and 
IFN-γ levels, which when combined are important in resolving enteric infections. 
Overall, these results demonstrate that an innate response plays a critical role during the 
initial infection, by holding the bacteria within the colon, and destroying any that escape 
the region. 
 
1.4.2.2 Adaptive response 
The adaptive response of a host is a delayed and specific cellular response.  At 
present, the majority of studies done on the adaptive response against A/E pathogens 
have been completed using the C. rodentium model. Initial studies with mice lacking 
acquired immunity, such as RAG-1- knockout mice deficient in mature T and B 
lymphocytes, demonstrated that challenge with C. rodentium does not allow the clearance 
of infection, but instead results in heavy shedding with high mortality. In contrast, 
infection of wildtype mice leads to a inflammatory response followed by crypt 
hyperplasia, with full recovery within 3 weeks (Vallance, Deng et al. 2002). The RAG1 
knockout mice initially showed a similar response to the wildtype, but quickly diverged 
within the first 2 weeks. This illustrates that the innate system produces a reaction that 
can hold a pathogen at bay, while the adaptive response may be necessary to resolve the 
infection. Interestingly, the IFN-γ expression levels differed significantly between the 
wildtype and the RAG-1-  knockout mice. These levels were raised substantially in the 
wildtype mice, while in the RAG-1-  knockout mice, IFN-γ expression dropped below 
uninfected levels. The expression of IFN-γ has been shown to be involved in the 
development of crypt hyperplasia (Artis, Potten et al. 1999).  
Other researchers demonstrated that mice with depleted CD4+ T cells showed 
greater shedding, and did not clear the C. rodentium infection, from both mucosal and 
systemic tissues. It was suggested that the reduction in CD4+ T cells decreased their 
ability to assist B cells causing a depleted antibody response. The use of μMT mice, 
which have no IgG+ or IgM+ B cells were shown to be extremely vulnerable to C. 
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rodentium infection (Macpherson, Lamarre et al. 2001; Simmons, Clare et al. 2003). This 
susceptibility to systemic immunity was reversed by adoptive transfer of immune sera, 
suggesting that antibodies play a crucial role during infection (Simmons, Clare et al. 
2003).  
Studies have shown that infection of STEC and EPEC in humans leads to elevated 
humoral and cell mediated immune responses (Li, Frey et al. 2000; Tacket, Sztein et al. 
2000). Although, C. rodentium infection can cause an inflammatory response with 
elevated cytokines that recruit neutrophils and macrophages, antibodies to A/E virulence 
factors can also inhibit bacterial attachment to the epithelial cells and reduce shedding 
(Potter, Klashinsky et al. 2004; La Ragione, Patel et al. 2006). Therefore, an antibody 
response could be an alternate to phagocytosis, as EPEC and STEC can inhibit this 
process during infection (Marches, Covarelli et al. 2008) 
Passive immunization studies using colostrum have highlighted the importance of 
antibodies in limiting STEC infection. It was recently demonstrated that in a murine 
model the oral administration of immunoglobulin enriched bovine colostrum containing  
antibodies against numerous bacterial antigens was able to protect against challenge with 
STEC O157 (Funatogawa, Ide et al. 2002). Widiasih and colleagues have recently shown 
that passive immunity through colostrum can effectively transfer antibodies against 
STEC O26, O111 and O157 to newborn calves (Widiasih, Matsuda et al. 2004). Passive 
immunity was confirmed by the fact that antibody titers in sera collected from the 
newborn calves rapidly increased.  
The relevance of antibody was also highlighted when mice were orally vaccinated 
with STEC antigens combined with a liposome vehicle resulting in elevated IgA and IgG 
responses in both serum and intestinal lavage fluid in mice (Tana, Watarai et al. 2003). 
The intestinal lavage fluid was then used in in vitro inhibition assays and shown to inhibit 
the attachment of STEC O157 to the intestinal cells. The overall importance of antibody 
in limiting a STEC infection in cattle was demonstrated using subcutaneous vaccination 
with Type III Secretion proteins. The production of IgG antibodies was induced and 
correlated with a reduction in the number of shedding animals, as well as the level of 
STEC shed in fecal samples (Potter, Klashinsky et al. 2004). 
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1.5 Treatment, control and prevention of STEC 
 
1.5.1 Treatment of STEC 
At this time, the most common treatment for STEC infections appears to be 
supportive care. The best plan for the prevention of HUS is to prevent the initial infection 
and spread of STEC (Tarr, Gordon et al. 2005). Several agents such as antimotility, 
narcotics and nonsteroidal medications should be discouraged. Antimotility 
pharmacological agents have been found to increase the probability of developing HUS 
and neurological effects (Cimolai, Morrison et al. 1992; Siegler and Oakes 2005). These 
agents can also cause seizures, as well as renal failure. In order to protect renal function, 
patients are put on rehydration with isotonic solutions (Ake, Jelacic et al. 2005). The use 
of peritoneal dialysis from the initial stages of infection to the point of recovery have 
shown to limit disease and mortality and should be encouraged. Rapid analysis of stool 
from suspected STEC infected patients should be completed by the diagnostic laboratory. 
This will alert physicians of the risk of HUS development allowing for immediate 
volume expansion (Ake, Jelacic et al. 2005). 
The use of antibiotics among suspected STEC infected patients should be 
restricted.  A study in 2000 reported a significant increase in the development of HUS in 
children who were treated with antibiotics, compared to children who were not (Wong, 
Jelacic et al. 2000).  Antibiotics are believed to increase the susceptibility of HUS by 
destroying STEC, which causes the liberation of Stx or the induction of the 
bacteriophages where the toxin genes are located (Siegler and Oakes 2005). In vitro 
results confirmed that certain antibiotics, such as ciprofloxacin, cefiximine, tetracycline 
and co-trimoxazole, increased the production and release of Stx by 169% to 436% among 
five different STEC strains (Walterspiel, Ashkenazi et al. 1992).  However, the antibiotic 
rifaximin has been recently shown to not increase the production of Stxs, or the 
bacteriophage lysis on 26 O157 and 31 non-O157 strains tested (Ochoa, Chen et al. 
2007).  
Several toxin-binding agents have been developed that could bind to the toxin 
during infection and reduce its uptake. A study showed that a polymer of the Stx Gb3 
receptor, which demonstrated high affinity and inhibition to Stx1 and Stx2, was able to 
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protect mice against fatal challenge of STEC O157 (Watanabe, Matsuoka et al. 2004). 
The oral dose of the Gb3 polymer protected mice, even after the infection was 
established. The mice also demonstrated reduced brain damage, and a reduction of serum 
levels to Stx. Another synthetic molecule called Synsorb-Pk which resembles the Gb3 
receptor, was tested in a group of 150 children, and was found to have no effect in 
preventing HUS compared to placebo group. It was believed that the reason why this 
molecule failed was because it was administered too late into the infection 
(MacConnachie and Todd 2004). A recombinant bacterium that expresses the Stx 
receptor Gb3 on its surface was recently tested, and appears to absorb and neutralize Stx 
toxin. Mice that were given three daily oral doses of live bacteria, or formaldehyde-killed 
bacteria, were completely protected against STEC challenge even 48 hours post-
challenge (Paton, Rogers et al. 2001).  
 Several monoclonal antibodies have been developed that could be given to a 
patient to neutralize the Stx. The advantage of monoclonal antibodies is the protein-
protein interaction and the productivity capabilities. Smith and colleagues have 
developed a monoclonal antibody that can neutralize the cytotoxic and lethal properties 
of Stx1 (Smith, Carvalho et al. 2006). This group has also developed a chimeric 
Stx1B/Stx2A toxoid protein, which can be protective when vaccinating mice, and could 
be used to develop monoclonal antibodies against both toxins (Smith, Teel et al. 2006). 
Another group has also demonstrated that monoclonal antibodies against Stx2 showed 
specificity and binding affinity to Stx2. This product could be used a potential 
prophylactic or therapeutic agent for patients with an STEC infection (Akiyoshi, Rich et 
al. 2005). 
 
1.5.2 Control and prevention of animal infection 
 
1.5.2.1 Management methods 
A number of interventions can be used to limit the spread of STEC infections. 
Due to its asymptomatic properties in cattle, complete eradication in a farm environment 
is unlikely. However, several practices can be applied to reduce shedding and 
colonization of animals. The reduction in shedding should result in a decrease of 
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contaminated water sources such as rivers, ponds, and lakes that are regularly 
contaminated by pasture run-off or underground water (McGowan, Wickersham et al. 
1989; McCarthy, Barrett et al. 2001; Neely, Bell et al. 2004). This decline would also 
reduce human infection, as humans commonly use these water sources for consumption 
and recreational activities. In addition, the reduction in shedding by asymptomatic 
ruminants could also reduce the contamination of meat and animal products as well as 
indirectly reduce the contamination of produce. 
The practice of spreading manure as fertilizer for crop fields can also increase the 
shedding of STEC (Jiang, Morgan et al. 2002). The method of proper composting prior to 
spreading on fields, can eradicate STEC O157 from manure, and should be used as a 
common practice (Lung, Lin et al. 2001).  Proper composting can apply to silage which is 
commonly fed to animals, and  has been shown to be a source of STEC infections 
(Fenlon and Wilson 2000). 
Water quality can play a critical role in the spread of STEC. In reality, if the water 
tests positive for STEC, the majority of the time the cattle in the region also test positive, 
demonstrating that water can be a vehicle for STEC (Davis, Cloud-Hansen et al. 2005). 
The daily cleaning of water troughs, and the treatment of water with chlorine, 
electrolyzed water and ozonation have been tested, and proven to reduce colonization 
(LeJeune, Besser et al. 2004). The water source used to fill water troughs and for use in  
daily farm maintenance should also be regularly tested for the contamination with STEC, 
since these sources are at risk for contamination and spread to new areas (Dorner, 
Anderson et al. 2007). The hygiene of feed also represents a candidate for the exposure 
reduction of STEC, since it plays a role in the introduction of the bacteria to cattle 
(Crump, Griffin et al. 2002). In European countries, strict feed hygiene controls have 
been established which have lowered the prevalence of Salmonella, another common 
zoonotic pathogen in cattle and swine (Boqvist, Hansson et al. 2003). Feed management 
has been suggested to reduce the spread STEC, since certain feeds such as cottonseed, 
corn silage, barley and beet pulp appear to increase prevalence (Berg, McAllister et al. 
2004).  
The housing of calves in the same unit, prior to weaning, can increase the 
shedding of STEC O157 since calves shed STEC O157 at higher volumes, and more 
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often than adults (Cray and Moon 1995). These calves can then act as vehicles for the 
spread of STEC, once they are divided and housed with adults. Therefore, the housing of 
calves separately, and the assurance that pens are kept clean by the removal of mud, and 
the accumulation of urine and fecal matter, can reduce the prevalence and spread of 
STEC (Smith, Blackford et al. 2001). The scraping of alleyways used by cattle also 
reduces the shedding of STEC, since the common practice of jet washing actually 
increases STEC shedding (Garber, Wells et al. 1999). In addition, hide washing with a 
mixture of 1.6% sodium hydroxide, 4% trisodium phosphate, 4% chlorofoam, or 4% 
phosphoric acid can reduce the amount of STEC O157 found on beef carcasses prior to 
processing (Bosilevac, Nou et al. 2005). The removal of super-shedders is also important 
since these animals shed STEC at higher rates then regular shedders within a feedlot or 
pasture (Matthews, McKendrick et al. 2006).  
 
1.5.2.2 Biological methods 
The use of probiotics to manipulate the normal flora of an animal and to add a 
competitive element against STEC O157 has been suggested as a possibility to reduce 
shedding. Probiotics have been used in the cattle industry for decades to improve the 
well-being of an animal. Researchers have also isolated a number of E. coli strains, 
capable of producing colicins, which inhibit colonization of other E. coli, and have shown 
promise in displacing and reducing shedding of STEC O157 in live cattle (Zhao, Tkalcic 
et al. 2003). Lactobacillus acidophilus has also been shown to reduce the amount of 
STEC O157 in up to 50% of tested animals, and is currently being used in US feedlots 
(Brashears, Galyean et al. 2003). 
Antimicrobials administered through feed can be used to reduce the shedding of 
STEC O157. A large study involving 73 feedlots including 689 pens, reported that the 
addition of antibiotics in the feed significantly reduced fecal shedding compared to the 
control groups (Sargeant, Sanderson et al. 2004). Another drug which has recently been 
approved for use in feed is ractopamine. Ractopamine when administered to animals is 
responsible for dramatic muscle growth, but it is not considered a steroid or hormone, 
rather a compound known as a beta-agonist. Recently, it was discovered that the addition 
of ractopamine to feed significantly reduces the shedding of STEC O157 compared to the 
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control groups is a large feedlot trial (Edrington, Callaway et al. 2006). However, the use 
of these compounds has become controversial due to the increase of antibiotic resistance 
worldwide. Neomycin sulfate used in cattle, has demonstrated a decrease in fecal 
shedding of STEC O157 (Galland, Hyatt et al. 2001). However, it belongs to the family 
of aminoglycosides, which includes gentamycin and streptomycin, regularly used in 
humans.  
Another controversial method is the use of bacteriophages to reduce the 
colonization of STEC O157. Bacteria are commonly lysed by bacteriophages found in the 
intestine of animals (Barrow, Lovell et al. 1998). Mouse experiments have shown 
promise, where the oral administration of a phage cocktail rapidly removed STEC O157 
from the gastrointestinal tract of mice and from the fecal matter (Tanji, Shimada et al. 
2005). A separate cocktail of bacteriophages isolated from STEC O157 was also tested as 
a control agent to eradicate STEC O157 spread.  This cocktail contained 3 distinct 
phages, which reduced a culture of STEC O157 5-fold in 1 hour at 37ºC (O'Flynn, Ross 
et al. 2004).  When this cocktail was tested in a beef meat trial, the cocktail completely 
eliminated the presence of the bacterium in seven of nine cases. Recently, a second 
cocktail of four bacteriophages was tested against human and bovine STEC O157 
isolates. A total of 422 isolates were tested where the combination of all four 
bacteriophages were able to successfully lyse all isolates tested (Niu, Johnson et al. 
2009).  
Two separate groups investigated the potential of administrating bacteriophages 
prior to infection by STEC O157 in cattle. One study involved the administration of 
STEC O157 bacteriophages at the rectal junction where it is believed that STEC O157 
also colonizes (Sheng, Knecht et al. 2006). In this study, the average counts of STEC 
were significantly lower than the control groups. However, even though the 
bacteriophages persisted, 80% of cattle tested still remained infected with STEC O157. 
The second study provided more promising evidence, where the delivery of 
bacteriophages in milk at day -7, -6, -1, 0 and 1 to young calves resulted in the complete 
eradication of STEC O157 shedding after a period of 8 days (Johnson, Gyles et al. 2008). 
These results imply that phage therapy may effectively control the shedding of STEC 
O157 under the proper circumstances.  
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Bacteriophage cocktails have also been used to investigate the reduction of 
contamination of vegetables, ground beef and hard surfaces by STEC O157 (Abuladze, 
Li et al. 2008). In an experimental contamination of hard surfaces, a phage cocktail 
containing three STEC O157 lytic phages was capable of reducing the number of 
bacterium by 97%. When the phage cocktail was tested in food products, such as ground 
beef, broccoli, spinach and tomatoes, similar results were observed, where the reduction 
of STEC O157 ranged from 100% in spinach to 94% in tomato samples. These results 
demonstrate that bacteriophage may play a role in reducing the contamination of fruits, 
vegetables, ground beef and surfaces by STEC O157. However, an important obstacle 
with bacteriophage treatment in either cattle or food products is acquiring Canadian Food 
Inspection Agency (CFIA) approval and public acceptance. 
 
1.5.3 Control and prevention of human infection 
In order to reduce human infection from direct contact with animals or other 
humans, proper hygiene practices should be applied. At slaughter houses, correct 
manufacturing procedures and good hygiene should be applied according to regulations 
implemented by CFIA to reduce contamination of meat products and carcasses. Schools 
and children visiting farms or petting zoos, must be supervised by adults to ensure that 
proper hand washing is enforced, particularly prior to food consumption (Caprioli, 
Morabito et al. 2005). Food hygiene must also be applied to prevent transmission of 
STEC. This involves the separation of raw and ready-to-eat products to ensure that no 
cross-contamination occurs. The proper cooking of meat, particularly hamburgers and 
other ground meat products, should be implemented in restaurants and house holds. 
If an outbreak occurs, several precautions can be taken to ensure that secondary 
transmission does not occur (Seto, Soller et al. 2007). These include hand washing, 
reducing contact with individuals with diarrhea, avoiding contact with feces, staying 
home from work, or school, when having diarrhea during an outbreak, and thorough 
preparation of food prior to consumption. Individuals with prolonged diarrhea, especially 
hemorrhagic colitis, should consult a physician so that proper diagnosis can be reached 
and further complications can be avoided. In addition, if an STEC infection is discovered, 
the source of infection can be quickly identified to lessen the spread.  
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1.5.4 Vaccines 
Vaccines are another preventative measure that can be taken to reduce the number 
of STEC infections and HUS cases.  The use of Stxs as a vaccine component to induce a 
strong immune response has been tested by several groups. Wen and colleagues 
developed a plant-based oral vaccine, which expressed Stx2 and induced Stx2-specific 
mucosal IgA and Stx2-neutralizing serum IgG (Wen, Teel et al. 2006). When tested in 
mice, this vaccine was able to protect against challenge with STEC. Other toxoid based 
vaccines have also been tested. One candidate used an inactive form of Stx, where a 
couple of amino acids are mutated in the B or A subunit (Yamasaki 2002). A recent study 
has demonstrated that the intranasal vaccination of mice with a HIS-tagged StxB 
including a mutant heat-labile enterotoxin prevented toxemia by STEC (Tsuji, Shimizu et 
al. 2008).  
However, other bacterial components have also been tested as vaccine targets. In 
a number of enteric pathogens such as S.  typhimurium, Shigallae and V. cholerae, 
surface LPS have been shown to induce protective immunity (Gupta, Szu et al. 1992; 
Robbins, Chu et al. 1992; Konadu, Lin et al. 2000). O-specific LPS conjugates are 
designed to induce serum anti-conjugate-IgG antibodies which can inhibit the 
colonization of enteric pathogens (Konadu, Robbins et al. 1994; Robbins, Schneerson et 
al. 1995). The use of O-specific polysaccharide from STEC O157 combined with the 
exotoxin A of Pseudomonas aeruginosa resulted in antibody titers 20-fold higher then the 
control group and appeared to be safe in young children tested (Ahmed, Li et al. 2006). A 
separate group also using the O-specific polysaccharide from STEC O157 combined with 
the exoprotein A of P. aeruginosa, demonstrated how vaccination elicited a 4-fold 
increase in anti-LPS IgG levels within a week in 80% of adult volunteers (Konadu, 
Robbins et al. 1994). This anti-LPS IgG antibody was shown to have bactericidal 
properties. Other studies using detoxified LPS conjugated with a non-toxic version of the 
B subunit of Stx1 were also able to elicite high titers in mice (Konadu, Donohue-Rolfe et 
al. 1999). This serum was then used in in vivo studies and shown to have bactericidal 
properties against STEC O157.  
Lipopolysaccharide was also incorporated in a cocktail liposomal complete-core 
LPS-based vaccine from Gram negative strains E. coli K-12, E. coli R1, Pseudomonas 
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aeruginosa, and Bacteroides fragilis (Bennett-Guerrero, McIntosh et al. 2000). Sera 
collected from vaccinated rabbits reacted against a number of Gram negative bacteria 
including E. coli serotypes O1, O4, O6, O8, O12, O15, O18, O75, O86, O157, and O111 
and numerous other bacteria such as P. aeruginosa, Klebsiella pneumoniae serotype O1, 
O2ab, and O3, B. fragilis, and Bacteroides vulgatus.. However, a disadvantage with this 
method is the possibility of raising cross-protective serum against bacterial species part of 
the normal flora. 
A number of antigen-delivery vehicles have been used to transport important 
antigens for the purpose of developing a protective immune response. One in particular is 
the use of monophosphoryl lipid A containing liposomes composed of 
almitoylphosphatidylcholine, dipalmitoylphosphatidylserine and cholesterol (1: 1: 2, 
molar ratio) (PS-liposome) which induces a significant systemic and mucosal immune 
response (Han, Watarai et al. 1997; Watarai, Han et al. 1998). This method has also been 
tested with STEC, where the oral vaccination of STEC antigens with the PS-liposome 
resulted in a significant increase in IgA and IgG responses in both serum and intestinal 
lavage fluid in mice (Tana, Watarai et al. 2003). Using Caco-2 cells in in vitro 
experiments, the IgA and IgG antibodies present in the intestinal lavages were shown to 
inhibit the adhesion of STEC O157 to the epithelial cells. 
Another method applied for the protection of a host against STEC O157 was the 
use of the Salmonella landau strain as a vaccine component. This Salmonella strain is of 
particular interest because it naturally expresses the O-antigen of STEC O157 and is 
avirulent in mice when given in high doses (Bundle 1985; Conlan, KuoLee et al. 1999). 
Conlen and colleagues demonstrated that the vaccination of mice by gavage with S. 
landau resulted in high titers to both the strain and the O-antigen of STEC O157, which 
persisted for several months. Following challenge with STEC O157, the mice showed 
some evidence of protection from colonization. The down side to this method is that 
protection would be serotype specific due to the nature of the O-antigen. However, this 
study reiterates that a local immune response against STEC O157 can increase the host 
resistance. 
The novel idea of vaccinating animals to protect humans has sparked plenty of 
interest. A number of vaccines have been tested using STEC O157 virulence factors. A 
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study demonstrated how the systemic vaccination of cattle with H7 flagellin reduced the 
colonization and delayed peak bacterial shedding (McNeilly, Naylor et al. 2008). This 
vaccination resulted in high levels of IgG in serum, and high levels of IgA in nasal 
secretion. Interestingly, detectable levels of both IgA and IgG were also found in rectal 
secretions. Dean-Nystrom and colleagues demonstrated that the vaccination of dams 
using intimin was capable of protecting against challenge with STEC O157 (Dean-
Nystrom, Gansheroff et al. 2002). Other potential vaccines have been tested using intimin 
as a component. A group vaccinated rabbits with a STEC strain containing a non-
functional intimin protein that protected against challenge (Agin, Zhu et al. 2005). 
Another study has demonstrated that a plant-based vaccine, including the carboxy-
terminal cell binding domain of intimin, given orally or intraperitoneolly, was proficient 
in reducing fecal shedding in mice challenged with STEC O157 (Judge, Mason et al. 
2004). Although intimin appears to be a potential vaccine component, a cross-protective 
vaccine based on this protein would be challenging, as over 16 different variations have 
been identified throughout STEC serotypes (Garrido, Blanco et al. 2006). 
In 2004 Potter et al, reported that the vaccination of cattle using secreted proteins 
of STEC O157 significantly reduced the numbers of bacteria shed in feces, the numbers 
of animals that shed, and the duration of shedding (Potter, Klashinsky et al. 2004). This 
vaccine has been recently tested in large scale feedlots and the results have been 
promising. A large feedlot study involving 20,556 cattle in 19 different feedlots 
demonstrated how a two-dose vaccination reduced the prevalence of fecal shedding and 
the probability of environmental transmission of STEC O157 (Smith, Moxley et al. 
2008). Another large feedlot trial using the same two-dose vaccination system vaccine, 
showed that vaccination of the majority of cattle within a pen, demonstrated significant 
herd immunity following challenge with STEC O157 (Peterson, Klopfenstein et al. 
2007).  
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2.0 HYPOTHESIS AND OBJECTIVES 
 
2.1 Hypothesis 
 That an E. coli O157:H7 vaccine containing T3SPs and other components 
will be capable of protecting cattle against a broad range of non-O157 STEC 
serotypes.  
 
2.2 Overall goals and rationale  
Our hypothesis is based on results that vaccination with STEC O157:H7 T3SPs is 
protective against colonization of cattle with STEC O157:H7. The majority of non-O157 
STEC serotypes produce A/E lesions, with the assistance of a T3SS that secretes effectors 
required for the colonization of cattle. These serotypes possess the LEE pathogenicity 
island, including all 41 ORFs, where many express proteins shown to play a conserved 
role in pathogenesis. We believe that vaccination with T3SPs from STEC O157:H7 will 
protect against a broad range of non-O157 STEC serotypes. We also believe that a T3SP 
supernatant-based vaccine or a cocktail of recombinant effector-based vaccine will be 
capable of inducing a humoral response which can reduce the number of bacteria shed in 
feces, the number of animals that shed the bacterium, as well as the duration of shedding. 
 
1. To test the cross reactivity of T3SPs of serotypes O26:H11, O103:H2, O111:NM 
and O157:H7. 
2. To develop a cross-protective vaccine against serotypes O26:H11, O103:H2, 
O111:NM and O157:H7. 
 
2.3 Objectives 
1. To characterize secreted proteins found in STEC serotypes O26:H11, O103:H2 
and O111:NM. 
2. Construction of a chimeric Tir protein containing numerous epitopes from non-
O157 STEC serotypes. 
3. To measure the cross-reactivaty and cross-protective properties of a recombinant 
secreted protein vaccine. 
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3.0 GENERAL MATERIALS AND METHODS 
 
3.1 Bacterial strains and growth conditions 
Bacterial strains used in this study included E. coli EDL933 (O157:H7) (Tarr, 
Neill et al. 1989) obtained from a HUS patient and kindly provided by Dr. B Brett Finlay 
(Michael Smith Laboratories Biochemistry & Molecular Biology Microbiology & 
Immunology, Vancouver, BC, Canada) (Table 3.1). All non-O157 STEC serotypes such 
as CL101 (O111:NM), CL9(O26:H11), and N01-2454 (O103:H2) (Karmali, 
Mascarenhas et al. 2003) were kindly provided by Dr. Mohamed Karmali (Laboratory for 
Foodborne Zoonoses Public Health Agency of Canada, Guelph, ON, Canada).  Strains 
were stored at -70
o
C in 30% glycerol and were grown in Luria-Bertani (LB) agar and LB 
broth (DIFCO, Becton-dickinson, Sparks, MD, USA) with the appropriate antibiotics at 
37
o
C with shaking.  
 
3.2 Preparation of competent cells 
Bacterial E. coli strains were grown in 1 L of SOB Medium (contains 20 g/L of 
Bacto Tryptone, 5 g/L of Yeast Extract, 0.58 g/L of NaCl and 19 g/L of KCl followed by 
4.07 g/L of MgCl2 6H2O after autoclaving) at 37
o
C with shaking to an absorbance at 
OD600 of 0.6 (approximately 5.5 hours). The cultures were centrifuged at 4,000 RPM for 
10 minutes at 4
 o
C. The cell pellets were then resuspended in 333.3 mL of RF1 solution 
(contains 12 g/L of RbCl, 9.9 g/L of MnCl2 4H2O, 2.94 g/L of CH3COOK, 1.5 g/L of 
CaCl2 and 150 g/L of glycerol, pH adjusted to 5.8 with 12.01 g/L of CH3CO2H), placed 
on ice for a period of 15 minutes followed by centrifugation at 8,000 RPM for 10 minutes 
at 4
 o
C. The pellets were then resuspended in 80 mL of RF2 solution (contains 2.09 g/L of 
3-(N- morpholino) propanesulfonic acid (MOPS), 1.2 g/L of RbCl, 11 g/L of CaCl2 2H2O 
and 150 g/L of glycerol, pH adjusted to 6.8 with NaOH) and once again placed on ice for 
15 minutes. The volume was then distributed into 1 mL aliquots, flash frozen and stored 
at -70
 o
C.  
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Table 3.1 List of bacterial strains and plasmids used. 
Strain Description  Reference 
STEC strains   
E. coli EDL933 O157:H7 Human clinical isolate (Potter, 
Klashinsky 
et al. 2004) 
CL101 O111:NM Human clinical isolate (Karmali, 
Mascarenhas 
et al. 2003) 
CL9 O26:H11 Human clinical isolate (Karmali, 
Mascarenhas 
et al. 2003) 
N01-2454 O103:H2 Human clinical isolate (Karmali, 
Mascarenhas 
et al. 2003) 
E. coli strains   
DH5 Used for the expression of Leukotoxin 
fused STEC gene 
Laboratory 
stock 
JM109 Used for the expression of histidine-tagged 
STEC genes  
Laboratory 
stock 
M15 Used for the expression of histidine-tagged 
STEC genes 
Laboratory 
stock 
BL21 Used for the expression of GST-tagged 
STEC genes 
Laboratory 
stock 
   
Plasmids   
pQE-30 Prokaryotic cell expression vector Qiagen 
pGEX-5X-1 Prokaryotic cell expression vector Pharmacia 
pAA352-Tir Prokaryotic cell expression vector Laboratory 
stock 
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3.3 Transformation of competent cells 
Competent cells were removed from -70
 o
C and thawed at room temperature. A 
volume of 200 μL of cells was transferred to a 15 mL pre-chilled plastic centrifuge tube.   
The quantity of DNA material to be transformed was added to the centrifuge tube, 
swirled and placed on ice for 30 minutes. Tubes are then heat shocked at 42
 o
C for 90 
seconds without agitation, and placed on ice for 2 minutes. The tubes were then removed 
from the ice and 800 μL of SOC medium [contains 3.6 g/L of glucose, 4.07 g/L of MgCl2 
6H2O, 4.33 of MgSO4 7H2O per L of SOB medium (BIO 101 Inc, Vista, CA, USA)] was 
added. Samples were incubated at 37
 o
C with shaking for 60 minutes, followed by 
centrifugation for 10 minutes at 2,000 RPM. The supernatant was discarded and the pellet 
re-suspended in the remaining supernatant and spread on LB agar with appropriate 
antibiotic. Plates are incubated at 37
 o
C overnight.  
 
3.4 Production of Type III secreted proteins. 
 Type III secreted proteins from all STEC serotypes were prepared essentially as 
described (Li, Frey et al. 2000). Briefly, overnight cultures of bacteria were diluted 100 
fold in M9 minimal medium (Sigma-Aldrich, St. Louis, MO, USA) (Adams 1959) 
supplemented with 4g/L of glucose, 50 g/L of Casamino acids,  NaHCO2, 6.24 g/L of 
MgSO4 and 4.51 g/L of KHCO3.  The cultures were then incubated without shaking at 
37
o
C in a 5% CO2 environment to an absorbance at OD600 of  0.6-0.8.  Cells were 
sedimented by centrifugation and the supernatant concentrated by precipitation with 10% 
Trichloroacetic acid. Samples were incubated with Trichloroacetic acid (111 μL per 1 mL 
of sample) for a period of 60 minutes on ice. Samples are then centrifuged at 15,000 
RPM for 60 minutes and the supernatant solution discarded. The cell pellets were then 
resuspended in an appropriate buffer.  
 
3.5 SDS-PAGE and Western Blot analysis.  
Protein samples where mixed with equal volumes of 2X protein loading dye [100 
mM Tris HCl, 4%  sodium dodecyl sulphate (SDS), 0.2 % bromophenol blue, 20% 
glycerol and 10% mercaptoethanol]. Samples are then heated for 5 min in a boiling water 
bath and loaded into the proper lane of a sodium dodecyl sulphate polyacrylamide gel 
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(SDS-PAGE). Proteins were separated using a power source (Model 250/2.5 BioRad) and 
visualized following staining with Coomassie Brilliant Blue (20% MeOH and 10% 
Glacial Acetic acid and 0.5 g/L of Coomassie Brilliant Blue ) for a period of 30 minutes 
and destained (20% MeOH and 10% Glacial Acetic acid) for 2 hours with regular buffer 
exchange (Laemmli 1970). For Western blot analysis, proteins were transferred to 
nitrocellulose membranes by electroblotting as recommended by the manufacturer 
(BioRad Laboratories). Briefly, the protein separation gels were soaked in transfer buffer 
(3 g/L tris, 1.41 g/L glycine, 20% MeOH) and placed on a nitrocellulose membrane 
(BioRad) with a piece of pre-cut Whatman filter paper on either side. This combination 
was placed in a power supply chamber (PowerPac200, BioRad) with chilled transfer 
buffer. The buffer was then kept cold with an ice filled plastic reservoir. The proteins 
were transferred to the nitrocellulose membrane at a current of 0.3 mA for a period of 45 
minutes. After transfer, the nitrocellulose membrane was placed in block solution (8.8 
g/L of NaCl, 0.2 g/L of KCl, 3 g/L of Tris base and 500 μL of Tween-20, pH adjusted to 
7.4) (TBS-T) with 3 % skim milk for 1 hour at room temperature. After incubation, the 
membrane was washed three times with TBS-T and incubated with primary antibody 
concentration for 1 hour at room temperature. After the incubation, the membrane was 
again washed three times with TBS-T and incubated with secondary antibody (1/2000) 
for 1 hour at room temperature. After the final antibody incubation, the membrane was 
washed once with TBS-T and once with alkaline (AP) buffer (12.11 g/L of Tris base, 
5.84 g/L of NaCl, 1.04 g/L of MgCl2 6H2O, pH adjusted to 9.5). The membranes were 
then incubated for 15 minutes with AP buffer and developed using nitroblue tetrazolium 
(NBT) salt (Sigma) and 5-bromo-4-chro-3-indolyl phosphate (BCIP) (Sigma) (De Jong, 
Van Kessel-van Vark et al. 1985). 
 
3.6 Enzyme-Linked Immunosorbent Assay  
Serological responses were measured using an enzyme-linked immunosorbent 
assay (ELISA) as described (Potter, Klashinsky et al. 2004). Antigen of choice was 
diluted to a concentration of 1 g/L in sodium carbonate buffer (1.5 g/L of NaCO4, 2.93 
g/L NaHCO4, pH adjusted to 9.6), and 100 μL plated per well of a 96-well plate 
(Immulon 2 HB, Thermo) and incubated overnight at 4 
o
C. The next morning, the plates 
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were washed six times with distilled water and blocked for 1 hour at room temperature 
with TBS-T with 1% skim milk. Serum of choice was then serially diluted in TBS-T with 
1% skim milk in four-fold dilutions starting at a dilution of 1:40, and incubated for 2 
hours at room temperature (100 μL per well). After the incubation period, the plates were 
washed six times with distilled water, and incubated for 1 hour with the secondary 
antibody in TBS-T with 1% skim milk (100 μL per well at a dilution of 1/2000). Plates 
were then washed and incubated to desired time with 100 μL of 1 g/L freshly prepared 
para-nitrophenyl phosphate (PNPP) (Sigma) in PNPP substrate buffer [10 mL/L of 
Diethanolamine (Sigma) and 47.61 g/L of MgCl2, with pH adjusted to 9.8 with HCl]. The 
absorbance was read on a microtiter plate reader at 405 nm with reference at 490 nm, 
while the serum titer was calculated by the intersection of least-square regression of A405 
versus logarithm of dilution. 
 
3.7 Expression and purification of HIS-tagged proteins 
An overnight LB culture was inoculated at 1:100 into fresh LB + ampicillin (100 
μg/mL). Culture was grown at 37ºC with shaking to an absorbance at OD600 of 0.6, and 
induced for 3 hrs with 0.1mM isopropyl-β-D-thiogalactopyranoside (IPTG). Bacteria 
were pelleted and HIS-tagged proteins were purified with Ni-NTA slurry (Qiagen) under 
denaturing conditions using the protocol from QIAexpressionist (Qiagen). Briefly, pellet 
is suspended in 5 mL of Buffer A (13.8 g/L of NaH2PO4 H2O, 1.2 g/L of tris base, 573 
g/L of guanidine hydrochloride, with pH adjusted to 8.0 using NaOH) or B (13.8 g/L of 
NaH2PO4 H2O, 1.2 g/L of tris base, 480.5 g/L of urea, with pH adjusted to 8.0 using 
NaOH) and incubated for 1 hour. Cells are centrifuged at 10,000 g for 20 minutes at room 
temperature. Supernatant is mixed with 1 mL of 50% Ni-NTA slurry (Qiagen) per 4 mL 
lysate and placed on a rotary shaker for 1 hour at room temperature. The lysate-resin 
mixture is put through a column and washed twice with 4 mL buffer C (13.8 g/L of 
NaH2PO4 H2O, 1.2 g/L of tris base, 480.5 g/L of urea, with pH adjusted to 6.3 using 
HCl). The HIS-tagged protein is then eluted four times with 0.5 mL of buffer D (13.8 g/L 
of NaH2PO4 H2O, 1.2 g/L of tris base, 480.5 g/L of urea, with pH adjusted to 5.9 using 
HCl) followed by four times with buffer E (13.8 g/L of NaH2PO4 H2O, 1.2 g/L of Tris 
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base, 480.5 g/L of urea, with pH adjusted to 4.5 using HCl). The purity of proteins was 
evaluated by SDS-PAGE using Coomassie Brilliant Blue (Laemmli 1970).  
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4.0 CROSS REACTIVITY OF ENTEROHEMORRHAGIC ESCHERICHIA COLI 
O157:H7-SPECIFIC SERA WITH NON-O157 SEROTYPES 
 
4.1 Introduction  
Shiga toxin-producing Escherichia coli  are significant zoonotic pathogens of 
humans that are capable of causing severe gastrointestinal disease that can lead to a 
number of sequelae, including Hemorrhagic Colitis, HUS (Van Dyck, Proesmans et al. 
1988; Tuttle, Gomez et al. 1999; Karmali, Petric et al. 2004) and TTP (Morrison, Tyrrell 
et al. 1986).  The association between HUS and STEC infection has been well 
documented over the past two decades (Kulkarni, Goldwater et al. 2002)  and is due to 
the production of one or more Shiga toxins which may be produced by the organism, 
alone or in combination (Dean-Nystrom, Gansheroff et al. 2002; Friedrich, Bielaszewska 
et al. 2002; Karmali, Petric et al. 2004).  Hemolytic-uremic syndrome is the most 
common cause of acute renal failure in children.  
The most prominent STEC serotype associated with disease in North America is 
O157:H7 (DeVinney, Stein et al. 1999; Elder, Keen et al. 2000).  The CDC has estimated 
that O157:H7 strains cause approximately 73,000 illnesses and 60 deaths per year in the 
USA, while non-O157 STEC strains cause an additional 37,000 cases (Mead, Slutsker et 
al. 1999). Non-O157 STEC serotypes, commonly associated with human disease, include 
O26:H11, 0103:H2, O111:NM and O113:H21 (Paton, Ratcliff et al. 1996; Karmali, Petric 
et al. 2004).  In many countries, including Australia, Chile and Argentina, non-O157 
STEC serotypes are associated with the majority of HUS cases (Karmali, Petric et al. 
2004).  The incidence of HUS in Argentina has been reported to be 5-10 times higher 
than in North America (Lopez, Diaz et al. 1989) and a recent Italian study demonstrated 
an increase in infections caused by non-O157 serotypes over the past five years (Tozzi, 
Caprioli et al. 2003). Taken together, these observations suggest that STEC strains of 
serotypes other than O157:H7 are an increasing source of disease on a global basis. 
Colonization of the host by STEC strains is mediated through the action of a 
T3SS which delivers effector molecules, including the translocated intimin receptor Tir, 
into host cells (DeVinney, Stein et al. 1999).  The organism subsequently binds to Tir via 
the outer membrane receptor, intimin (DeVinney, Stein et al. 1999; Frankel, Phillips et al. 
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2001).  Many of the genes coding for the structural components of the T3SS, as well as 
effector proteins, are located on the locus of enterocyte effacement (LEE) pathogenicity 
island (McDaniel, Jarvis et al. 1995; Perna, Mayhew et al. 1998).  However, effector 
molecules involved in colonization and disease are also encoded by genes located at other 
sites on the chromosome (Karmali, Mascarenhas et al. 2003). While Type III secreted 
proteins are required for virulence (Donnenberg, Kaper et al. 1997), they have also been 
shown to be targets of the immune system in humans (Li, Frey et al. 2000). These 
proteins are also required for colonization of cattle, the primary reservoir of E. coli 
O157:H7. Certain non-O157 serotypes also produce a T3SS and have been associated 
with cattle (Frankel, Phillips et al. 1998).   
A number of methods are being developed to control levels of E. coli O157:H7 in 
cattle, including the use of probiotics (Zhao, Doyle et al. 1998), bacteriophages (Kudva, 
Jelacic et al. 1999), treatment of drinking water (Rice, Clark et al. 1999) and vaccination 
(Potter, Klashinsky et al. 2004). Vaccination with T3SPs has been shown to reduce 
shedding of the organism under both experimental and field conditions (Potter, 
Klashinsky et al. 2004) and antibodies against structural components of the Type III 
secretion system (EspA) as well as effector molecules (Tir) appear to be associated with 
decreased colonization.  In order to be broadly cross-protective, a vaccine will also need 
to block colonization by non-O157 serotypes.  Thus, the objective of this study was to 
determine the degree of serological relatedness between T3SPs of serogroups O26, O103, 
O111 and O157.  
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4.2 Materials and Methods 
 
4.2.1 Bacterial strains and growth conditions  
Bacterial strains used in this study included E. coli EDL933 (O157:H7) (Tarr, 
Neill et al. 1989), CL101 (O111:NM), CL9 (O26:H11), and N01-2454 (O103:H2) 
(Karmali, Mascarenhas et al. 2003).  Strains were stored at -70
o
C in 30% glycerol and 
were grown on LB agar and LB broth at 37
o
C. All non-O157 STEC strains were kindly 
provided by Dr. M. Karmali (Laboratory for Foodborne Zoonoses, Guelph, Ontario). For 
visualization by immunofluorescence microscopy, strains of all serotypes were 
transformed with plasmid pNR78 which expresses the gene for the green fluorescent 
protein (Quantum Biotechnologies) under the control of the GroEL promoter. 
Recombinant Tir and EspA were produced in E. coli K12 as described (Li, Frey et al. 
2000). 
 
4.2.2 Sequence analysis. 
 Extraction of genomic DNA from E. coli strain N01-2454 was carried out as 
described (Sambrook 1989) and the tir gene was amplified using primers based upon the 
O26:H11 sequence.  The sequence of the forward primer (TirF) and reverse primer (TirR) 
were (5’-GCCTATTGGTAATCTTGGCCACAATCCC-3’) and (5’-   
TAAACGAAACGTGCGGGTCCCGGCGTTG-3’), respectively. Sequences of the PCR 
product were determined using overlapping primers on a CEQ200 model sequencer as 
recommended by the manufacturer (Beckman-Coulter).   
 
4.2.3 Production of Type III secreted proteins 
Type III secreted proteins from all STEC serotypes were prepared essentially as 
described (Li, Frey et al. 2000).  Briefly, overnight cultures of bacteria were diluted 100 
fold in M9 minimal medium (DeVinney, Stein et al. 1999) supplemented with 0.4% 
glucose, 0.1% Casamino acids, 44 mM NaHCO2, 8 mM MgSO4 and 45 mM KHCO3.  
Cultures were then incubated without shaking at 37
o
C in a 5% CO2 environment to an 
OD600 of 0.6-0.8.  Cells were pelleted by centrifugation and the supernatant concentrated 
by precipitation with 10% Trichloroacetic acid dissolved in water. 
 86 
 
4.2.4 SDS-PAGE and Western blot analysis  
Proteins were separated by SDS-PAGE and were visualized following staining 
with Coomassie Brilliant Blue (Laemmli 1970). Proteins were transferred to 
nitrocellulose membranes by electroblotting as recommended by the manufacturer 
(BioRad Laboratories) and as described (Section 3.5).  Western blot analysis was then 
carried out using anti-Tir, anti-EspA and anti-STEC T3SPs antibodies as described 
(Laemmli 1970; Li, Frey et al. 2000). Bovine polyclonal antibodies against serotype 
O157:H7 T3SPs were raised as described (Potter, Klashinsky et al. 2004). Anti-EspAO157 
and anti-TirO157 monoclonal antibodies were acquired from Bioniche Life Sciences 
(Belleville, Canada). 
 
4.2.5 Real-Time reverse transcriptase PCR  
Total RNA from the strains described was prepared using the RNeasy mini kit 
(Qiagen) according to the manufacturer’s protocol. Contaminating DNA was removed by 
treatment with Dnase 1 (Qiagen) in RNeasy mini columns (Qiagen). The RNA 
concentration and integrity was determined by capillary electrophoresis on a Bioanalyzer 
(Agilent Technologies). Oligonucleotides used for quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR) were designed with Beacon designer V2.13 
(PREMIER Biosoft International) and were synthesized by Sigma Laboratories The 
sequence of the forward primer (TirrtF) and reverse primer (TirrtR) were (5’-
TCAGACCTCAACCTCAACTTC-3’) and (5’- 
AATACCCGTCGCCGCCAACCCTATC-3’), respectively. Complementary DNA was 
synthesized using Superscript III Reverse transcriptase (Invitrogen) following priming 
with the oligonucleotides described above. Quantitative RT-PCR and data analyses were 
performed as described (Fortin, Mulchandani et al. 2001). Briefly, The qRT-PCR 
reaction was performed in 96 well plates (BioRad) with the iCycler
TM 
iQ real-time PCR 
detection system (BioRad) for 45 cycles of 95ºC for 15sec, 55ºC for 30 sec and 72ºC for 
30sec after holding for 2 min at 50C and 95ºC, respectively. The qRT-PCR was 
completed using Platinum SYBR green qPCR SuperMix-UDG (Invitrogen). Triplicate 
qRT-PCR reactions were performed for each STEC serotype. After real-time data 
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acquisition, the cycle threshold (CT) value was calculated by determining the point at 
which fluoresce exceeded an arbitrary threshold signal (10-fold higher than base line). 
 
4.2.6 Construction of Tir deletions for the identification of epitope recognized by 
anti-Tir monoclonal antibody 
Three different sized fragments of STEC O157 EDL933 tir gene from the N-
terminus [fragment A = 559 base pairs, fragment B= 1118 base pairs and fragment C= 
1677 base pairs (full sized tir gene)] were initially selected for the identification of the 
epitope recognized by an anti-Tir monoclonal antibody. Primers used for the construction 
of fragments are described in Table 4.1. A copy of each fragment was amplified by PCR 
and cloned into the pUEX1 plasmid (GenBank Accession L08867), which was digested 
with BamHI and PstI for fragment A and B and BglII and PstI for fragment C, followed 
by ligation. Plasmids were transformed and bacteria were grown as described (Howell 
and Hargreaves 1988). 
Eight other deletions in the tir gene were constructed from the N-terminus of the 
Tir protein. These deletions were named N-terminus 100, N-terminus 200, N-terminus 
300, N-terminus 400, N-terminus 220, N-terminus 240, N-terminus 260 and N-terminus 
280 based on the number of deleted base pairs from the 5’ end of the tir gene. Primers 
used for the construction of deletions are described in Table 4.1. All fragments were 
amplified by PCR, digested with BglII and PstI and ligated into the pUEX1 plasmid 
(GenBank Accession L08867). Plasmids were then transformed and bacteria were grown 
as described (Howell and Hargreaves 1988). 
 
4.2.7 Expression of tir deletions  
Cloned fragments of tir were expressed in plasmid  pUEX1 as described (Howell 
and Hargreaves 1988). Briefly, 2 mL cultures were grown overnight at 30ºC. A dilution 
at 1/50 from the overnight culture was made in 10 mL of LB broth and grown with 
shaking to an absorbance at OD600 of 0.6. The bacterial culture was then split into two 5 
mL aliquots and one was placed at 30ºC as the control sample while the other was placed 
at 42 ºC to allow the expression of tir deletions proteins by removing the temperature  
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Table 4.1. Oligonucleotide primers used for the construction of STEC tir deletions. 
Nucleotide sequence is from 5’ to 3’. F= forward primer; R= reverse primer. Primers 
were used for PCR for the construction of fragments. Fragments were digested with the 
appropriate restriction enzymes and cloned into the pUEX1 plasmid (GenBank Accession 
L08867), followed by ligation. Values listed on primer names represent the number of 
deleted nucleotides from the tir gene.  
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repression of the λ promoter. A volume of 1.5 mL of culture was centrifuged for 5min at 
20,000 g to pellet the cells. The pellet was resuspended in 120 μL of 2X loading buffer 
with 10% mercaptoethanol and the sample was boiled for 5 minutes. A total of 3 μL was 
used on a SDS-PAGE gel for Western blot analysis. 
 
4.2.8 Vaccination with Type III secreted proteins 
Vaccines containing T3SPs from the strains described above were prepared by 
formulating 100 µg of total protein with the adjuvant VSA3 as described (Potter, 
Klashinsky et al. 2004).  Groups of 8 six-month old calves were vaccinated twice with 
T3SPs from one of four STEC strains with 21 days between each immunization. The 
placebo group received an identical formulation without antigen (Potter, Klashinsky et al. 
2004).  Serum samples were collected at the time of each immunization as well as two 
weeks following the second vaccination.  The Tir, EspA and T3SP-specific serological 
responses were measured using an ELISA as described (Potter, Klashinsky et al. 2004), 
using T3SPs antigen prepared from homologous and heterologous serotypes.  Differences 
were considered significant at a P-value < 0.05 (Wilcoxon Rank Sum Test) using sera 
collected on day 21. 
 
4.2.9 Adherence Inhibition assays 
             The adherence of STEC O157:H7 and non-O157 serotypes of E. coli to HEp-2 
cells was examined by a modification of the assay of Leverton et al (Leverton and Kaper 
2005). Bacterial strains were subcultured from an overnight culture in LB broth into pre-
warmed DMEM at a 1/50 dilution and this culture was then incubated without shaking 
for a period for 2 hours at 37ºC in 5% CO2. Eight-well chamber slides were seeded with 2 
x 10
5
 HEp-2 cells and incubated overnight at 37ºC in 5% CO2. At the time of infection, 
DMEM was removed from chambers and replaced with a combination of 225 µl of fresh 
DMEM, 25 µL (O157:H7 O103:H2, O111:NM) or 50 µl (O26:H11) of bacterial culture 
and 12.5 µL of homologous or heterologous pre- and post immunization bovine 
antiserum per well. Infections were allowed to proceed at 37ºC in 5% CO2 for 3 hours 
(O157:H7), 3.5 hours (O26:H11) or 4 hours (O103:H2, O111:NM). Slides were washed 6 
times with phosphate-buffered saline and air dried. A coverslip was added and slides 
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were visualized using immunofluorescence microscopy. Homologous and heterologous 
sera used in the Adherence Inhibition assays were collected on day 21 after vaccination.  
A total of eight chambers were prepared per sample and four grids from each were 
selected randomly and bacteria per cell counted. Each data point represents the average of 
these values from a single experiment. 
 
4.2.10 Preparation of STEC O157:H7 acetone powder and its absorption against 
rabbit polyclonal antibody 
              A culture of STEC O157:H7 in LB was grown overnight with shaking at 37ºC. 
Bacterial cells from a 350 mL culture were pelleted, the supernatant removed and pellet 
resuspended in approximately 4 mL of saline. The resuspended culture was transferred to 
ice for 5 minutes. A volume of 16 mL of cold Acetone (Merck) was added to the bacterial 
cell suspension, mixed vigorously and incubated at 0ºC for 30 minutes with occasional 
mixing. The solution was then centrifuged for 10 minutes at 10, 000 x g and the 
supernatant was discarded. The pellet was resuspended in cold Acetone (Merck), mixed 
vigorously and incubated at 0ºC for 10 minutes. The precipitate was collected by 
centrifugation for 10 minutes at 10,000 x g. The pellet was then transferred to a clean 
piece of 3 MM filter paper (Whatman) and the precipitate was spread and allowed to air-
dry 1 hour at room temperature. Any large pieces which did not break into fine powder 
were removed.  
            A total of 0.1 gram of acetone powder was added to 1 mL of rabbit sera 
containing polyclonal antibody raised against STEC O157 T3SPs.  The rabbit sera was 
raised by immunizing female New Zealand white rabbits subcutaneously with one 
millilitre quantity containing 50 μg of STEC O157 T3SPs, and 30% of Emulsigen®- D 
(MVP laboratories). The animals received two boosts, three weeks apart before being 
euthanized. The serum sample containing the acetone powder was placed on a nutator 
(Clay Adams brand) to mix for 30 minutes at 4 ºC. After the 30 minutes, the sample was 
centrifuged for 10 minutes at 10, 000 x g and the supernatant was collected. The 
supernatant was subsequently used in the adherence inhibition assay. 
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4.3 Results 
 
4.3.1 Cross reactivity of Tir and EspA specific antibodies 
 To measure the degree of cross-reactivity of immune responses against T3SPs of 
serotypes O157:H7, O26:H11, O103:H2 and O111:NM, we focused initially on 
measuring responses against EspA, a protein involved in the translocation of effector 
proteins, including Tir. Both monoclonal and polyclonal antibodies specific for serotype 
O157:H7 proteins were used.  The EspAO157 monoclonal antibody was capable of 
recognizing the EspA protein produced by serotypes O26:H11 and O111:NM (Figure 
4.1a), but it did not react with EspA of serotype O103:H2.  An identical result was 
obtained using EspAO157-specific polyclonal antibodies (Figure 4.2a).   
In contrast, a TirO157-specific monoclonal antibody did not react against Tir from any of 
the heterologous serotypes. TirO157-specific polyclonal antibodies did react with Tir from 
all serotypes (Figure 4.2b) albeit to a lesser extent than against the serotype O157:H7 
proteins.  The least reactive T3SPs were those produced by serotype O103:H2, similar to 
the result obtained using the anti-EspA monoclonal antibody (see above).  Although the 
same amount of total protein was used from each serotype, the concentration of 
individual components could have differed due to differences in transcriptional 
regulation.  In order to determine if this was the case, we carried out qRT-PCR analysis 
of tir transcripts and the results showed similar levels of RNA from each serotype (Figure 
4.3). The STEC O26 cycle threshold mean was 16.2, the STEC O103 cycle threshold 
mean was 18.7 and the STEC O111 cycle threshold mean was 22.6.  
 
4.3.2 Identification of the epitope recognized by an anti-Tir monoclonal antibody 
A number of deletions in the Tir protein were constructed to identify the location 
of the Tir epitope recognized by the anti-Tir monoclonal antibody supplied by Bioniche 
Life Sciences. Initially, three constructs were expressed which divided the Tir protein 
into three different sized fragments [fragment A = 559 base pairs, fragment B= 1118 base 
pairs and fragment C= 1677 base pairs (full sized tir gene)] (Figure 4.4). After the 
completion of a Western blot analysis, it was observed that all three fragments reacted  
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Figure 4.1 Western blot analysis using anti-TirO157 and anti-EspA O157 monoclonal 
antibodies against non-O157 STEC serotypes. Proteins were separated by SDS-PAGE, 
transferred to nitrocellulose and probed with anti-EspAO157  (Panel A) and anti-TirO157  
(Panel B)  monoclonal antibodies Lane 1,purified Tir or EspA: lane 2, O26:H11 T3SPs: 
lane 3, O103:H2 T3SPs: lane 4, O111:NM T3SPs: lane 5, O157:H7 T3SPs.  
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Figure 4.2 Western blot analysis using anti-TirO157 and anti-EspA O157 polyclonal 
antibodies against non-O157 STEC serotypes. Proteins were separated by SDS-PAGE, 
transferred to nitrocellulose and probed with  anti-EspA O157 (Panel A) and anti-Tir O157 
(Panel B)  polyclonal antibodies Lane 1, purified Tir or EspA: lane 2, O26:H11 T3SPs: 
lane 3, O103:H2 T3SPs: lane 4, O111:NM T3SPs: lane5, O157:H7 T3SPs.  
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STEC 
Serotypes 
Ct (Cycle Threshold) 
O26:H11 15.9 
O26:H11 16.2 
O26:H11 16.5 
O103:H2 19 
O103:H2 18.5 
O103:H2 18.7 
O157:H7 22.7 
O157:H7 22.7 
O157:H7 22.5 
 
Figure 4.3 qRT-PCR results demonstrating cycle threshold for the transcription of 
the tir gene by three STEC serotypes (O26:H11, O103:H2, O157:H7). Quantitative 
RT-PCR and data analyses were performed as described (Fortin, Mulchandani et al. 
2001). Briefly, The qRT-PCR was performed in 96 well plates (BioRad) with iCycler
TM 
iQ real-time PCR detection system (BioRad) for 45 cycles of 95ºC for 15sec, 55ºC for 
30sec and 72ºC for 30sec after holding for 2 min at 50ºC and 95ºC respectively. qRT-
PCR was completed using Platinum SYBR green qPCR SuperMix-UDG (Invitrogen). 
Triplicate qRT-PCR reactions were performed for each STEC serotype. After real-time 
data acquisition, the cycle threshold (CT) value was calculated by determining the point at 
which fluoresnce exceeded an arbitrary threshold signal (10-fold higher than the base 
line). 
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Figure 4.4. Identification of the epitope recognized by the anti-Tir O157:H7 
monoclonal antibody. Three different sized fragments of STEC O157 EDL933 tir gene 
from the N-terminus [fragment A = 559 base pairs, fragment B= 1118 base pairs and 
fragment C= 1677 base pairs (full sized tir gene)] were initially selected for the 
identification of the epitope recognized by the Tir monoclonal antibody. All three 
fragments reacted with the monoclonal antibody. The lanes at 30ºC represent the control 
samples which are expected to be negative due to repression of the promoter. 42 ºC 
samples allow for the expression of tir deletions by removing the temperature repression 
of the λ promoter. These results demonstrate that the epitope recognized by the Tir 
monoclonal antibody is present on Fragment A. The arrow on the Western blot represents 
migrating path of proteins.  
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with the anti-Tir monoclonal antibody. These results demonstrate that sequence coding 
for the epitope is located on the first 559 nucleotides (fragment A) of the tir gene from 
the 5’ to 3’. 
Based on the above results, we constructed four other tir gene deletions where the 
first 500 nucleotides were deleted 100 nucleotides at a time. These deletions were named  
N-terminus 100, N-terminus 200, N-terminus 300 and N-terminus 400 based on the 
number of deleted base pairs from the 5’ end of the gene.  After constructs were 
expressed and the products analyzed by Western blotting, both the N-terminus 100 and 
N-terminus 200 deletions reacted against the anti-Tir monoclonal antibody, while no 
reactivity was observed with the other two deletions (Figure 4.5). These results 
demonstrate that the starting point of the epitope recognized by the anti-Tir monoclonal 
antibody is between the first 200 and 300 nucleotides of the tir gene from the 5’ end. This 
area is identified on Figure 4.5. 
To further map the position of the epitope, four tir gene deletions between the 
nucleotides 200-300 from the 5’ end of the tir gene were constructed. Each one of these 
deletions eliminated 20 nucleotides from this region of the tir gene. These deletions were 
named N-terminus 200, N-terminus 240, N-terminus 260 and N-terminus 280 based on 
the number of deleted base pairs from the 5’ end of the tir gene. After constructs were 
expressed and the products used in Western blot analysis, it was observed that 3 out of 4 
deletions reacted with the anti-Tir monoclonal antibody, only the N-terminus 280 
fragment failed to react (Figure 4.6). These results demonstrate that the starting point of 
the epitope is located between nucleotides 260-280 of the tir gene. This area is identified 
on Figure 4.6.  
An amino acid sequence alignment was completed on the Tir protein from STEC 
serotype O157, O26, O103 and O111 (Figure 4.7). The entire sequence alignment 
between all serotypes revealed a significant amount of variation, which also appears to be 
evenly distributed. In the region recognized by the monoclonal antibody of the suspected 
epitope is located, a large amount of variability was observed (Figure 4.7B).  
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Figure 4.5. Identification of the N-terminus starting point of the epitope recognized 
by the anti-Tir O157:H7 monoclonal antibody within fragment A. Four Tir deletions 
were constructed based on the reactive fragment A from the N-terminus of the tir gene. 
These deletions were named N-terminus 100, N-terminus 200, N-terminus 300 and N-
terminus 400 based on the number of deleted base pairs from the 5’ end. Two of the four 
deletions reacted with the monoclonal antibody. Although both control samples at 30ºC 
and expression samples at 42 ºC were expressed, only the 42 ºC samples were analysed 
by Western blot. These results demonstrate the epitope recognized by the Tir monoclonal 
antibody starts within 200 bases of the N-terminus of the tir gene. The deletion where the 
epitope begins is highlighted by the black box. The arrow on the Western blot represents 
migrating path of proteins.  
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Figure 4.6. Identification of the N-terminus starting point of the epitope recognized 
by the anti-Tir O157:H7 monoclonal antibody within the N-terminus 200 deletion. 
Four Tir deletions were constructed based on the last reactive Tir deletion from Figure 
4.5. (N-terminus 200). These deletions were named N-terminus 220, N-terminus 240, N-
terminus 260 and N-terminus 280 based on the number of deleted base pairs from the 5’ 
end. Three of the four deletions reacted with the monoclonal antibody. Although both 
control samples at 30ºC and expression samples at 42 ºC were expressed, only the 42 ºC 
samples were analyzed by Western blot. These results demonstrate the epitope 
recognized by the Tir monoclonal antibody starts within 260 bases of the N-terminus of 
the tir gene. The deletion where the epitope begins is highlighted by the black box. The 
arrow on the Western blot represents migrating path of proteins.  
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Figure 4.7. Sequence alignment of Tir protein from STEC O157 and non-O157 
serotypes. A) Whole Tir sequence alignment. Amino acid sequence was aligned for 
serotype STEC O157, O26, O103 and O111 B) Amino acid region (101 AA) representing 
the location of the epitope recognized by the anti-Tir monoclonal antibody. The letters in 
white correspond to the variable amino acids while the green correspond to the 
homologous amino acids. (-) represent missing amino acids for that specific serotype. 
Based on the predicted sequence of the Tir protein for STEC serotype O157 (GenBank 
NC_002655), serotype O103 (GenBank AJ303141), serotype O26 (GenBank AJ277443) 
and serotype O111 (GenBank AF025311). 
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4.3.3 Immunization of cattle with Type III secreted proteins of various STEC 
serotypes  
Since the sera used in the experiment described was directed against only O157 
proteins, cattle were immunized with T3SPs from all four serotypes in order to determine 
individual cross-reactivities.  All groups of cattle demonstrated a significant serological 
response following a single immunization (Figure 4.8), a trend which continued after a 
second dose of vaccine was administered.  The increase in antibody levels ranges from 
23-fold following a single immunization to 69-fold following the boost. When ELISA 
titers were calculated against heterologous T3SPs (Figure 4.9) a different pattern was 
observed.  Animals vaccinated with the O26:H11 proteins did not have a significant titer 
against the heterologous antigens while those animals vaccinated with T3SPs from the 
other three serotypes showed varying degrees of cross reactivity, with the group which 
received the O111:NM vaccine formulation showing the highest degree of cross 
reactivity.  However, all were significantly lower than the response against the 
homologous serotype.  The Tir-specific and EspA-specific responses were also measured 
using antigen produced from serotype O157:H7 (Figure 4.10).  No significant cross 
reactivity was seen for either antigen with the exception of the group that received the 
O157:H7 vaccine formulation. Taken together, these results suggest that there is 
significant antigenic variability in T3SPs produced by these four serotypes.  
 
4.3.4 Adherence Inhibition of STEC serotypes  
Sera collected from cattle vaccinated with T3SPs were also used in a functional 
inhibition assay in order to study its capacity to inhibit adherence of STEC serotypes to  
HEp-2 cells. Hyperimmune sera were able to strongly inhibit the adherence of 
homologous STEC serotypes when compared to the pre-immune sera (Figure 4.11). 
However, when heterologous sera were tested, the level of inhibition was decreased in all 
groups. The greatest degree of inhibition of attachment by heterologous sera was 
observed with O157:H7 strain (Figure 4.11d), while attachment of serotype O111:NM 
was inhibited the least (Figure 4.11c). Overall the capacity of sera to inhibit attachment of 
heterologous strains was significantly lower than for the homologous strain.  These  
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Figure 4.8 Serological responses following vaccination of cattle with Type III 
secreted proteins.  The response against T3SPs of the homologous serotype for each 
vaccinated group was measured by ELISA as described above. (■) Placebo, (▲) O26, 
(▼) O103, (♦) O111, (●) O157. Arrows represent vaccinations given at day 0 and day 21.  
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Figure 4.9 Cross reactivity of sera against Type III secreted proteins from 
heterologous serotypes. Panel a, responses against  O26 T3SPs;  Panel b, O103 T3SPs; 
Panel c, O111 T3SPs; Panel d, O157 T3SPs; (■) Placebo, (▲) O26, (▼) O103, (♦) O111, 
(●) O157. Responses were grouped statistically [A, B, C ; Wilcoxon Rank Sum Test (p < 
0.05)] using sera collected on day 21.  
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Figure 4.10 Reactivity of sera collected from cattle vaccinated with Type III secreted 
proteins from serotypes O26:H11, 0103:H2, O111:NM, and O157:H7 against TirO157 
and EspA O157. (■) Placebo, (▲) O26, (▼) O103, (♦) O111, (●) O157. Responses were 
grouped statistically [A, B; Wilcoxon Rank Sum Test (p < 0.05)] using sera collected on 
day 21.  
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Figure 4.11 Inhibition of colonization of STEC serotypes by homologous and 
heterologous sera raised against T3SPs. Panel a, inhibition of O26 colonization; Panel 
b, inhibition of 0103 colonization; Panel c, inhibition of O111 colonization; Panel d, 
inhibition of O157 colonization; (●) Preimmune sera, (▲) anti-O157, (▼) anti-O26 , (♦) 
anti-O111, (■) anti-O103. [A, B, C ; Wilcoxon Rank Sum Test (p < 0.05)] using sera 
collected on day 21.  
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results further suggest significant antigenic variability within T3SPs of the serotypes 
tested. 
 
4.3.5 Adherence Inhibition of STEC O157 using absorbed and unabsorbed sera 
In order to determine if the adherence inhibition observed was due to T3SPs or 
surface proteins and/or LPS, rabbit serum raised against STEC O157 T3SPs was 
absorbed with acetone powder prepared from STEC O157 whole cells. Both the absorbed 
and unabsorbed rabbit serum were still capable of inhibiting the adherence of STEC 
O157 when compared to the preimmune serum (Figure 4.12). In addition, both the 
absorbed and unabsorbed rabbit serum were used in a Western blot analysis to confirm 
that a reduction in antibody raised against other possible proteins aside from T3SPs was 
removed (Figure 4.13). When the cell lysate was used, a clear difference can be seen with 
both seras tested, where the unabsorbed serum reacts with components of the lysate while 
the absorbed serum does not. Both the absorbed and unabsorbed sera reacted with STEC 
O157 T3SPs in the Western blot. The absorbed serum produced bands that were much 
sharper than those produced by the unabsorbed serum. Overall, these results demonstrate 
that the adherence inhibition observed is mainly due to serum raised against T3SPs. 
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Figure 4.12 Inhibition of colonization of STEC O157 by absorbed and unabsorbed 
rabbit serum raised against STEC O157 T3SPs. Absorbed serum was treated with 
acetone powder made from STEC O157. Panel A, inhibition of O157:H7 colonization 
with unabsorbed rabbit serum; Panel B, inhibition of O157:H7 colonization with 
preimmune serum; Panel C, inhibition of O157:H7 colonization with absorbed rabbit 
serum. 
 
 
 
 
 
 
 
 
 
 
 113 
 
 
 
Figure 4.13 Western blots using absorbed and unabsorbed rabbit serum raised 
against STEC O157 T3SPs. Absorbed serum was treated with acetone powder made 
from STEC O157. A) Western blot using unabsorbed sera B) Western blot using 
absorbed sera.  Lane 1 = cell lysate from STEC O157. Lane 2 = T3SPs from STEC O157. 
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4.4 Discussion 
The objective of this study was to determine the degree of immunological cross 
reactivity between the serotype O157:H7 T3SPs and those of other STEC serotypes. We 
chose to monitor responses against Tir and EspA since they represented both a secreted 
effector and a member of the translocation apparatus, respectively, and have been shown 
to induce immune responses in humans and animals following natural infection and 
vaccination (Martinez, Taddei et al. 1999; Li, Frey et al. 2000; Potter, Klashinsky et al. 
2004). Amino acid homologies for individual members of these two groups of proteins 
range from 60-85% and studies performed in Citrobacter rodentium, which also produces 
attaching and effacing lesions, have suggested functional similarities between the same 
proteins from various species (Deng, Li et al. 2001).  Thus, we expected that there would 
be significant immunological cross reactivity between Tir and EspA from different STEC 
serotypes.  An EspAO157-specific monoclonal antibody was able to cross react with 
protein of all serotypes with the exception of O103:H2 (Figure 4.1a) whereas there was 
significantly less cross reactivity and hence more divergence in the protein when a 
TirO157-specific monoclonal antibody was used. Further evidence of divergence of these 
proteins among the serogroups was shown as the bovine antisera from the non-O157 
serotypes did not react with the O157 Tir and EspA antigens (Figure 4.6).  The Tir0157-
specific monoclonal antibody did not react with the Tir protein from any heterologous 
serotype.   
  Initially it was not well understood if the lack of cross-reactivity with the TirO157-
specific monoclonal antibody was due to antigenic variation or a lack of production of the 
Tir protein by non-O157 serotypes.  The latter explanation for the lack of cross-reactivity 
was disproven, since the use of qRT-PCR showed that all serotypes tested produced 
equivalent levels of the Tir transcripts (Figure 4.3). This was further confirmed as the Tir 
polyclonal antibody produced using O157 T3SPs was capable of reacting with the Tir 
protein from all non-O157 serotypes tested (Figure 4.2). Therefore, these results 
suggested that there is some degree of antigenic variation and not a lack of production of 
the Tir protein. However, the epitope recognized by TirO157-specific monoclonal antibody 
is not known.  
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A number of Tir deletions were constructed and expressed to identify the location 
of the epitope recognized by the Tir monoclonal antibody. Using these deletions we were 
able to pinpoint the possible location of the epitope on all serotypes tested (Figure 4.4, 
4.5, and 4.6). Further investigation of the sequence of the epitope shown on Figure 4.7, 
demonstrates that the differences in antibody reactivity appear to reflect the divergence of 
the epitopes over time. An obvious variability is observed over the entire amino acid 
region of the epitope (Figure 4.7B). A single amino acid difference could be enough to 
prevent the Tir monoclonal antibody from recognizing the epitope in the other Tir 
proteins from the non-O157 STEC serotypes.  A previous study involving evaluation of 
subunit vaccine components from Streptococcus uberis and Streptococcus dysgalactiae 
demonstrated that proteins with 92% identity did not confer cross-protection following 
immunization due to the presence of non-conserved regions containing the protective 
epitopes (Fontaine, Perez-Casal et al. 2002).  Therefore, it is perhaps not surprising that 
cross-reactivity did not occur due to the significant variability between the T3SPs, 
specifically EspA and Tir, of the four serotypes. 
In order to quantify the serological relatedness between the T3SPs produced by 
these four serotypes, antisera were raised in cattle and the degree of cross-serotype 
reactivity determined using ELISA analysis. There was a remarkable lack of cross 
serotype reactivity when sera from immunized groups were tested against secreted 
proteins from the heterologous serotypes (Figure 4.5), suggesting considerable 
divergence of the epitopes of the secreted proteins presented to the immune system.  The 
sera from the group which received the O26:H11 vaccine did not cross-react significantly 
with proteins of any other serotype, suggesting it produced proteins which were most 
divergent. In contrast antisera from O111:NM T3SPs showed significant cross-reaction 
with all other groups. 
The adherence inhibition assay provided a functional method to test the adherence 
inhibition properties of antiserum raised against a specific antigen (Darfeuille-Michaud, 
Forestier et al. 1986; Darfeuille-Michaud, Aubel et al. 1990). In addition, the inability to 
inhibit adherence may be reflected in the ability to inhibit colonization. In this assay the 
use of a bovine intestinal epithelial cell line would have been preferable, but only primary 
cell lines which are uncharacterized were available. Thus, HEp-2 cells were used which 
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are of human origin, but are well characterized and have been used extensively in 
bacterial adherence assays.  A lack of cross-serotype reactivity was observed as the 
heterologous sera was unable to inhibit adhesion to the same extent as homologous sera, 
thus confirming the ELISA results. However, the sera against the O111:NM proteins 
showed the weakest response, while the anti-O157:H7 sera showed the most significant 
cross-inhibition between all groups. This was surprising, since cattle immunized with the 
O111:NM antigens showed the greatest cross-serotype reactivity when measured by 
ELISA, suggesting that the response was due to epitopes not involved in attachment. 
Another possibility for these conflicting results with STEC O111:NM could be that in an 
ELISA the antigens tested are significantly more denatured. Unlike the previous 
experiment, O26:H11 was capable of demonstrating some level of cross inhibition. 
Overall cross-reactivity using heterologous sera was limited between groups, where 
inhibition was only clearly evident when homologous serum was tested. However, there 
are several instances where the levels of serological cross-reactivity with heterologous 
T3SPs by ELISA or adherence inhibition assay, although less than that seen with sera 
against the homologous T3SPs, were significantly greater than the corresponding 
preimmune sera (Figures 4.5 and 4.7).  This was also reflected by the lack of cross-
reactivity against TirO157 and EspAO157 which suggests that other T3SPs were the cross-
reactive components.  Based on the adherence inhibition assays, the use of serotype 
O157:H7 antigens as a platform for measuring cross-reactive response appears to be 
appropriate. 
In order to ensure that the adherence inhibition was due to antibody raised against 
T3SPs and not other components of the bacteria such as cellular debris, LPS and surface 
proteins, that could have contaminated the supernatant, we absorbed the serum raised 
against STEC O157 T3SPs with acetone powder made from whole cells from STEC 
O157. This treatment enabled any antibody present in the sera against contaminating 
factors to attach to the acetone powder. This powder was then centrifuged and removed 
from the serum leaving behind antibody raised against other factors present in the 
supernatant such as T3SPs. The removal of antibody against contaminants was confirmed 
(Figure 4.9) where a clear reduction was seen with the reactivity with whole cell extract. 
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The absorbed sera still functioned like the unabsorbed sera in the inhibition assay 
confirming that the adherence inhibition was a result of antibody against secreted T3SPs. 
A number of potential vaccines have been tested for their ability to reduce 
colonization of cattle by E. coli O157:H7.  These include formulations containing LPS 
(Milon, Esslinger et al. 1992; Conlan, Cox et al. 1999; Conlan, KuoLee et al. 2000) as 
well as intimin (Dean-Nystrom, Gansheroff et al. 2002).  While both have met with some 
success, the serotype-specificity of these molecules suggests that they may have limited 
utility in preventing colonization by non-O157 strains.  Taken together, the data 
described above suggests that this will also be the case for Type III-secreted proteins 
produced by STEC serotypes due to the lack of cross-reactivity obtained, suggesting that 
new approaches to vaccine development will be required if the goal of cross-protection 
against colonization of cattle by multiple STEC serotypes is to be achieved. 
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5.0 VACCINATION OF MICE WITH A RECOMBINANT CHIMERIC TIR 
PROTEIN CONTAINING EPITOPES FROM NON-O157 SEROTYPES  
 
5.1 Introduction 
Shiga toxin-producing Escherichia coli O157:H7 is a zoonotic pathogen 
responsible for numerous outbreaks worldwide. Shiga toxin-producing E. coli O157:H7 
infection can lead to hemorrhagic colitis, resulting in serious complications such as HUS 
and TTP (Karmali, Petric et al. 1983; Morrison, Tyrrell et al. 1986; Karmali, Petric et al. 
2004). Hemolytic-uremic syndrome is a consequence of Shiga toxins produced by STEC, 
which were previously identified in Shigella dysenteriae (Paton and Paton 1998; 
Kulkarni, Goldwater et al. 2002).  Although STEC O157:H7 is the most common 
serotype in North America, non-O157 serotypes are responsible for frequent global 
outbreaks (Gonzalez Garcia 2002; Bielaszewska, Zhang et al. 2007). Improved detection 
and isolation of non-O157 serotypes have identified many non-O157 serotypes as culprits 
in recent outbreaks, which could have been previously misdiagnosed.  
To cause infection, STEC uses a T3SS which allows intimate interaction between 
an epithelial cell and the bacterium. This interaction results in the formation of attaching 
and effacing (A/E) lesions, which are the hallmark of STEC infection (Jarvis and Kaper 
1996; Gyles 2007). The genes responsible for the secretion apparatus are located on a 
pathogenicity island called LEE (Elliott, Sperandio et al. 2000). Several effectors on the 
LEE Island, as well as numerous non-LEE effectors are secreted through the T3SS (Tobe, 
Beatson et al. 2006). One of the most important and best studied LEE effectors is Tir. 
The study of Tir began with the identification of the STEC outer membrane adhesion 
protein called intimin (Jerse, Yu et al. 1990). Initially, it was assumed that intimin bound 
to a 90 kDa host protein called Hp90. However, in 1997 Kenny and colleagues 
discovered that the Hp90 was actually a LEE encoded T3SS effector protein, eventually 
re-named Tir (Kenny, DeVinney et al. 1997). The surprising ability of a bacterial 
pathogen to carry its own receptor was a trait only observed in A/E pathogens.  
Once Tir is translocated through the T3SS, it spontaneously localizes to the 
plasma membrane of the eukaryotic cell (Kenny, DeVinney et al. 1997; Deibel, Kramer 
et al. 1998). This protein contains two trans-membrane domains, which form a surface-
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exposed extracellular loop responsible for binding the intimin protein, while the N and C 
termini are implanted within the eukaryotic cell (de Grado, Abe et al. 1999; Hartland, 
Batchelor et al. 1999; Kenny 1999). The extracellular loop is 104 amino acids long and is 
critical for intimin binding and pedestal formation (de Grado, Abe et al. 1999). Both Tir 
and intimin proteins are dimers, allowing each intimin monomer to bind to a monomer of 
the Tir protein, resulting in an intimate interaction between the bacterium and the host 
cell (Luo, Frey et al. 2000). The intracellular N and C termini of the Tir protein can 
recruit and interact with a number of intracellular host and bacterial proteins. These 
interactions result in actin polymerization and pedestal formation as observed with 
typical STEC infection.  
Ruminants are a natural reservoir of STEC, where they shed the organism 
asymptomatically year round. Cattle are the most studied animal reservoir due to their 
close contact with humans and their ability to indirectly infect people through the 
contamination of water and food products (Caprioli, Morabito et al. 2005). Several 
vaccines aimed at reducing shedding of STEC, based on LEE proteins, have been tested.  
The vaccination of pregnant dams using the LEE protein intimin showed promise as it 
protected against challenge with STEC O157:H7 (Dean-Nystrom, Gansheroff et al. 
2002). However, with over 17 distinct variants of STEC identified, this potential vaccine 
appeared to be serotype specific (Garrido, Blanco et al. 2006). In 2004, Potter and 
colleagues demonstrated that vaccination of cattle with secreted proteins containing LEE 
and non-LEE effectors from STEC O157:H7, was able to significantly reduce the number 
of bacteria shed, as well as the number of shedding animals (Potter, Klashinsky et al. 
2004). However, this vaccination using T3SPs also appears to be serotype specific 
(Asper, Sekirov et al. 2007). Interestingly, vaccination with T3SPs from a ∆tir STEC 
O157 strain did not protect against challenge as effectively as the wildtype strain.  This 
demonstrates that Tir likely plays an important role in protection against STEC O157. 
The Tir protein has also been shown to be highly immunogenic, and commonly reacts 
with sera from HUS patients shortly after onset of STEC infection (Li, Frey et al. 2000; 
Asper, Sekirov et al. 2007). 
In this study we constructed, a chimeric STEC Tir protein, containing the STEC 
O157:H7 Tir protein and several non-O157 immunogenic peptides in order to test its 
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cross-serotype protective properties. These results could produce a potential candidate for 
a recombinant cross-protective STEC vaccine. 
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Materials and Methods 
 
5.2.1 Bacterial strains and growth conditions  
Bacterial strains used in this study included STEC EDL933 (O157:H7) (Tarr, 
Neill et al. 1989), CL101 (O111:NM), CL9 (O26:H11), and N01-2454 (O103:H2) 
(Karmali, Mascarenhas et al. 2003).  Strains were stored at -70
o
C in 30% glycerol and 
were grown in LB broth and on LB agar at 37
o
C. All non-O157 STEC strains were kindly 
provided by Dr. M. Karmali (Laboratory for Foodborne Zoonoses, Guelph, Ontario). 
 
5.2.2 Production of Type III–secreted proteins and rabbit anti-T3SP polyclonal 
antibodies 
Type III-secreted proteins from all STEC serotypes were prepared as described 
(Li, Frey et al. 2000). Briefly, overnight cultures of STEC serotypes were diluted 100-
fold in M9 minimal media with the addition of 0.4% glucose, 0.1% Casamino acids, 44 
mM NaHCO2, 8 mM MgSO4 and 45 mM KHCO3. Cultures were incubated without 
shaking at 37ºC in a 5% CO2 environment to an OD600 of 0.6-0.8. The bacteria were 
pelleted by centrifugation and the secreted proteins present in the supernatant were 
concentrated by precipitation with 10% trichloroacetic acid. One millilitre quantities 
containing 50 μg of STEC T3SPs, and 30% of Emulsigen®- D (MVP laboratories) were 
used to subcutaneously immunize female New Zealand white rabbits. The animals 
received two boosts, three weeks apart, before being euthanized. 
 
5.2.3 Peptide synthesis 
Based on the predicted sequence of the Tir protein for STEC serotype O157 
(GenBank NC_002655), serotype O103 (GenBank AJ303141), serotype O26 (GenBank 
AJ277443) and serotype O111 (GenBank AF025311) thirty-mer peptides with five amino 
acid overlaps were synthesized as described (Fields and Noble 1990) (Table 5.1). All 
peptides were purified to homogeneity by high-performance liquid chromatography.  
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Table 5.1. Sequence of STEC O157:H7 Tir and non-O157 Tir peptides used in this 
study.  All peptides are thirty-mers with 5 amino acid overlaps. Underlined peptides in 
O157 section represent the intimin binding domain. In total seven thirty-mer peptides 
were constructed for each of the non-O157 STEC serotypes (O26:H11, O103:H2 and 
O111:NM). 
 
O157   
1-MPIGNLGHNPNVNNSIPPAPPLPSQTDGAG Tir O157 AA 1-30 
2-TDGAGGRGQLINSTGPLGSRALFTPVRNSM Tir O157 AA 26-55 
3-VRNSMADSGDNRASDVPGLPVNPMRLAASE Tir O157 AA 51-80 
4-LAASEITLNDGFEVLHDHGPLDTLNRQIGS Tir O157 AA 76-105 
5-RQIGSSVFRVETQEDGKHIAVGQRNGVETS Tir O157 AA 101-130 
6-GVETSVVLSDQEYARLQSIDPEGKDKFVFT Tir O157 AA 126-155 
7-KFVFTGGRGGAGHAMVTVASDITEARQRIL Tir O157 AA 151-180 
8-RQRILELLEPKGTGESKGAGESKGVGELRE Tir O157 AA 176-205 
9-GELRESNSGAENTTETQTSTSTSSLRSDPK Tir O157 AA 201-230 
10-RSDPKLWLALGTVATGLIGLAATGIVQALA Tir O157 AA 226-255 
11-VQALALTPEPDSPTTTDPDAAASATETATR Tir O157 AA 251-280 
12-ETATRDQLTKEAFQNPDNQKVNIDELGNAI Tir O157 AA 276-305 
13-LGNAIPSGVLKDDVVANIEEQAKAAGEEAK Tir O157 AA 301-330 
14-GEEAKQQAIENNAQAQKKYDEQQAKRQEEL Tir O157 AA 326-355 
15-RQEELKVSSGAGYGLSGALILGGGIGVAVT Tir O157 AA 351-380 
16-GVAVTAALHRKNQPVEQTTTTTTTTTTTSA Tir O157 AA 376-405 
17-TTTSARTVENKPANNTPAQGNVDTPGSEDT Tir O157 AA 401-430 
18-GSEDTMESRRSSMASTSSTFFDTSSIGTVQ Tir O157 AA 426-455 
19-IGTVQNPYADVKTSLHDSQVPTSNSNTSVQ Tir O157 AA 451-480 
20-NTSVQNMGNTDSVVYSTIQHPPRDTTDNGA Tir O157 AA 476-505 
21-TDNGARLLGNPSAGIQSTYARLALSGGLRH Tir O157 AA 501-530 
22-GLRHDMGGLTGGSNSAVNTSNNPPAPGSHRFV Tir O157 AA 526-558 
O26   
1-RADPKLWLSLGTIAAGLIGMAATGIAQAVA Tir O26 AA 218-247 
2-AQAVALTPEPDDPITTDPDAAANTAEAAAK Tir O26 AA 243-272 
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3-EAAAKDQLTKEAFQNPDNQKVNIDENGNAI Tir O26 AA 268-297   
4-NGNAIPSGELKDDVVAQIAEQAKAAGEQAR Tir O26 AA 293-322 
5-GEQARQEAIESNSQAQQKYDEQHAKREQEM Tir O26 AA 318-347 
6-REQEMSLSSGVGYGISGALILGGGIGAGVT Tir O26 AA 343-372 
7-GAGVTAALHRKNQPAEQTITTRTVVDNQPT Tir O26 AA 368-397 
O103   
1-RADPKLWLSLGTIAAGLIGMAATGIAQAVA Tir O103 AA 218-247 
2-AQAVALTPEPDDPTTTDPDTAASTAEAATK Tir O103 AA 243-272 
3-EAATKDRLTQEAFQDPDKQKVNIDENGNAI Tir O103 AA 268-297 
4-NGNAIPSGELIDDVVAQIAEQAKAAGEQAR Tir O103 AA 293-322 
5-GEQARQEAIESNSQAQKKYDEQHAKREQEM Tir O103 AA 318-347 
6-GEQARQEAIESNSQAQKKYDEQHAKREQEM Tir O103 AA 343-372 
7-GAGVTAALHRKNQPAEQTITTRTVVDNQPT Tir O103 AA 368-397 
O111   
1-RSDPKFWVSIGAIAAGLAGLAATGITQALA Tir O111 AA 229-258 
2-TQALALTPEPDDPTTTDPEQAASAAESATR Tir O111 AA 254-283 
3-ESATRDQLTQEAFKNPENQKVSIDEIGNSI Tir O111 AA 279-308  
4-IGNSIPSGELKDDVVAKIEEQAKEAGEAAR Tir O111 AA 304-333 
5-GEAARQQAVESNAQAQQRYDTQYARRQEEL Tir O111 AA 304-333 
6-RQEELELSSGIGYSLSSALIVGGGIGAGVT Tir O111 AA 354-383 
7-GAGVTTALHRRNQPAEQTTTTTTHTVVQQQ Tir O111 AA 379-408 
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5.2.4 The construction of chimeric Tir proteins 
           Strains EDL933 (O157:H7) (Tarr, Neill et al. 1989), CL101 (O111:NM), CL9 
(O26:H11), and N01-2454 (O103:H2) were used as the source of DNA (Karmali, 
Mascarenhas et al. 2003). The desired DNA was amplified by PCR with unique 
restriction sites and cloned into the pQE-30 plasmid (Qiagen) for the chimeric 6x HIS-
tagged protein (Qiagen) and into the pAA352-Tir plasmid (already has Tir from EDL933 
cloned into the vector) for the Leukotoxin::chimeric Tir fusion (LKt::TirO157non-O157pep) 
protein. Ligations were completed using the Rapid DNA Ligation Kit (Fermentas), and 
plasmids were chemically transformed into E. coli JM105 cells. Primers and restriction 
sites for DNA fragments cloned can be found in Table 5.2. Glycine and serine amino acid 
nucleotide sequences were included in the primers to introduce or increase flexibility of 
the translated protein. 
 
5.2.5 Expression and purification of HIS-tagged chimeric Tir protein.  
An overnight LB culture was inoculated at 1:100 into fresh LB + 100 μg/mL 
ampicillin. Culture was grown at 37ºC with shaking to an OD600 of  0.6 and induced for 3 
hours by the addition of 0.1 mM IPTG (isopropyl-β-D-thiogalactopyranoside). Bacteria 
were pelleted and HIS-tagged proteins were purified with Ni-NTA Agarose (Qiagen) 
under denaturing conditions using the protocol from QIAexpressionist (Qiagen). The 
purity of proteins was assessed by  SDS-PAGE followed by Coomassie Brilliant Blue 
staining (Laemmli 1970).  
 
5.2.6 Expression and purification of Leukotoxin::chimeric Tir protein fusion 
The expression of the LKt::TirO157non-O157pep tir gene was induced by the addition 
of 5 M IPTG and the protein was purified as insoluble aggregates as described (Gerlach, 
Anderson et al. 1992). Briefly, after induction bacterial culture was centrifuged and 
supernatant was discarded. The pellet was re-suspended in a 25% sucrose/50 mM Tris 
solution and placed at -70ºC for 30 minutes.  The cells were then thawed and a lysozyme 
solution (10 mg lysozyme per mL of 0.25 M Tris pH 8.0) was added to the cells and 
incubated on ice for 15 minutes. A total of 30 mL of freshly prepared RIPA/TET was 
added and incubated for 5 minutes. The sample was then sonicated (3 x 30 seconds with  
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Table 5.2. Oligonucleotide primers used for the amplification of STEC Tir and non-
O157 Tir peptides. Nucleotide sequence is from 5’ to 3’. AA-cloned amino acids. All 
four fragments are separated by glycines and serines. F= forward primer; R= reverse 
primer. Primers were used for PCR for the construction of fragments. Fragments were 
digested with the appropriate restriction enzymes and cloned into the pQE-30 plasmid 
(Qiagen) for the chimeric 6x HIS-tagged protein (Qiagen) and into the pAA352-Tir 
plasmid (already has Tir from EDL933 cloned into the vector) for the LKt::TirO157non-
O157pep protein, followed by ligation. Ligations were completed using the Rapid DNA 
Ligation Kit (Fermentas), and plasmids were chemically transformed into E. coli JM105 
cells. 
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1 second pulse, 12 mm probe with max power, Vibra-Cell, Sonics & Materials Inc, 
Dansbury, USA). The solution was then centrifuged for 20 minutes at 12,000 rpm and the 
supernatant discarded.  The pellet containing the aggregated proteins was solubilized in 4 
M guanidine hydrochloride and the concentration of the LKt::TirO157non-O157pep protein 
was estimated following SDS-PAGE and Coomassie Brilliant Blue staining using bovine 
serum albumin standards (BioRad Laboratories) (Laemmli 1970). 
 
5.2.7 SDS-PAGE and Western blot analysis 
Proteins were separated by SDS-PAGE and visualized following Coomassie 
Brilliant Blue staining (Laemmli 1970). Proteins were transferred to a nitrocellulose 
membrane by electroblotting as described by the manufacturer (BioRad Laboratories). 
Western blot analysis was carried out as described in Section 3.5. After blocking, the 
primary STEC Tir O157:H7 monoclonal antibody (Bioniche Life Sciences) was added at 
a dilution of 1/5000 and incubated for an hour. After washes, the secondary antibody 
consisting of phosphatase labelled goat-anti-mouse IgG (Kirkegaard & Perry 
Laboratories) was added at a concentration of 1/2000 and also incubated for an hour at 
room temperature.  After the secondary antibody, the membrane is washed and developed 
using NBT salt and BCIP (Sigma) (De Jong, Van Kessel-van Vark et al. 1985). 
 
5.2.8 Production of rabbit anti-chimeric Tir protein polyclonal antibodies 
One milliliter volumes containing 50 μg of STEC HIS-tagged chimeric Tir 
protein or LKt::TirO157non-O157pep fusion protein with the addition of 30% of Emulsigen
®
- 
D (MVP laboratories) were used to subcutaneously immunize female New Zealand white 
rabbits. Rabbits received two boosts, three weeks apart, before being euthanized. Rabbits 
were bled according to the guidelines provided by the University Council on Animal 
Care (UCAC), under protocol number 1994-213. The collected blood was centrifuged 
and the serum was stored at -20ºC until further use. 
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5.2.9 Enzyme-Linked ImmunoSorbent Assay 
  Enzyme-Linked ImmunoSorbent Assays using rabbit or mouse polyclonal 
antibodies against HIS-tagged chimeric Tir protein or LKt::TirO157non-O157pep protein 
were completed as described (Li, Frey et al. 2000). Briefly, plates (Immulon 2HB, 
Thermo) were coated with antigen overnight at 4ºC. Plates were then blocked for 1 hour 
with nonfat dried milk (CO-OP, Canada) in Tris-Buffered Saline pH 7.6 with the addition 
of 0.05% Tween-20 (Sigma) (TBST). Serial 4-fold dilutions starting at 1/40 were 
completed for primary antibody and incubated for 2 hours at room temperature. After 6x 
H2O washes, phosphatase-labelled goat-anti-rabbit IgG (Kirkegaard & Perry 
Laboratories) or phosphatise-labelled goat-anti-mouse IgG (Kirkegaard & Perry 
Laboratories) at 1/2000 was added and incubated for 1 hour at room temperature, and the 
alkaline phosphate activity was detected with p-nitrophenyl phosphate (PNPP) (Sigma). 
The absorbance was measured at 405 nm using a BioRad model 1350 microplate reader.  
 
5.2.10 Challenge of mice with STEC serotypes following vaccination with a HIS-
tagged chimeric Tir protein        
          A total of 4 groups of 10 Balb/c mice were used in the vaccination trial. Group 1 
and group 3 were vaccinated with 0.1 M PBS and used as placebo groups, while group 2 
and group 4 were vaccinated with 0.5 μg per mouse of the HIS-tagged chimeric Tir 
protein + 30% Emulsigen
®
- D. All groups received two vaccinations 21 days apart. 
Fourteen days following the second vaccination, groups 1 and 2 were challenged orally 
with 10
9
 CFU per mL of nal
r
 E. coli O157 EDL933 strain while groups 3 and 4 were 
challenged with 10
10
 CFU per mL of Amp
r
 E. coli O111:NM strain. Both challenges were 
delivered in 0.1 M PBS with 20% sucrose. Two days prior to challenge, water was treated 
with 5 g/L of streptomycin to remove intestinal flora. Mice were also deprived of food 
and water 18 hours prior to challenge. Fecal samples were collected every 2 days for 2 
weeks after challenge to measure STEC shedding. 
          On average, 0.1 gram of fecal matter was collected from each mouse (3-4 pellets) 
and placed in an Eppendorf tube. One milliliter of LB broth was added to the tube and 
incubated at room temperature for 3 hours to allow pellet to soften. The tubes were then 
vortexed to allow the dispersal of pellets. For group 1 and 2, samples were diluted in PBS 
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to 10
-6
 and plated onto CT-SMAC agar plates (Mackonkey agar + cefiximine 0.05 mg/L 
+ tellurite 2.5 mg/L + nalidixic acid 15 mg/L). For group 3 and 4, samples were diluted in 
PBS to   10
-8 
and plated onto LB-Amp agar plates (ampicillin 10 mg/L). All plates were 
incubated at 37ºC for 18 hours. 
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5.3 Results  
 
5.3.1 Identification of immunogenic STEC O157 and non-O157 Tir epitopes 
  A total of twenty two thirty-mer peptides were constructed for the STEC O157 
Tir protein. These peptides were tested with sera raised against T3SPs from STEC 
serotypes (O157:H7, O111:NM, O26:H11 and O103:H2) to measure their 
immunogenicity. Shiga toxin-producing Escherichia coli O157-specific sera showed the 
highest level of reactivity and reacted with the most peptides (Figure 5.1). Shiga toxin-
producing Escherichia coli O103-specific sera also reacted with a large number of 
peptides while O26- and O111-specific sera showed limited reactivity with the STEC 
O157 Tir peptides. Overall the homologous sera showed the greatest reactivity. 
For each of the non-O157 STEC Tir proteins seven, thirty-mer peptides for the 
intimin binding region were designed and constructed. All peptides were tested against 
O26-, O103-, O111- and O157-specific sera. With all peptides (excluding O26) the 
homologous sera demonstrated the highest levels of reactivity and was capable of 
reacting with most peptides (Figure 5.2).  For the peptides from O26 and O103 serotypes, 
peptide number three was recognized by all sera tested, while O111 and O157 peptides 
demonstrated limited reactivity from heterologous sera. In contrast, the STEC O26 
peptides showed limited reactivity with the homologous sera; where reactivity with 
peptide 3 was lower for O26-specific sera than for the O103-, O111- and O157-specific 
sera tested. The sera tested with peptides from STEC O103, O111 and O157 were able to 
identify individual peptides, which are only recognized by homologous sera. These 
include peptide 5 for O103, peptides 3, 4 and 5 for O111 and peptide 3 for O157. The 
limited reactivity with the O26 peptides could be a result of the titer instead of the 
reactivity against the peptide and could only be properly confirmed by the measure of 
total IgG.  
Interestingly, the pattern of recognized peptides for serotype O26 and O103 was 
nearly identical with the exception of peptide 5 for O103 with all sera tested. The selected 
non-O157 immunogenic peptides for the construction of the chimeric protein are listed in 
Table 5.2. These consist of peptide 5 from O103, peptides 2 and 3 from O26 and peptides 
3, 4 and 5 from O111. This is shown in Figure 5.3. 
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Figure 5.1. STEC O157:H7 Tir epitope mapping. Twenty two thirty-mer peptides with 
5 amino acid overlaps were constructed for the STEC O157:H7 Tir protein. Rabbit anti-
non O157 STEC T3SPs was tested for reactivity against STEC O157:H7 Tir protein 
thirty-mer peptides. Anti-O157 T3SPs rabbit sera; Anti-O26 T3SPs rabbit sera; 
Anti-O103 T3SPs rabbit sera; Anti-O111T3SPs rabbit sera. 
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Figure 5.2. Cross-reactivity of STEC polyclonal antibodies against STEC non-O157 
peptides. Seven thirty-mer peptides were constructed for each of the non-O157 STEC 
serotypes (O26:H11, O103:H2 and O111:NM). A) STEC O26:H11 peptides. B) STEC 
O103:H2 peptides. C) STEC O111:NM peptides. D) STEC O157:H7 peptides Anti-
O157 T3SPs rabbit sera; Anti-O26 T3SPs rabbit sera; Anti-O103 T3SPs rabbit 
sera; Anti-O111T3SPs rabbit sera. 
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Table 5.3. Designated peptides to be fused to with STEC O157:H7 Tir protein. A)  
Selected peptides. Chosen peptides are noted with an X and are as follows: peptide 5 for 
STEC O103; peptide 2 and 3 for STEC O26; peptide 3 to 5 for STEC O111. B) Sequence 
of selected peptides. 
 
 
A) 
 
 
 
STEC  non-O157 peptide 
targets 
Serotypes 
Peptides O103:H2 O26:H11 O111:NM 
1    
2   X  
3   X X 
4   X 
5 X  X 
6    
7    
X= Selected peptides to be used in the chimeric Tir protein 
 
 
B) 
 
Selected Peptides Sequence (Amino Acid) 
Peptide 5 (O103) GEQARQEAIESNSQAQKKYDEQHAKREQEM 
Peptide 2 (O26) AQAVALTPEPDDPITTDPDAAANTAEAAAK 
Peptide 3 (O26) EAAAKDQLTKEAFQNPDNQKVNIDENGNAI 
Peptide 3 (O111) ESATRDQLTQEAFKNPENQKVSIDEIGNSI 
Peptide 4 (O111) IGNSIPSGELKDDVVAKIEEQAKEAGEAAR 
Peptide 5 (O111) GEAARQQAVESNAQAQQRYDTQYARRQEEL 
 
 
 134 
 
 135 
Figure 5.3. Construction of Tir chimeric protein. Diagram of fused chimeric Tir 
proteins. 1) Fragments fused with STEC O157:H7 Tir protein. 2) Fragments fused with 
STEC O157:H7 Tir protein and Leukotoxin. Individual fragments cloned and location of 
glycines (G) and serines (S). tirO157- The entire tir gene from O157:H7. tirO111- 240 bases 
from the STEC O111 tir gene which transcribes peptide 3 to 5 from Table 5.2. tirO26- 165 
bases from the STEC O26 tir gene which transcribes peptide 2 and 3 from Table 5.2. 
tirO103- 90 bases from the STEC O103 tir gene which transcribes peptide 5 from Table 
5.2. Glycine and serine amino acids were cloned in between fragments to allow for 
proper flexibility of chimeric protein. 
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5.3.2 STEC O157:H7 Tir monoclonal antibody tested against chimeric Tir proteins 
  The monoclonal antibody for the STEC O157 Tir protein reacted with all proteins 
tested, including the STEC O157 Tir protein, the chimeric Tir protein, the LKt::TirO157 
fusion protein and the LKt::TirO157non-O157pep protein (Figure 5.4). A clear size difference 
was observed between the wildtype Tir protein and the chimeric Tir protein where the 
chimeric protein had a higher molecular weight in a polyacrylamide gel, due to the 
inclusion of the non-O157 peptides. A similar profile is observed with the 
LKt::TirO157non-O157pep protein (Figure 5.4).  
 
5.3.3 Antibody response of vaccinated rabbits to fused non-O157 Tir peptides 
Rabbit polyclonal antibody raised against the constructed recombinant proteins 
was tested in an ELISA against the chimeric Tir protein and the LKt::TirO157non-O157pep 
protein. Both sera responded well to their respective proteins, where the chimeric Tir 
protein resulted in nearly a four log difference, while the LKt::TirO157non-O157pep protein 
showed a two log difference when compared to the preimmune sera (Figure 5.5). Both 
rabbit sera were also tested against the individual components of the chimeric Tir 
proteins (Figure 5.6). These components consisted of three STEC O111 peptides (PEP 3-
5), two STEC O26 peptides ( PEP 2 & 3) and one STEC O103 peptide (PEP 5) (Table 
5.2) and the native STEC O157 Tir proteins. Both sera, consisting of antisera specific for 
the chimeric Tir protein, and antisera specific for the LKt::TirO157non-O157pep protein, 
responded well to all peptides tested in comparison to the preimmune sera. A significant 
response was also seen when the sera were tested against the STEC O157 Tir protein. 
Overall, the sera raised against the chimeric Tir protein showed greater reactivity to each 
individual peptide than the sera against the LKt::TirO157non-O157pep protein. The difference 
is highlighted with the response observed with peptide 5 from STEC 103 and peptide 5 
from STEC O111. The peptide SN11 was used as a negative control where the rabbit 
titers were the same for all sera tested. 
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Figure 5.4. Immunological reactivity of monoclonal STEC O157 Tir antibody 
against purified chimeric Tir protein and LKt::TirO157non-O157pep protein. All 
proteins were analysed on a 12% SDS-PAGE gel. A) Coomassie stained gel. B) Western 
blot was completed using an STEC O157:H7 anti-Tir monoclonal antibody. 1- 
LKt::TirO157 protein; 2- LKt::TirO157non-O157pep protein; 3- Tir protein; 4- Tir 
protein::non-O157 Tir peptides. 
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Figure 5.5. Antibody titers of vaccinated rabbits against chimeric Tir protein and 
Leukotoxin::Chimeric Tir fusion protein. A) Sera tested against chimeric Tir protein 
containing non-O157 peptides B) Sera tested against Leukotoxin::Chimeric Tir fusion 
protein containing non-O157 peptides. Rabbits were vaccinated with 50 μg of 
recombinant chimeric proteins followed by two boosts, three weeks apart before being 
euthanized. 
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Figure 5.6. Antibody titers of vaccinated rabbits against individual non-O157 
peptides within chimeric Tir protein and Leukotoxin::Chimeric Tir fusion protein. 
A) Peptide 1 [O26]. B) Peptide 2 [O26]. C) Peptide 5 [O103]. D) Peptide 3 [O111] E) 
Peptide 4 [O111]. F) Peptide 5 [O111]. G) peptide SN11 H) STEC O157 Tir protein. 
Rabbits were vaccinated with 50 μg of recombinant chimeric proteins followed by two 
boosts, three weeks apart before being euthanized. 
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5.3.4 Fecal shedding of STEC serotypes after vaccination with a HIS-tagged 
chimeric Tir protein 
Mice were vaccinated with a HIS-tagged chimeric Tir protein and challenged with 
either STEC O157 or STEC O111 to determine if a reduction in shedding could be 
observed after challenge. Placebo groups were also challenged. 
Overall there appeared to be no significant difference between the placebo groups 
and the vaccinated groups following challenge with either STEC O157 or STEC O111 
(Figure 5.7 and Figure 5.8). Throughout the 14 days, both groups vaccinated with the 
HIS-tagged chimeric Tir protein shed equivalent amounts compared to the placebo 
groups. However, differences between the groups challenged with STEC O157 and 
STEC O111 were observed. The level of shedding of STEC O157 decreased significantly 
throughout the trial from roughly 10
9
 to 10
5 
(Figure 5.7). In contrast shedding by the mice 
challenged with STEC O111 appeared to fluctuate within two logs of the initial shedding 
observed on day 2 (Figure 5.8). 
Statistical analysis of mouse fecal shedding was completed by incorporating 
repeated measures using the ANOVA test where the data were summed over time.  The 
sums which were not normally distributed were log transformed and one-way ANOVA 
test was used followed by Tukey’s comparison of means test. Over the duration of the 
study there was no significant difference between the groups.   
 
5.3.5 Immunological response of mice to vaccination with HIS-tagged chimeric Tir 
protein 
 Sera collected from the mice involved in the shedding trial were used in an 
ELISA to test if the mice vaccinated with HIS-tagged chimeric Tir protein seroconverted. 
Overall mice used in both trials in Figure 5.7 and Figure 5.8 were able to successively 
seroconvert after vaccination (Figure 5.9). The mice in the placebo groups did not 
produce significant titers since they were not vaccinated with the chimeric Tir protein. 
The lowest titers were observed on day 0 while the highest on day 48.  
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Figure 5.7. Challenge of mice with STEC O157 following immunization with HIS-
tagged chimeric Tir protein. Two groups of 10 Balb/c mice were vaccinated with 0.5 
μg per mouse. (■) Group 1 received PBS (placebo group); (▲) Group 2 was vaccinated 
with chimeric Tir protein  + 30%  Emulsigen
®
- D. Both groups received two vaccinations 
21 days apart. Two weeks following the last vaccination all mice were challenged with 
100µL oral dose of 10
9
 CFU per mL of Nal
r
 E. coli O157 strain in 20% sucrose. Two 
days prior to challenge, water was treated with 5 g/L of streptomycin to remove intestinal 
flora. Mice were also deprived of food and water 18 hours prior to challenge. Fecal 
samples were collected every 2 days for 2 weeks to investigate STEC shedding following 
vaccinations. 
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Figure 5.8. Challenge of mice with STEC O111 following immunization with HIS-
tagged chimeric Tir protein. Two groups of 10 Balb/c mice were vaccinated with 0.5 
μg per mouse. (■) Group 1 received PBS (placebo group); (▲) Group 2 was vaccinated 
with a chimeric Tir protein + 30% Emulsigen
®
- D. Both groups received two 
vaccinations 21 days apart. Two weeks following the last vaccination all mice were 
challenged with 100µL oral dose of 10
10
 CFU per mL of Amp
r
 E. coli O111 strain in 
20% sucrose. Two days prior to challenge, water was treated with 5 g/L of streptomycin 
to remove intestinal flora. Mice were also deprived of food and water 18 hours prior to 
challenge. Fecal samples were collected every 2 days for 2 weeks to investigate STEC 
shedding following vaccinations. 
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A) 
 
B) 
 
 
Figure 5.9. Serological responses following vaccination of mice with a HIS-tagged 
chimeric Tir. The response against the HIS-tagged chimeric Tir was measured by 
ELISA as in Section 5.2.9. A) Titers from mice challenged with STEC O157; B) Titers 
from mice challenged with STEC O111 (■) Placebo, (▲) chimeric Tir protein. 
Vaccinations were given on day 0 and day 21. 
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5.4 Discussion 
Shiga toxin-producing E. coli is a zoonotic pathogen responsible for worldwide 
outbreaks, resulting in complications such as TTP and HUS. At present, HUS is the 
leading cause of renal failure in children. Shiga toxin-producing E. coli utilize a T3SS to 
attach  to and colonize intestinal epithelial cells of infected hosts. The hallmark of an 
STEC infection is the development of A/E lesions, as result of the intimate interaction 
between the intimin protein and the secreted effector Tir.  
Several studies have reported that Tir is highly immunogenic and capable of 
producing high antibody titers when used as an antigen for vaccination (Asper, Sekirov et 
al. 2007). Interestingly, human sera collected from HUS patients, shortly after the onset 
of an STEC infection, reacted strongly with the Tir protein from STEC O157:H7 (Li, 
Frey et al. 2000). These results demonstrate that Tir could be a potential candidate for a 
recombinant STEC vaccine. To further support this hypothesis, Potter and colleagues 
demonstrated that the vaccination of cattle with T3SPs from a wildtype O157 strain was 
able to reduce the shedding and protect cattle from challenge with STEC O157:H7 
significantly better than T3SPs harvested from a ∆tir STEC O157 strain (Potter, 
Klashinsky et al. 2004).  
A number of vaccines have been tested based on proteins translated from the LEE 
Pathogenicity Island. The STEC receptor, intimin, was shown to protect pregnant dams 
against challenge with E. coli O157:H7 (Dean-Nystrom, Gansheroff et al. 2002). 
However, due to the many identified variants of this protein, protection would be 
serotype specific. Several other LEE encoded proteins have also been tested such as EspB 
(unpublished results) and EspA (Dziva, Vlisidou et al. 2007), which resulted in minimal 
protection against STEC O157:H7 challenge. At present, the Tir protein is a component 
of the STEC O157:H7 vaccine called Econiche® (Bioniche Life Sciences) which is based 
on T3SPs. Although this vaccine works efficiently against STEC O157:H7 challenge, it 
appears to be serotype specific (Asper, Sekirov et al. 2007). To our knowledge, there is 
no STEC vaccine or study which reports the ability to cross-protect against a number of 
STEC serotypes.  
In this study we investigated the protective properties of a chimeric Tir protein 
against STEC serotypes. To construct a cross-protective protein, we initially identified a 
 146 
number of immunogenic peptides containing epitopes unique to a particular serotype 
(Figure 5.2 and Table 5.2). These peptides are unique because they are only recognized 
by the homologous sera. A candidate peptide represents an immunogenic epitope which 
is unique to a particular serotype and distinguishes it from the other serotypes. 
 Using thirty-mer peptides constructed to the entire Tir protein from STEC 
O157:H7, we also identified several peptides which contain immunogenic epitopes 
throughout the entire O157 Tir protein. Previously it was understood that the Tir protein 
was immunogenic (Asper, Sekirov et al. 2007). However, the location of the actual 
immunogenic epitopes had not been identified. Many of these epitopes are also unique 
since non-O157 antisera against T3SPs (which includes Tir) did not recognize many of 
the peptides from the O157 Tir protein. In fact, only antisera against T3SPs from STEC 
O103 demonstrated any considerable reactivity. Another explanation for the difference in 
specificity could result from the length of the peptides used. All the peptides were thirty-
mers with five amino acid overlaps. It is believed that a common epitope ranges from 5 to 
15 amino acids (Flower 2005). One must assume that based on sequence lengths 
involving the addition or deletion of amino acids throughout the Tir sequence of STEC 
serotypes, some epitopes could have landed in between the 5 amino acid overlaps. This 
would result in a false negative since the epitope would be split. Overall, these results 
suggest that there is a considerable level of diversity among the Tir protein specifically 
the intimin binding domain from STEC serotypes. 
All non-O157 peptides constructed for this study were selected from the intimin 
binding domain. This segment was selected because it is the only region of the Tir protein 
which is exposed on the outside of the infected intestinal epithelial cell, and is also the 
intimin binding site. It is possible that by raising an antibody response against this region, 
it may possibly bind and block the intimate attachment between Tir and intimin, which is 
critical for the colonization and the development of A/E lesions. After the identification 
of a number of unique immunological peptides from serotypes other than O157, we 
constructed a chimeric Tir protein and were able to demonstrate that sera from vaccinated 
rabbits reacted with each individual peptide, and the entire Tir protein from the STEC 
O157 serotype (Figure 5.5 and Figure 5.6). This provided evidence that the chimeric 
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protein had the potential to be a vaccine candidate that would confer protection against a 
number of serotypes. 
Initially two chimeric proteins were constructed. They were identical except that 
one was fused to leukotoxin. Leukotoxin is the lktA gene product from Mannheimia 
haemolytica which has been shown to have adjuvant properties (Hughes, Campos et al. 
1992). The fusion of leukotoxin with other proteins has shown to provide a simple 
antigen-adjuvant formulation that not only acts at the same site as the antigen, but can 
also target antigen presenting cells (Hughes, Campos et al. 1992; Hughes, Campos et al. 
1994). In spite of this both proteins produced significant titers in vaccinated rabbits, the 
HIS-tagged chimeric Tir protein was selected for the mice vaccination trial because of 
superior overall titers to the individual non-O157 peptides. Therefore in this case the 
leukotoxin did not confer immunogenicity  
The STEC O157 Tir protein has been shown to be highly immunogenic. This 
protein is also believed to play a protective role since T3SPs from a STEC O157 Tir 
mutant did not protect against challenge as well as the T3SP from the wildtype (Potter, 
Klashinsky et al. 2004; Asper, Sekirov et al. 2007). However, in this study, we have 
shown that the vaccination of mice with a HIS-tagged chimeric Tir protein which 
includes the entire STEC O157 Tir protein and a number of non-O157 peptides 
containing immunogenic epitopes does not protect against STEC O157 and STEC O111 
challenge in the streptomycin-treated mice model. The lack of protection was not due to 
failure to recognize the protein as mice vaccinated with the HIS-tagged chimeric protein 
seroconverted (Figure 5.9). However, as described, similar results have been observed 
with other LEE proteins such as EspA, EspB and intimin, as well as  STEC colonization 
factors such as Efa1, where a strong antibody titer was induced, but protection was not 
observed (Dziva, Vlisidou et al. 2007; van Diemen, Dziva et al. 2007).  
Based on the limited protection following vaccination with the HIS-tagged Tir 
protein, one can speculate that the protection seen with the Econiche® (Bioniche Life 
Sciences) vaccine could result from the cumulative effect of a number of immunogenic 
secreted proteins present in the bacterial supernatant used for vaccination.  To further test 
this hypothesis, the identification of immunogenic proteins present in the supernatant 
need to be identified. 
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6.0 SEROLOGICAL RESPONSE OF SHIGA-TOXIN PRODUCING 
ESCHERICHIA COLI TYPE III SECRETED PROTEINS IN VACCINATED 
RABBITS, NATURALLY INFECTED CATTLE AND HUMAN SERA 
 
6.1 Introduction 
Shiga toxin-producing Escherichia coli is an important zoonotic pathogen 
responsible for hemorrhagic colitis, TTP and HUS (Karmali, Petric et al. 1983; Morrison, 
Tyrrell et al. 1986; Karmali, Petric et al. 2004). Hemolytic-uremic syndrome is attributed 
to the action of Shiga toxins (Stx1 and Stx2), initially identified in Shigella dysenteriae, 
produced by STEC either alone or in combination, (Paton and Paton 1998; Kulkarni, 
Goldwater et al. 2002). Hemolytic-uremic syndrome is also the leading cause of acute 
renal failure in children worldwide. 
The most common STEC serotype in North America is O157, where an estimated 
73,000 illnesses occur each year in the United States resulting in 2000 hospitalizations 
and 60 deaths (Mead, Slutsker et al. 1999). The most frequent non-O157 serotypes 
responsible for disease are O26, O103, O111 and O145 with numerous outbreaks 
reported worldwide. In Denmark it is estimated that 68% of STEC infections resulted 
from non-O157 serotypes (Nielsen, Scheutz et al. 2006). It is also estimated that 58% of 
all cases in Argentina, which has the highest reported frequency of HUS worldwide, 
result from non-O157 serotypes (Lopez, Diaz et al. 1989; Su and Brandt 1995). 
Cattle are the main reservoir for STEC where the organism is asymptomatic, 
resulting in year round shedding. Colonization of both cattle and human hosts is mediated 
through the action of effector molecules secreted through a T3SS (Jarvis and Kaper 1996; 
Gyles 2007). These effectors contribute to the formation of (A/E) lesions, which are the 
hallmark of STEC infection (Jerse, Gicquelais et al. 1991). The genes which express the 
structural proteins of the T3SS and many of its effectors are located on a pathogenicity 
island called LEE (Elliott, Sperandio et al. 2000). Many of these proteins such as Tir , 
EspA, EspB and EspD are critical for the virulence of STEC (Gyles 2007). The recent 
discovery of non-LEE effectors such as NleA, TccP and NleB, whose genes are located 
in small pathogenicity islands and prophages, emphasize the important role effectors play 
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in the colonization and virulence of STEC (Gruenheid, Sekirov et al. 2004; Kelly, Hart et 
al. 2006; Tobe, Beatson et al. 2006; Roe, Tysall et al. 2007).  
A number of experimental vaccines based on LEE proteins have been tested. The 
vaccination of  pregnant dams using intimin from STEC O157 protected suckling piglets 
against challenge (Dean-Nystrom, Gansheroff et al. 2002), yet a cross-protective vaccine 
based on this protein would be challenging, as over 17 serologically distinct variants have 
been identified (Garrido, Blanco et al. 2006). Potter and colleagues demonstrated that 
vaccination with secreted proteins from STEC O157:H7 was able to significantly reduce 
the number of bacteria shed, as well as the number of shedding animals in an 
experimental setting (Potter, Klashinsky et al. 2004). However, vaccination using T3SPs 
appears to be serotype specific (Asper, Sekirov et al. 2007). At present, the repertoire of 
T3SPs in the supernatant which are harvested for vaccination, as well as their 
immunogenic properties, are unknown. In a natural infection, it is also unclear which 
T3SPs are secreted by STEC and recognized by cattle and human hosts. 
In this study we have cloned and expressed the genes coding for 66 structural and 
effector proteins which include 37 LEE-encoded proteins and 29 non-LEE effectors to 
assess their immunological cross-reactivity using sera from vaccinated and naturally 
infected animals as well as human sera from HUS patients.  These studies could identify 
potential candidates for a recombinant STEC vaccine.  
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6.2 Materials and Methods   
 
6.2.1 Bacterial strains and growth conditions 
Bacterial strains used in this study included E. coli EDL933 (O157:H7) (Tarr, 
Neill et al. 1989), CL101 (O111:NM), CL9 (O26:H11), and N01-2454 (O103:H2) 
(Karmali, Mascarenhas et al. 2003).  Strains were stored at -70
o
C in 30% glycerol and 
were grown in LB agar and LB broth at 37
o
C. All non-O157 STEC strains were kindly 
provided by Dr. M. Karmali (Laboratory for Foodborne Zoonoses, Guelph, Ontario).   
 
6.2.2 Cloning of LEE and non-LEE genes 
           The STEC O157:H7 strain EDL933 was used as the source of DNA. The desired 
region of chromosomal DNA was amplified by polymerase chain reaction (PCR), 
allowing for the introduction of unique restriction sites cloned into the pQE-30 plasmid 
(Qiagen) for 6x HIS-tagged proteins (Qiagen) and the pGEX-5X-1 plasmid for 
Glutathione S-transferase (GST)-fused proteins. Ligations were completed using the 
Rapid DNA Ligation Kit as described by the manufacturer (Fermentas). Plasmids were 
chemically transformed into E. coli JM105 cells (pQE-30) and E. coli BL21 cells (pGEX-
5X-1). Primers and restriction sites for genes cloned can be found on Table 6.1. 
 
6.2.3 Expression and purification of HIS-tagged LEE and non-LEE proteins 
An overnight LB culture was inoculated at 1:100 into fresh LB supplemented with 
ampicillin (100 μg/mL). The culture was grown at 37ºC with shaking to an OD600 of 0.6, 
and induced for 3 hours with 0.1 mM IPTG (isopropyl-β-D-thiogalactopyranoside). 
Bacteria were pelleted and HIS-tagged proteins were purified with Ni-NTA Agarose 
under denaturing conditions using the protocol from QIAexpressionist (Qiagen). The 
purity of proteins was assessed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) followed by Coomassie Brilliant Blue staining (Laemmli 
1970).  
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Table 6.1. Oligonucleotide primers used for the amplification of LEE and non-LEE 
genes. Nucleotide sequence is from 5’ to 3’. Restriction sites incorporated into the 
primers are listed. *=GST fused genes.  
 
Genes   Sequence 
 
Restriction 
site 
LEE genes  
ler F CGCGGATCCCGGAGATTATTTATTATGAATATGGAAAATAATTCAC BamHI 
  R 
CCCAAGCTTTTAAATATTTTTCAGCGGTATTATTTCTTCTTCAGTGT
CC HindIII 
orf2 F CGCGGATCCATAACGATAACTGAGCTGGAAGATG BamHI 
  R CCCAAGCTTCTATTTATTATTAATCCTGATTCGC HindIII 
cesA/B F CGCGGATCCAGTATTGTGAGCCAAACAAGAAATAAAG BamHI 
  R CCCAAGCTTTCATACTATTTTTCTATTATTTCTATTCCG HindIII 
orf4 F CGCGGATCCACAATTTTTAATAAAATAGAC BamHI 
  R CCCAAGCTTTCATAAAGTTTCATAAGGC HindIII 
orf5 F CGCGGATCCCTTACAGAAGATATCATACCAGAGG BamHI 
  R CCCAAGCTTTCATTCCTGAATAATGCTAAG HindIII 
escS* F CGCGGATCCCC GTTATCGGTATTATTATTAGTCTGG BamHI 
  R ACGCGTCGACTTAGCCGTTCACCTTCGGAATC SalI 
escT F CGCGGATCCAATGAGATAATGACGGTCATAGTATC BamHI 
  R CCCAAGCTTTCACTCATTAATCATGCTCGGTAAC HindIII 
rorf13 F CGCGGATCCAAAAAAATAATACTGAGCATCATTCTC BamHI 
  R CGCGGATCCAAAAAAATAATACTGAGCATCATTCTC HindIII 
grlR F CGCGGATCCATTATGAAGGATGGCATCTATAGC BamHI 
  R CCCAAGCTTTTATTTTAAATAAACTTGTGGCATTCCTGTG HindIII 
grlA F CGCGGATCCGAATCTAAAAATAAAAATGGCGAC BamHI 
  R CGCGGATCCGAATCTAAAAATAAAAATGGCGAC HindIII 
cesD F CGCGGATCCAGCAGGAAATTTAGCTCTCTAG BamHI 
  R CCCAAGCTTTTACTCTGTATTACCTAAC HindIII 
escC F CGCGGATCCAAAAAAATAAGTTTTTTTATTTTTACAGCACTATTTTGCTGCAGTGCACAAGCTGCCCC BamHI 
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  R CCCAAGCTTTTATTCGCTAGATGCAGATTTTATCGGGGTTGCTTTAATTAAAAAGAGTCGAACAAC HindIII 
sepD F CGCGGATCCAACAATAATAATGGCATAGCAAAGAATG BamHI 
  R CCCAAGCTTTTACACAATTCGTCCTATATCAGAAAAC HindIII 
escJ F CGCGGATCCAAAAAACACATTAAAAACCTTTTTTTATTGGCTGC BamHI 
  R CCCAAGCTTTTACCCGTCCTGTCCTGAGGATGACTTGATAACAAC HindIII 
orf8 F CGCGGATCCGATGTATTATGCCCTTGCCTCTTTCATAAAAAG BamHI 
  R CGCGGATCCGATGTATTATGCCCTTGCCTCTTTCATAAAAAG HindIII 
sepZ F CGCGGATCCGAAGCAGCAAATTTAAGTCCTTC BamHI 
  R CCCAAGCTTTTAGGCATATTTCATCGCTAATGCAC HindIII 
orf12 F CGCGGATCCAATCTTTTAGTTAAAAGAAACGTTG BamHI 
  R CCCAAGCTTTCATGATGTCATCCTGCGAACG HindIII 
escN F CGCGGATCCATTTCAGAGCATGATTCTGTATTG BamHI 
  R CGCGGATCCATTTCAGAGCATGATTCTGTATTG PstI 
orf15 F CGCGGATCCTTGGACAGAATTTTATCTATTCGT BamHI 
  R CCCAAGCTTCTAGTCAAAGTAATGTTCCTTTATGGC HindIII 
orf16 F CGCGGATCCGCTTCTTTATGGAAGAGATTGTTTTACTCCTCGGG BamHI 
  R CCCAAGCTTTTAATTTTCATATTCAATTGTGAACTCAATGGC HindIII 
sepQ F CGCGGATCCAAGCCATTGAGTTCACAATTG BamHI 
  R CCCAAGCTTTTAATCACATACTATGCTAACAG HindIII 
espH F CGCGGATCCTCGTTATCAGGAGCGGTATTCAAG BamHI 
  R CCCAAGCTTTCATAATACGCTATAAGAGGAAGC HindIII 
cesF F CGCGGATCCAATGAGAAATTTCGCACAGACCTTG BamHI 
  R CCCAAGCTTTCAAGGTAAAAAATCTGTAGGTCTGG HindIII 
map F CGGGGTACCTTTAGTCCAATGACAATGGCAGGC KpnI 
  R CCCAAGCTTCTACAATCGGGTATCCTGTACATG HindIII 
tir F CGGGGTACCCCTATTGGTAATCTTGGTCATAATC KpnI 
  R CCCAAGCTTTTAGACGAAACGATGGGATCCC HindIII 
cesT F CGCGGATCCTCATCAAGATCTGAACTTTTATTAG BamHI 
  R CCCAAGCTTTTATCTTCCGGCGTAATAATG HindIII 
escD F CGCGGATCCTTATCCTCATATAAAATAAAAC BamHI 
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  R CGCGGATCCTTATCCTCATATAAAATAAAAC HindIII 
sepL F CGCGGATCCGCTAATGGTATTGAATTTAATC BamHI 
  R AAACTGCAGTCAAATAATTTCCTCCTTATAGTCG PstI 
espA F CGCGGATCCGATACATCAAATGCAACATCCGTTG BamHI 
  R AAACTGCAGTTATTTACCAAGGGATATTGCTG PstI 
espD F CGCGGATCCCTTAACGTAAATAACGATACCCTG BamHI 
  R CGGGGTACCTTAAATTCGGCCACTAACAATACG KpnI 
espB F CGCGGATCCAATACTATTGATAATACTCAAGTAACGATGG BamHI 
  R AAACTGCAGTTACCCAGCTAAGCGACCCGATTGCCCC PstI 
cesD2 F CGCGGATCCGTCGATACGTTTAATGATGAAGTG BamHI 
  R AAACTGCAGTTAACTATTTACGTTCATTACGAACC PstI 
escF F CGCGGATCCAATTTATCTGAAATTACTCAAC BamHI 
  R CCCAAGCTTTTAAAAACTACGGTTAGAAATGG HindIII 
orf29 F CGCGGATCCGTTAATGATATTTCTGCTAATAAGATACTGG BamHI 
  R AAACTGCAGTTAAAATCCTCGTACCCAGCCACTACC PstI 
espF F CGCGGATCCCTTAATGGAATTAGTAACGCTGC BamHI 
  R CCCAAGCTTTTACCCTTTCTTCGATTGCTCATAGG HindIII 
rorf1* F CGCGGATCCCCTCACCTCAAGAACACTCACTTTC BamHI 
  R ACGCGTCGACTTACTTATTAGGGACAAATTTC SalI 
espG F CGCGGATCCATACTTGTTGCCAAATTGTTC BamHI 
  R AAACTGCAGTTAAGTGTTTTGTAAGTACGTTTCAGATGCGG HindIII 
        
Non-LEE genes  
nleA F GGAAGATCTAACATTCAACCGACCATACAATC BglII 
  R TCCCCCCGGGTTAGACTCTTGTTTCTTGG XmaI 
nleB F CGCGGATCCTTATCTTCATTAAATGTCCTTCAATCCAGC BamHI 
  R CCCAAGCTTTTACCATGAACTGCAGGTATACATACTG HindIII 
nleB-1 F CGCGGATCCCTTTCACCGATAAGGACAACTTTC BamHI 
  R CGGGGTACCTTACCATGAACTGCATGTATACTG KpnI 
nleC F CGCGGATCCAAAATTCCCTCATTACAGTCCAAC BamHI 
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  R CCCAAGCTTTCATTGCTGATTGTGTTTGTCCAC HindIII 
nleD F CGCGGATCCCGCCCTACGTCCCTCAACTTGGTATTAC BamHI 
  R CCCAAGCTTCTAAAGCAATGGATGCAGTCTTACCTG HindIII 
nleE F 
CGCGGATCCATTAATCCTGTTACTAATACTCAGGGCGTGTCCCCTATAAATACTAAATATGCTGAACAT
G BamHI 
  R CCCAAGCTTCTACTCAATTTTAGAAAGTTTATTATTTATGTATTTCATATAACTGTCTATTTCCCCAGGC HindIII 
nleF F CGCGGATCCTTACCAACAAGTGGTTCTTCAGC  BamHI 
  R CCCAAGCTTTCATCCACATTGTAAAGATCCTTTG HindIII 
nleG F CGCGGATCCCCTGTCATATTAAACTTTTCGAGTG BamHI 
  R CCCAAGCTTTCAAATTCTAGTGCATATATTTTGTGTGGC HindIII 
nleH1-1 F CGCGGATCCTTATCGCCCTCTTCTATAAATTTGGGATGTTCATGG BamHI 
  R CCCAAGCTTTTATATCTTACTTAATACTACACTAATAAGATCCAGC HindIII 
nleI F CGCGGATCCCAGGTTCTTCGTGCTCAAATGG BamHI 
  R CCCAAGCTTTCATAAATACATTGTTCTTGAC HindIII 
nleG2-1 F CGCGGATCCAATGTCCTTCGAGCTCAAGTAGCATCTAG BamHI 
  R CCCAAGCTTTTAACTATCTTTTATAATGAAGTTTCCC HindIII 
nleG2-2 F CGCGGATCCCCATTAACCTCAGATATTAGATCAC BamHI 
  R CCCAAGCTTTCAATTACCCTTTATAACGAAGTTTCC HindIII 
nleG3 F CGCGGATCCGTAATGCCTGGATTAGTATC BamHI 
  R CCCAAGCTTTTAATGCAATTGAAATAAATAAG HindIII 
nleG5-1 F CGCGGATCCCCTGTAGATTTAACGCCTTATATTTTACCTGGG BamHI 
  R CCCAAGCTTTTAATTTTTTAAAACGAAGTTACCTCTGTCAGGG HindIII 
nleG6-1 F CGCGGATCCCCTGTTACCACCTTAAGTATCCC BamHI 
  R CGGGGTACCTCACTTACAACAAAAAGCTTCTC KpnI 
nleG8-2 F CGCGGATCCCCAGTCATATTAAATTTTTCTAATGGAAGTG BamHI 
  R CCCAAGCTTTTAAATACTGTTTTGTTGAAGTGGGTATATG HindIII 
nleG9 F CGCGGATCCGACGCTTTTATTGTAGATCCTGTTC BamHI 
  R CCCAAGCTTCTACACTGAATAACAATCACTCC HindIII 
espK F CGCGGATCCATGCTTCCTACATCGCAATTACGAC BamHI 
  R CCCAAGCTTTTAAGAATATTTATATGTGGAACCAGAG HindIII 
espL2 F CGGATCCCCAATAATAAACAAATCGGCATCAAATTATG BamHI 
 155 
  R CCCAAGCTTTCAATTGGAATAATAATTATATACATCGAGG HindIII 
espM2 F CGCGGATCCCCGATGAATACTACAGGTATGTC BamHI 
  R CCCAAGCTTTCATCCCTGTATAGCACGCATC HindIII 
espR1 F CGCGGATCCAAATTCCCTTCAATATTTAACAAAATAAAACC BamHI 
  R CGGGGTACCTTAGTGATAAAAAGGCCATGAGCTGGAGG KpnI 
tccp F CGCGGATCCATTAACAATGTTTCTTCACTTTTTCC BamHI 
  R CCCAAGCTTTCACGAGCGCTTAGATGTATTAATG HindIII 
espV F CGCGGATCCAGCGGAACCTCAGGTTCCTCG BamHI 
  R CCCAAGCTTTCACAAAAAAGATTGGGGAGG HindIII 
espW F CGCGGATCCCCCAAAATATCATCAGTTGTATCATC BamHI 
  R CCCAAGCTTTTAATTTCTAACCAAGGGGTCCCATG HindIII 
espX2 F CGCGGATCCGATTGTTCAAAATGCAATGGTTATG BamHI 
  R CCCAAGCTTTTACAGCCATGCGTCTGGCGTCCAC HindIII 
espX7 F CGCGGATCCAAACATATAGAAGGTTCCTTTCCTG BamHI 
  R CGGGGTACCTCAACGCCACGCAACAGGATAATAC KpnI 
espY1 F CGCGGATCCAAAGTATCAGTTCCAGGCATGC BamHI 
  R CCCAAGCTTTCATTCAATAATTGCGTTGTCAG HindIII 
espY2 F CGCGGATCCAAAGTAAGAAACCCAGAACAGATTAG BamHI 
  R CCCAAGCTTTCAGTCATACCAACGGCTATTGTTCG HindIII 
espY3 F CGCGGATCCATGAAAACCATCACCAAACAACCG BamHI 
  R CCCAAGCTTTCAGTCGACGAACTCATAATAATTGCTC HindIII 
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6.2.4 Expression and purification of GST fusion proteins 
Glutathione S-transferase fusion proteins were expressed and purified as 
described (Johnson, Osheim et al. 2004). Briefly,  500 mL LB + ampicillin (100 μg/mL) 
+ chloramphenicol (50 μg/mL) was inoculated with 3 mL of an overnight culture 
containing the desired plasmids in BL21 cells. Bacteria were grown at 37ºC with shaking 
to an absorbance of 0.2 at 600 nm, where IPTG was added at a concentration of 0.25 mM 
and cultures were incubated for an additional 3 hours at 30ºC. Bacteria were sedimented 
by centrifugation, and resuspended in binding buffer (540 mM NaCl, 2.7 mM KCl, 10.15
 
mM Na2HPO4, 1.75 mM KH2PO4, 10 mM MgCl2, 1% [vol/vol] Triton
 
X-100, 50 µg of 
DNase I, 30 µg/mL PMSF, 1
 
µg/mL aprotinin 1 µg/mL pepstatin A,
 
10 µg/mL leupeptin 
[pH 7.4), followed by sonication (3 x 30 seconds with 1 second pulse, 12 mm probe with 
max power, Vibra-Cell, Sonics & Materials Inc, Dansbury, USA). Glutathione S-
transferase fused proteins were purified by adding 1 mL of 1:1 slurry of Glutathione 
Sepahrose 4B beads (Amersham) in PBS to 10 mL of cleared lysate. The beads were then 
washed four times with 15 mL of binding buffer. The purity of proteins was assessed 
following  SDS-PAGE using Coomassie Brilliant Blue staining (Laemmli 1970).  
 
6.2.5 SDS-PAGE and Western blot analysis 
Proteins were separated by SDS-PAGE and visualized by staining with 
Coomassie Brilliant Blue (Laemmli 1970). Proteins were transferred to nitrocellulose 
membranes by electroblotting as described by the manufacturer (BioRad Laboratories). 
Western blot analysis was carried out using rabbit anti-T3SPs, STEC (O157, O26, O111 
& O103) antibodies, anti-6x HIS monoclonal antibody (Becton, Dickinson) and bovine 
anti-STEC O157 polyclonal antibodies as described (Laemmli 1970; Li, Frey et al. 2000).  
 
6.2.6 Production of Type III –secreted proteins and rabbit anti-T3SP polyclonal 
antibodies 
Type III-secreted proteins from all STEC serotypes were prepared as described 
(Li, Frey et al. 2000). Briefly, overnight cultures of STEC serotypes were diluted 100-
fold in M9 minimal media containing of 0.4% glucose, 0.1% Casamino acids, 44 mM 
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NaHCO2, 8 mM MgSO4 and 45 mM KHCO3. Cultures were then incubated without 
shaking at 37ºC in a 5% CO2 environment to an OD600 of 0.6-0.8. Bacteria was pelleted 
by centrifugation and the supernatant proteins concentrated by precipitation with 10% 
trichloroacetic acid. One mL quantities containing 50 μg of STEC T3SPs, and 30% 
Emulsigen
®
- D (MVP laboratories) were used to immunize female New Zealand white 
rabbits subcutaneously. The animals received two boosts, three weeks apart before being 
euthanized. Rabbits were bled according to the guidelines provided by the University 
Council on Animal Care (UCAC), under protocol number 1994-213. The collected blood 
was centrifuged and the serum was stored at -20ºC until further use. 
 
6.2.7 Experimentally infected cattle 
Two year old cattle were obtained from farms in Saskatchewan and housed at the 
University of Saskatchewan. Both animals were screened prior to challenge for shedding 
and existing titers against T3SPs from STEC O157:H7. Cattle received two oral 
challenges, 21 days apart of 500 mL containing 10
9
 CFU/mL of STEC O157:H7. 
Serological conversion was measured by ELISA and Western blots. 
 
6.2.8 Enzyme-Linked ImmunoSorbent Assay  
  Enzyme-Linked ImmunoSorbent Assays using rabbit anti-T3SPs serotypes STEC 
(O157, O26, O111 & O103), polyclonal antibodies against 6x HIS-tagged LEE and non-
LEE proteins were completed as described (Li, Frey et al. 2000).  The preimmune sera 
used was collected from a naïve animal with no previous history of diarrhea or previous 
contact with STEC serotypes. Briefly, plates (Immulon 2 HB, Thermo) were coated with 
antigen overnight at 4ºC. Plates were blocked for 1 hour with 1% nonfat dried milk (CO-
OP, Canada) in Tris-Buffered Saline pH 7.6 with the addition of 0.05% Tween-20 
(Sigma) (TBST). Serial dilutions were completed for primary antibody and incubated for 
2 hours at room temperature. After washes, phosphatise-labelled labelled goat anti-rabbit 
IgG (Kirkegaard & Perry Laboratories) at a dilution of 1/2000 in TBST was incubated for 
1 hour at room temperature, and the alkaline phosphate activity was detected using p-
nitrophenyl phosphate (PNPP) (Sigma). The optical density was measured at 405nm 
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using a BioRad model 1350 microplate reader. Data are reported as median values and 
their ranges (Table 6.2 and Table 6.3).  
For human sera, single-well dilutions were completed for each protein (in 
duplicate). Duplicate wells using naïve human sera were calculated to measure the 
background of each protein. The graphed ELISA OD value was measured by subtracting 
the naive value (from uninfected individuals) from the HUS-positive human sera. 
Duplicate values were averaged and three standard deviations calculated before 
subtraction. This subtraction method was selected over the traditional titer presentation 
due to limited volumes of HUS-positive human sera. The subtraction method was also 
used with the experimentally infected cattle sera in order to compare results with HUS-
positive human sera. 
 
6.2.9 Sera from human HUS patients 
            Sera were obtained from six HUS patients, who developed HUS as a result of 
STEC O157:H7 infections. All serum samples were collected roughly one week after the 
onset of clinical signs of disease. Naïve sera were collected from individuals with no 
history of recent diarrhea.  
 
6.2.10 Challenge of mice with STEC O157 following immunization with two 
combinations of T3SPs 
            Four groups of 10 Balb/c mice were vaccinated with 0.5 μg of different 
combinations of T3SPs per mouse (Table 6.4). Group 1 received PBS (placebo group), 
Group 2 was vaccinated with STEC O157:H7 T3SPs + 30% Emulsigen
®
- D, Group 3 
vaccinated 5 STEC recombinant proteins (EspG, NleH2-1, NleA, Chimeric Tir, and 
EspA) + 30%  Emulsigen
®
- D and Group 4 with (EspG, NleH2-1, NleA, Chimeric Tir, 
EspRI, EspF, EspB,  
EspD and EspA) + 30% Emulsigen
®
- D. All groups received two vaccinations 21 days 
apart. Fourteen days following the last vaccination all mice were challenged orally with 
100µL of 10
9
 CFU per mL of Nal
r
 E. coli O157 EDL933 strain in 20% sucrose. Two days 
prior to challenge, water was treated with 5 g/L of streptomycin to remove intestinal flora 
as described (Babiuk, Asper et al. 2008). Mice were also deprived of food  
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Table 6.2. ELISAs using anti-Type III secreted protein E. coli O157:H7 and non-
O157 sera against recombinant STEC O157 LEE proteins. All proteins which had a 
positive reaction in the Western blots using rabbit anti-T3SPs E. coli O157, anti-T3SPs E. 
coli O26 anti-T3SPs E. coli O103 and anti-T3SPs E. coli O111  sera, were also tested 
with the same sera in ELISAs for quantitative measure. A total of 20 proteins were tested 
including 18 proteins which were positive in Western blots (summarized on Table 2) and 
2 negative proteins (NleG6-1 and Map). Preimmune = preimmune sera; O157 = rabbit 
anti-O157 T3SPs polyclonal antibodies; O26 = rabbit anti-O26 T3SPs polyclonal 
antibodies; O103 = rabbit anti-O103 T3SPs polyclonal antibodies; O111 = rabbit anti-
O111 T3SPs polyclonal antibodies. Values present ELISA titers. Responses were 
grouped statistically [A, B, C, D, E; differences in reactivity were examined using one-
way ANOVA (P<0.05)]. All proteins were expressed and purified from STEC STEC 
O157:H7. The different letters (A, B, C, D, and E) represent statistical differences among 
the serum from the different serotypes tested against a single protein.  Example, if the 
letters are the same for two serum tested, then it means that there is no statistical different 
between the two samples against the particular protein. 
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Table 6.3 ELISAs median data using anti-Type III secreted protein E. coli O157:H7 
and non-O157 sera against recombinant STEC O157 LEE proteins including 
minimum and maximum ranges. Preimmune = preimmune sera; O157 = rabbit anti-
O157 T3SPs polyclonal antibodies; O26 = rabbit anti-O26 T3SPs polyclonal antibodies; 
O103 = rabbit anti-O103 T3SPs polyclonal antibodies; O111 = rabbit anti-O111 T3SPs 
polyclonal antibodies. Values present ELISA titers. The minimum and maximum ranges 
are present in brackets. 
 
 
  Preimmune   O157 
Protein Median (minimum, maximum) Protein Median (minimum, maximum) 
EscC 1525 (1472, 1620) EscC 6684 (6471, 7008) 
SepD 265 (245, 284) SepD 6453 (6197, 6709) 
Tir 419 (404, 451) Tir 567692 (559658, 582009) 
EspA 234 (213, 254) EspA 637500 (522683, 752317) 
EspD 224 (221, 236) EspD 412851 (306215, 512608) 
EspB 179 (160, 198) EspB 511393 (412605, 610181) 
EspF 332 (320, 352) EspF 937 (895, 1047) 
EspG 398 (394, 401) EspG 386863 (343485, 430241) 
NleA 128 (125, 130) NleA 460507 (450098, 470915) 
NleE 1177 (1076, 1200) NleE 6345 (6302, 6548) 
NleF 313 (290, 337) NleF 1362 (1320, 1404) 
EspRI 3225 (1810, 3687) EspRI 156521 (114068, 190076) 
NleH 4283 (3764, 4508) NleH 24373 (22145, 25682) 
NleI 413 (381, 443) NleI 5738 (5397, 5744) 
NleG2-1 388 (381, 394) NleG2-1 4566 (4200, 4932) 
NleG2-2 953 (461, 1445) NleG2-2 6719 (6346, 7092) 
TccP 368 (358, 378) TccP 1447 (1390, 1504) 
EspY1 1958 (1859, 1961) EspY1 1874 (1735, 1893) 
NleG6 395 (394, 1233) NleG6 4386 (4349, 4602) 
Map 381 (372, 401) Map 4542 (4508, 4801) 
 
  O26   O103 
Protein Median (minimum, maximum) Protein Median (minimum, maximum) 
EscC 22390 (21205, 24306) EscC 7304 (6621, 7436) 
SepD 760 (428, 1092) SepD 197773 (163840, 231705) 
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Tir 522874 (499472, 528599) Tir 130202 (102125, 121999) 
EspA 297646 (260080, 335212) EspA 299648 (205319, 393977) 
EspD 5694 (5653, 5879) EspD 384520 (231705, 537615) 
EspB 99719 (99200, 100238) EspB 474865 (472049, 477681) 
EspF 6995 (6850, 7110) EspF 25672 (24581, 40120) 
EspG 5643 (5394, 5891) EspG 1123 (1074, 1171) 
NleA 63889 (5615, 7162) NleA 55801 (25169, 86432) 
NleE 1224 (957, 1546) NleE 2443 (1805, 2778) 
NleF 392 (376, 408) NleF 512229 (475930, 548527) 
EspRI 6543 (6253, 6859) EspRI 4407 (1731, 4649) 
NleH 5997 (5714, 9078) NleH 19138 (17513, 19431) 
NleI 1757 (1662, 3378) NleI 19969 (18922, 30433) 
NleG2-1 2587 (1487, 3687) NleG2-1 121235 (99200, 143270) 
NleG2-2 2574 (1568, 3579) NleG2-2 84860 (76006, 93713) 
TccP 132429 (101018, 163840) TccP 27261 (26488, 28033) 
EspY1 7273 (7239, 7593) EspY1 8455 (2703, 5823) 
NleG6 1350 (1171, 1549) NleG6 1502 (1340, 1587) 
Map 469 (457, 484) Map 1271 (1177, 1358) 
 
  O111 
Protein Median (minimum, maximum) 
EscC 17222 (15864, 17924) 
SepD 1381 (1346, 1415) 
Tir 489475 (463410, 537615) 
EspA 395028 (384477, 405578) 
EspD 288509 (196625, 307269) 
EspB 497104 (475930, 518278) 
EspF 86078 (68886, 98494) 
EspG 422629 (388984, 456274) 
NleA 20062 (18357, 21767) 
NleE 5714 (5397, 5832) 
NleF 4155 (3579, 4731) 
EspRI 6891 (5757, 7585) 
NleH 2919 (1563, 3310) 
NleI 5310 (4964, 5399) 
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NleG2-1 6563 (6145, 6981) 
NleG2-2 7027 (7022, 7031) 
TccP 6875 (6828, 6922) 
EspY1 6318 (6282, 6878) 
NleG6 1399 (1336, 1493) 
Map 1530 (1504, 1697) 
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  Table 6.4 Vaccination groups used in the challenge of mice with STEC O157 
following immunization. Four groups of 10 Balb/c mice were vaccinated with different 
combinations of T3SPs.  
 
 
Group 1 0.1 M PBS (Placebo) 
Group 2 STEC O157:H7 T3SPs + 30% Emulsigen
®
- D 
Group 3 EspG, NleH2-1, NleA, Chimeric Tir, and EspA + 30%  Emulsigen
®
- 
D 
Group 4 EspG, NleH2-1, NleA, Chimeric Tir, EspRI, EspF, EspB, EspD and 
EspA + 30%  Emulsigen
®
- D 
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and water 18 hours prior to challenge. Fecal samples were collected every 2 days for 2 
weeks to investigate STEC shedding following vaccinations. 
             On average, 0.1 gram of fecal matter was collected from each mouse (3-4 pellets) 
and placed in an Eppendorf tube. One milliliter of LB broth was added to each tube 
which was incubated at room temperature for 3 hours to allow the pellet to soften. The 
tubes were then centrifuged to allow the dispersal of pellets. Samples were diluted in PBS 
to 10
-6
 and plated on CT-SMAC agar plates (Mackonkey agar + cefiximine 0.05 mg/L + 
tellurite 2.5 mg/L + nalidixic acid 15 mg/L). Plates were then incubated overnight at 37 
ºC. The next morning colonies were counted and E. coli O157 confirmed by latex 
agglutination tests (Dry S-SPOT, Oxoid, UK).  
 
6.2.11 Statistical analysis 
Differences in antisera reactivity with each protein were examined using one-way 
analysis of variance (ANOVA). When data were normally distributed, the ANOVA was 
performed on the raw data.  Non-normally distributed data were either rank or log 
transformed and the ANOVA was then performed on the data. Means of raw or 
transformed data were compared using the Least Significant Difference method. 
Differences were considered significant when P<0.05. 
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6.3 Results 
 
6.3.1 Western blot analysis of bovine and rabbit sera specific to STEC O157:H7 and 
non-O157 T3SPs against recombinant purified STEC O157:H7 secreted proteins 
 Bovine and rabbit sera raised against STEC O157:H7 T3SPs were tested against 
37 LEE purified proteins to investigate if the pattern of reactive proteins was similar. 
Both rabbit and bovine sera reacted with the same proteins (Tir, EspA, EspB, EspG and 
EspD) and the only difference observed was in the band intensity (Figure 6.1B and 6.1G). 
Rabbit O26-, O103-, O111- and O157-specific sera raised against T3SPs were also tested 
against the 37 LEE proteins to determine which cross-reactive proteins were present in 
the bacterial culture supernatant and to investigate the cross-reactive properties of the 
proteins with non-O157 sera (Figure 6.1 A-E and summarized on Table 6.5). The pattern 
of recognized LEE proteins was comparable, where Tir, EspA, EspB, and EspD reacted 
with sera from all serotypes. The EspF and EspG protein were detected by the majority of 
the sera and SepD and EscC were detected by at least one individual serum tested.  
A total of 29 non-LEE purified STEC O157:H7 secreted proteins were also tested 
against rabbit O26-, O103-, O111- and O157-specific sera (Figure 6.2 and 6.3 and 
summarized on Table 6.5). This pattern of recognized proteins varied, where only NleA 
and TccP reacted with all sera, NleE and NleH with the majority, and EspY1, NleG2-1, 
NleG2-2, NleI, EspR1 and NleF with at least one individual serum tested. Overall, O157-
specific serum reacted to the least number of purified proteins (8 of 66) while O103- 
specific serum reacted to the most proteins (15 of 66). Rabbit preimmune serum was used 
as a negative control against all proteins (Figure 6.1F, Figure 6.2F and 6.3F), as well as 
an anti-6x HIS monoclonal antibody to ensure that the correct protein was purified 
(Figure 6.1H, Figure 6.2H and 3H). The Tir protein, which was not HIS-tagged, was 
supplied by Bioniche Life Sciences.  
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Figure 6.1. Western blots using anti- Type III secreted protein E. coli O157:H7 and 
non-O157 sera against recombinant STEC O57 LEE proteins. In total 40 LEE genes 
were selected for over expression and purification. All genes were cloned and sequenced 
using the Qiagen pQE-30 HIS-tagged vector cloning system (except EscS and Rorf1 
cloned into the pGEX-5X-1 for GST fusion purification). Thirty seven proteins were 
purified and tested against sera. A) Proteins visualized by SDS-PAGE using Coomassie 
Brilliant Blue. B) Western blots using rabbit anti-T3SPs E. coli O157. C) Western blots 
using rabbit anti-T3SPs E. coli O26. D) Western blots using rabbit anti-T3SPs E. coli 
O103. E) Western blots using rabbit anti-T3SPs E. coli O111. F) Western blots using 
rabbit preimmune sera. G) Western blots using bovine anti-T3SPs E. coli O157. H) 
Western blots using anti-6x HIS monoclonal antibody. # = GST fused proteins; + = 
Membrane proteins not purified. * = Tir protein supplied by Bioniche Life Sciences. Orf 
unknown function , chaperone , intimin , secreted protein , regulator , 
translocator protein , structural protein  . 
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Table 6.5. Summary of reactive recombinant STEC O157 Type III secreted proteins 
against rabbit O26-, O103-, O111- and O157-specific sera, and sera from O157-
experimentally infected and O157-vaccinated cattle. A) Table represents LEE and 
non-LEE proteins which reacted against O26-, O103-, O111- and O157-specific sera in 
Western blots. O157 = rabbit anti-O157 T3SPs polyclonal antibodies; O26 = rabbit anti-
O26 T3SPs polyclonal antibodies; O103 = rabbit anti-O103 T3SPs polyclonal antibodies; 
O111 = rabbit anti-O111 T3SPs polyclonal antibodies. B) Table represents LEE and non-
LEE proteins which reacted against sera from O157-experimentally infected and O157-
vaccinated cattle. + = represent reactivity. 
 
 
 
 169 
 
 
 
Figure 6.2. Western blots using anti- Type III secreted protein E. coli O157:H7 and 
non-O157 sera against recombinant STEC O57 LEE proteins. Seventeen Nle genes 
were selected for over -expression and purification. All genes were cloned and sequenced 
using the Qiagen pQE-30 HIS-tagged vector cloning system. Seventeen proteins were 
purified and tested against sera. A) Proteins separated by SDS-PAGE and visualized 
using Coomassie Brilliant Blue stain. B) Western blots using rabbit anti-T3SPs from E. 
coli O157. C) Western blots using rabbit anti-T3SPs from E. coli O26. D) Western blots 
using rabbit anti-T3SPs from E. coli O103. E) Western blots using rabbit anti-T3SPs 
from E. coli O111. F) Western blots using rabbit preimmune sera. G) Western blots using 
bovine anti-T3SPs E. coli O157. H) Western blots using anti-6x HIS monoclonal 
antibody. Secreted protein  .  
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Figure 6.3. Western blots using anti- Type III secreted protein E. coli O157:H7 and 
non-O157 sera against recombinant STEC O57 LEE proteins. Twelve non-LEE 
genes were selected for over expression and purification. All genes were cloned and 
sequenced using the Qiagen pQE-30 HIS-tagged vector cloning system. Twelve proteins 
were purified and tested against sera. A) Proteins seperated by SDS-PAGE and visualized 
using Coomassie Brilliant Blue stain. B) Western blots using rabbit anti-T3SPs from E. 
coli O157. C) Western blots using rabbit anti-T3SPs E. coli O26. D) Western blots using 
rabbit anti-T3SPs E. coli O103. E) Western blots using rabbit anti-T3SPs E. coli O111. F) 
Western blots using rabbit preimmune sera. G) Western blots using bovine anti-T3SPs E. 
coli O157. H) Western blots using anti-6x His monoclonal antibody. Secreted  protein 
.  
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6.3.2 A serological analysis by ELISA of rabbit sera raised to STEC O157:H7 and 
non-O157 T3SPs against recombinant purified STEC O157:H7 secreted proteins 
  To obtain a quantitative measure of the response against STEC T3SPs, ELISAs 
were used to determine the reactivity of purified STEC O157:H7 secreted proteins with 
rabbit sera raised to STEC O157, O26, O103 and O111 T3SPs. A total of 20 proteins 
were tested including 18 proteins which reacted positively in Western blots (summarized 
in Table 6.2) and 2 proteins (NleG6-1 and Map) that did not react. The majority of 
proteins gave similar findings when compared with the Western blot results described 
(Table 6.5). Antiserum which was reactive in Western blots gave ELISA titers that were 
significantly higher than both the preimmune and non-reactive sera. The two proteins 
used that did not react to any of the sera tested in Western blots showed low readings in 
ELISA analysis compared to the reactive proteins, even though some of the antisera was 
significantly different from the preimmune serum.  However, a number of proteins which 
were positive in Western blots with O26-, O103-, O111- and O157-specific sera 
demonstrated mixed results using ELISA analysis (NleE, NleH and EspY1). Statistical 
differences were considered significant when P<0.05. 
 
6.3.3 Western blot and ELISA analysis of sera from STEC O157:H7 experimentally 
infected cattle against recombinant purified STEC O157:H7 secreted proteins 
Sera collected from cattle which had been experimentally infected with STEC 
O157:H7 was tested against the 66 purified STEC O157:H7 secreted proteins. Using 
Western blot analysis, 6 of these 66 proteins reacted against the sera from infected cattle 
(summarized on Table 6.5). Four of these 6 proteins also reacted with sera from cattle 
vaccinated with STEC O157:H7 T3SPs (Tir, EspA, EspB and EspD) (Figure 6.1G). In 
addition, sera from infected cattle also recognized TccP and EspM2 (Table 6.5), while 
vaccinated cattle recognized NleA and EspG (Figure 6.1G, appendix Figure 6.2G and 
summarized on Table 6.5). ELISA analysis was also completed using the 66 proteins 
against sera from experimentally infected cattle. A total of 7 proteins gave an ELISA 
OD600 value greater than 0.050 after the subtraction calculation from the preimmune 
control sera (Figure 6.4 and Figure 6.5). Five of the 7 proteins resulted in significant 
reactivity when  
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Figure 6.4. Antibody response of sera from STEC O157:H7 experimentally infected 
cattle and human sera from HUS patients against STEC O157 secreted proteins. 
Sixty six purified proteins were tested where only reactive proteins (ELISA OD higher 
than 0.050) were graphed. Negative proteins not shown on graph consist of: Ler, Orf2, 
CesA/B, Orf4, Orf5, EscT, Rorf13, GrlR, CesD, EscC, SepD, EscJ, Orf8, SepZ, Orf12, 
EscN, Orf16, EspH, CesF, Map, CesT, EscD, SepL, CesD2, EscF, Orf29, EspF, NleB, 
NleB2-1, NleC, NleE, NleG, NleH1-2, NleI, NleG2-2, NleG3, NleG5-1, NleG6-1, 
NleG8-2, NleG9, EspK, EspL2, EspR1, TccP, EspV,EspW, EspX2, EspX7, EspY1, 
EspY2 and EspY3.  Single well dilutions of sera were used for each protein. Preimmune 
cattle serum was used to calculate background values against each protein. The graphed 
ELISA OD value represents the mean plus a standard deviation of samples (6 samples of 
human HUS patients and 2 samples from experimentally infected cattle) which were 
calculated by subtracting the preimmune value from the infected cattle value. Duplicate 
values were averaged and three standard deviations calculated before subtraction. Sera 
from experimentally infected cattle , sera from human from HUS patients . 
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Figure 6.5. Antibody response of sera from STEC O157:H7 experimentally infected 
cattle against STEC O157 secreted proteins. Sixty six purified proteins were tested 
where only reactive proteins (ELISA OD higher than 0.050) were graphed. Negative 
proteins not shown on graph consist of: Ler, Orf2, CesA/B, Orf4, Orf5, EscS, EscT, 
Rorf13, GrlR, GrlA, CesD, EscC, SepD, EscJ, Orf8, SepZ, Orf12, EscN, Orf16, SepQ, 
EspH, CesF, Map, CesT, EscD, SepL, CesD2, EscF, Orf29, EspF, EspG, NleB, NleB2-1, 
NleC, NleE, NleF, NleG, NleH1-2, NleI, NleG2-1, NleG2-2, NleG3, NleG5-1, NleG6-1, 
NleG8-2, NleG9, EspK, EspL2, EspM2, EspR1, TccP, EspV, EspW, EspX2, EspX7, 
EspY1, EspY2 and EspY3.  Single well dilutions of sera were used for each protein. 
Preimmune cattle serum was used to calculate background values against each protein. 
The graphed ELISA OD value was measured by subtracting the preimmune value from 
the infected cattle value. Duplicate values were averaged and three standard deviations 
calculated before subtraction.  Animal 1 , animal 2 . 
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either the sera from experimentally infected or vaccinated animals against T3SPs were 
used (Tir, EspA, EspD, EspB and NleA).  
 
6.3.4 Reactivity of human sera from HUS patients against recombinant purified 
STEC O157:H7 secreted proteins 
 To determine the profile of T3SPs recognized by sera from HUS patients 
previously infected with STEC, we tested sera from six individuals against the 66 
purified STEC O157:H7 secreted proteins. Twelve proteins gave an ELISA OD reading 
of over 0.050 after the subtraction of background values calculated from the naive sera. 
Four proteins (Tir, EspD, EspA and NleA) reacted with the majority of sera tested 
(Figure 6.4 and Figure 6.6), while EspG, EspB, Rorf1 and EscS demonstrated significant 
levels of reaction to at least one individual serum sample. The highest level of reactivity 
was seen with the Tir protein where all six samples demonstrated elevated readings.  
 
6.3.5 Protective capacity of a recombinant Type III secreted proteins 
      Two different mixtures of secreted proteins (5 proteins and 9 proteins) were used to 
vaccinate mice and test the level of shedding following challenge with STEC O157. Both 
cocktails were also evaluated against a placebo group and the current Econiche STEC 
O157 T3SPs vaccine. A significant difference was observed in shedding overall and can 
be clearly seen from day 2 to 8 (Figure 6.7). After day 8 the shedding appears to plateau 
for all groups. The cocktail that contained 9 proteins (EspG, NleH2-1, NleA, Chimeric 
Tir, EspRI, EspF, EspB, EspD and EspA) reduced shedding to levels equivalent to the 
STEC O157 T3SP vaccine. On the other hand the cocktail that contained 5 proteins 
(EspG, NleH2-1, NleA, Chimeric Tir, and EspA) did not significantly reduce shedding 
when compared to the placebo. A significant difference was observed in shedding 
between the placebo group and the STEC O157 T3SPs group. 
          Statistical analysis of mouse fecal shedding was completed by incorporating 
repeated measures using the ANOVA test where the data was summed over time.  The 
sums which were not normally distributed were log transformed and one-way ANOVA 
test used followed by Tukey’s comparison of means test. Over the duration of the study  
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Figure 6.6. Antibody response of human sera from hemolytic-uremic syndrome 
patients against STEC O157 secreted proteins. Sixty six purified proteins were tested 
where only reactive proteins (ELISA OD higher than 0.050) were graphed. Negative 
proteins not shown on graph consist of: Ler, Orf2, CesA/B, Orf4, Orf5, EscT, Rorf13, 
GrlR, GrlA, CesD, EscC, SepD, EscJ, Orf8, SepZ, Orf12, EscN, Orf16, EspH, CesF, 
Map, CesT, EscD, SepL, CesD2, EscF, Orf29, EspF, NleB, NleB2-1, NleC, NleE, NleG, 
NleH1-2, NleI, NleG2-2, NleG3, NleG5-1, NleG6-1, NleG8-2, NleG9, EspK, EspL2, 
EspR1, TccP, EspV,EspW, EspX2, EspX7, EspY1, EspY2 and EspY3. Single well 
dilutions of human sera at 1:500 were used for each protein. Naïve human sera were 
calculated to measure the background of each protein. The graphed ELISA OD value was 
measured by subtracting the naive value from the HUS positive human sera. Duplicate 
values were averaged and three standard deviations calculated before subtraction. 
Sample 1 , sample 2 , sample 3  , sample 4 , sample 5 , sample 6 
. 
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Figure 6.7. Challenge of mice with STEC O157 following immunization with two 
combinations of T3SPs. Four groups of 10 Balb/c mice were vaccinated with 0.5 μg of 
different combinations of T3SPs per mouse.(■) Groups 1 received PBS (placebo group); 
(▲) Group 2 was vaccinated with STEC O157:H7 T3SPs + 30% Emulsigen®- D; (♦) 
Group 3 vaccinated 5 STEC recombinant proteins (EspG, NleH2-1, NleA, Chimeric Tir, 
and EspA) + 30%  Emulsigen
®
- D; (▼) Group 4 with (EspG, NleH2-1, NleA, Chimeric 
Tir, EspRI, EspF, EspB, EspD and EspA) + 30%  Emulsigen
®
- D. All groups received 
two vaccinations 21 days apart. Two weeks following the last vaccination all mice were 
challenged with 100µL oral dose of 10
9
 CFU per mL of Nal
r
 E. coli O157 strain in 20% 
sucrose. Two days prior to challenge, water was treated with 5 g/L of streptomycin to 
remove intestinal flora. Mice were also deprived of food and water 18 hours prior to 
challenge. Fecal samples were collected every 2 days for 2 weeks to investigate STEC 
shedding following vaccinations. 
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there were significant differences among the groups (P<0.0001).  Both groups 2 and 3 
were significantly different from group 1 and group 2. 
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 6.4 Discussion 
 
The production and secretion of T3SPs used for the colonization of a host are 
essential to the virulence of STEC O157:H7.  These proteins are involved in the 
formation of A/E lesions which are critical for bacterial survival in both bovine and 
human hosts. Type III secreted proteins have been shown to have protective properties, as 
vaccination with a culture supernatant containing T3SPs significantly reduced the number 
of animals shedding STEC, as well as the number of STEC O157:H7 shed in individual 
fecal samples, after an experimental challenge (Potter, Klashinsky et al. 2004). At this 
time, only a small number of LEE and non-LEE secreted proteins have been identified as 
being present in the supernatant used for vaccination. Since the supernatant contains 
several proteins which are critical for protection, it would be beneficial to discover which 
specific secreted proteins are responsible for this effect. In this study, a total of 66 LEE 
and non-LEE proteins were studied to determine their immunogenicity and serological 
cross-reactivity, and to investigate their presence in the bacterial supernatant previously 
used to vaccinate against STEC O157:H7. 
Initially we attempted to express and purify all genes found within the LEE Island 
(excluding intimin). We were however, unable to express and purify three structural 
proteins (EscR, EscU and EscV). These proteins are believed to be part of the inner 
membrane structure of the Type III apparatus and are not thought to be crucial in 
protection against infection. 
 The majority of LEE proteins that reacted with serum raised against STEC 
O157:H7 secreted proteins consisted of secreted effectors and structural proteins involved 
in the assembly of the external portion of the secretion apparatus. These results were 
expected since the majority of regulators, inner membrane and periplasmic structural 
proteins do not appear to be secreted but instead remain within the bacterium. The 
reaction of structural and regulatory proteins (SepD and EscC) with sera raised against 
T3SPs could be a result of bacterial lysis leading to contamination of the supernatant with 
these proteins.  
 Several LEE proteins such as Tir and EspA have been shown to be cross-reactive 
with sera raised against T3SPs from non-O157 serotypes (Asper, Sekirov et al. 2007). In  
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this study we have identified several other LEE and non-LEE proteins which are also 
cross-reactive with O26-, O103-, O111- and O157-specific sera. The initial cross-
reactivity observed with Tir and EspA was accredited to their sequence homology within 
STEC serotypes. Although many of the STEC serotypes used in this study have not been 
fully sequenced, the observed cross-reactivity in this study could also be related to 
sequence homology.  
 The ELISA results presented in Table 6.2 were in agreement with the Western 
blot results for the majority of proteins which reacted against the STEC T3SP antisera 
(summarized in Table 6.5). Proteins which were identified as reactive by Western 
blotting gave ELISA readings that were significantly higher than the preimmune or a 
non-reactive serum. In general, for many of the proteins,  non-reactive serum still gave an 
ELISA value that was significantly higher than the preimmune sera. However, this value 
when compared to a positive serum value for the same protein was still significantly less. 
The values acquired with the non-responsive sera could also be explained due to the level 
of sensitivity of the assays, where the sensitivity of ELISAs is much higher than a 
Western blot. A number of proteins gave mixed results. Proteins such as NleE which are 
positive on Western blots did not respond strongly on an ELISA. Interestingly, the 
reactivity on the Western blots was very weak, which could explain the mixed and small 
response on ELISA. Two other proteins, NleH and EspY1, also produced mixed results in 
ELISA values. In both cases, a Western blot based non-reactive serum, gave ELISA 
values equivalent to a reactive sera to the particular protein. These results could also be 
linked to the sensitivity of the assay and the level of protein denaturation which occurs 
between the two assays. Proteins, when used in a Western blot, undergo an SDS 
treatment that allows proteins to denature more than in an ELISA. Denaturation allows 
the exposure or the concealment of epitopes, which could explain the varying results.   
 The ELISA data in Table 6.2 also demonstrates how STEC strains can be grouped 
based on reactivity and secretion profiles. For example, proteins such as Tir, EspA, EspB 
and NleA are all secreted and appear to be cross-reactive with sera specific for all 
serotypes tested. Other proteins such as EspF, TccP, NleG2-1 and NleG2-2 are cross-
reactive with a number of non-O157 serotypes such as STEC O103 but not with STEC 
O157 serum, as clearly observed by the low titers with the STEC O157 sera. The lack of 
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reactivity observed with STEC O157 sera could be a result of low secretion levels of the 
specific protein. However, further testing is required to confirm this hypothesis. For the 
majority of proteins which resulted in low titers with non-O157 sera, we are unable to 
conclude if these results are due to reduced homology, secretion levels, or the presence or 
absence of specific epitopes, since all proteins were expressed from STEC O157 genes. 
Interestingly, in chapter 5, the epitope mapping of the intimin binding domain of the Tir 
protein from STEC serotypes O157, O26, O103 and O111 has shown STEC O157 only 
possesses a single reactive epitope using homologous sera, while the non-O157 serotypes 
possess and react against multiple epitopes. However, in order to properly answer this 
question all proteins tested would have to also be purified from all non-O157 serotypes 
used.  
 The main reservoir for STEC is ruminants, and cattle are considered the most 
important source of human infection. These animals are colonized by highly virulent 
STEC strains without ever causing disease. Interestingly, STEC are still able to cause 
A/E lesions in cattle intestinal epithelia (Dean-Nystrom, Stoffregen et al. 2008). In 
humans, STEC infection involving A/E lesions leads to hemorrhagic colitis which results 
in complications such as HUS and TTP (Gyles 2007). In this study we compared sera 
from experimentally infected cattle and human HUS patients against LEE and non-LEE 
T3SPs to investigate the recognized pattern of purified proteins. In general, the majority 
of immunogenic proteins were recognized by both bovine and human sera. While the 
cattle response against the purified proteins was fairly consistent, the magnitude of the 
response by the human HUS sera appears to differ.  However, the Tir protein gave the 
highest response of all tested proteins. Although Tir is one of the largest proteins that we 
purified the size does not correlate with the response, but instead is related to the 
immunogenicity of the protein. The bulk of positive immunogenic proteins appear to be 
structural components involved in the secretion of T3SPs. These results, in combination 
with the development of A/E lesions previously reported in humans and cattle, confirm 
that protein secretion is functional during natural infection of both hosts. In addition the 
above immunogenic proteins are found in genetic mobile elements which have been 
highlighted by Karmali and colleagues to play a role in the characterization of serotypes 
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into seropathotypes A through E, which are based on the occurrence in human disease, 
outbreaks and HUS cases (Karmali, Mascarenhas et al. 2003). 
The majority of immunogenic proteins were LEE-based (Tir, EspB, EspD and 
EspA) and have been shown to participate in the colonization by STEC serotypes. 
Purified EspB, EspA and Tir have been previously tested with sera from HUS patients, 
where results also demonstrated that these proteins are recognized by a host during 
natural infection (Li, Frey et al. 2000). The only purified non-LEE protein that appears to 
be highly immunogenic is NleA. This protein has been previously shown to be involved 
in the modulation of virulence by the A/E pathogen, Citrobacter rodentium (Lee, Kelly et 
al. 2008). However, the role of NleA in the colonization of humans and cattle remains 
unknown.  
In 2004 Potter et al, reported that the vaccination of cattle using secreted proteins 
of STEC O157 significantly reduced the numbers of bacteria shed in feces, the numbers 
of animals that shed, and the duration of shedding (Potter, Klashinsky et al. 2004). This 
vaccine has been recently tested in large scale commercial feedlots and the results have 
been promising. A large study involving 20,556 cattle in 19 different feedlots 
demonstrated that a two-dose vaccination reduced the prevalence of fecal shedding and 
the probability of environmental transmission of STEC O157 (Smith, Moxley et al. 
2008). The result of another large feedlot trial using the same two-dose vaccination 
schedule showed that vaccination of the majority of cattle within a pen resulted in 
significant herd immunity following challenge with STEC O157 (Peterson, Klopfenstein 
et al. 2007).  
A dilemma with the current T3SPs vaccine is the production cost and time 
necessary to produce large quantities of antigen. The optimal path would be the 
development of a second generation recombinant vaccine, which would simplify 
production and reduce costs. However, a second generation vaccine must be able to 
protect and reduce shedding as efficiently as, if not better than, the current version. Based 
on the identification of a number of immunogenic effector proteins, we have developed a 
vaccine cocktail that contains 9 immunogenic effectors which reduced the shedding of 
STEC O157 as efficiently as the Econiche® vaccine in a streptomycin treated mouse 
model. Although these results are promising for the development of a second generation 
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vaccine, the next step must involve the testing of this vaccine cocktail in large animals 
such as cattle.   
In summary, this study has demonstrated that proteins such as Tir, EspB, EspD, NleA 
and EspA are highly immunogenic in both vaccinated and naturally infected subjects and 
as such could be potential candidates for a recombinant STEC vaccine. We have also 
shown that mice vaccinated with a cocktail vaccine containing 9 immunogenic effectors 
including Tir, EspB, EspD, NleA and EspA was capable of reducing shedding as 
effectively as the current STEC T3SPs vaccine, Econiche®.  
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7.0 GENERAL DISCUSSION AND CONCLUSIONS 
 
7.1 General discussion 
The goal of this study was to investigate the potential of developing a cross-
protective vaccine against STEC serotypes. When the study began, no FDA approved 
vaccines which could protect against colonization or reduce shedding of STEC serotypes 
in cattle were available. Various candidate vaccines had been tested, however they 
appeared to be either serotype specific or had limited efficacy. The focus on reducing 
animal shedding is important as it is believed that this reduction would indirectly 
decrease the occurrence of human disease, which is most commonly transmitted 
zoonotically from animals such as cattle.  
Potter and colleagues demonstrated that the vaccination with T3SPs was effective 
in the reduction of shedding of STEC O157 under both experimental and field conditions 
(Potter, Klashinsky et al. 2004). This vaccine, which is now called Econiche® (Bioniche 
Life Sciences) is based on T3SPs from STEC O157:H7, which are secreted and harvested 
from the supernatant of the bacterial culture. Since the homology among STEC serotypes 
of many of these proteins is over 90%, we hypothesized that Econiche® was a strong 
vaccine candidate to provide cross-protection against a number of virulent non-O157 
STEC serotypes such as O26, O103 and O111. 
Preliminary in vitro studies using immunogenic LEE-encoded proteins EspA and 
Tir, which are present in the current Econiche® vaccine and critical for the formation of 
the T3SS, were encouraging. Western blot analysis using polyclonal antibodies against 
Tir and EspA from STEC O157:H7 revealed a significant level of cross-reactivity against 
Tir and EspA proteins from non-O157 serotypes. These early studies were promising, 
which led us to pursue the possibility of cross-protection based on the Econiche® 
vaccine. However, more detailed studies using both ELISAs, as well as functional 
inhibition assays which are commonly used in STEC studies, demonstrated limited cross-
reactivity amongst all STEC serotypes tested. Homologous sera raised against T3SPs 
proteins was capable of inhibiting STEC from attaching to HEp-2 cells, the same sera 
failed to inhibit the attachment of any other serotype suggesting that  protection based on 
T3SPs, which is the basis of the Econiche® vaccine, will  be serotype specific. This is in 
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agreement with other studies that have shown similar results. A subunit vaccine from 
Streptococcus uberis and Streptococcus dysgalactiae using  proteins with 92% identity 
did not confer cross protection following immunization due to the presence of non-
conserved regions that contained the protective epitopes (Fontaine, Perez-Casal et al. 
2002). Therefore, it is perhaps not surprising that cross reactivity did not occur due to the 
significant variability of the T3SPs EspA and Tir, among the four serotypes tested.  
Since our initial hypothesis was proven incorrect we decided to test the potential 
of a recombinant vaccine using a chimeric protein in order to achieve cross-protection 
against STEC serotypes. Chimeric proteins have been commonly used as vaccine 
components and have been successful in achieving protection and eliciting high titers. 
The target we focused on was the STEC O157:H7 Tir protein, since several studies have 
reported that Tir is highly immunogenic and capable of producing high antibody titers 
when used as an antigen for vaccination (Asper, Sekirov et al. 2007). Human sera 
collected from HUS patients shortly after the onset of an STEC infection reacted strongly 
with the Tir protein from STEC O157:H7 (Li, Frey et al. 2000). Potter and colleagues 
have also demonstrated that the vaccination of cattle with T3SPs harvested from a ∆tir 
STEC O157 strain did not reduce shedding as efficiently as T3SPs from a wildtype O157 
strain (Potter, Klashinsky et al. 2004). These results demonstrate that a chimeric Tir 
protein had the potential to protection against heterologous serotypes. 
To provide cross-protection we believed that the chimeric Tir protein would 
require the inclusion of immunogenic epitopes from non-O157 Tir proteins. The 
identification of peptides focused on the intimin binding domain as this region is the only 
part of the Tir protein which is exposed on the outside of the epithelial cell during 
infection. This region is required for the binding of intimin which allows for the 
formation of A/E lesions. Although Tir has a significant homology amongst STEC 
serotypes the pattern of immunogenic epitopes where very different amongst the different 
serotypes (Figure 5.2). 
The use of the chimeric Tir protein as a vaccine did not result in a reduction in 
shedding of either STEC O157 or O111 in the streptomycin-treated mouse model. 
Interestingly similar results have also been seen with other LEE proteins such as EspA, 
EspB and intimin, as well as  STEC colonization factors such as Efa1, where a strong 
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antibody titer was induced, but protection was not observed (Dziva, Vlisidou et al. 2007; 
van Diemen, Dziva et al. 2007). Based on these results we believe that the protection seen 
with the Econiche® vaccine could be a result of the cumulative effect of a number of 
immunogenic secreted proteins present in the bacterial supernatant used for vaccination.   
In order to confirm this hypothesis, we cloned and expressed 66 LEE and non-
LEE encoded genes followed by purification using the HIS-tagged method. The purified 
proteins were tested using sera raised against T3SPs from STEC O157 and non-O157 
serotypes and a number of proteins which were not only highly immunogenic, but also 
cross-reactive were identified. These proteins have the potential to be incorporated into a 
cross-protective vaccine which would protect against a number of virulent serotypes such 
as O157, O26, O103 and O111. 
Cattle are one of the most important animal reservoirs and are a major source of 
STEC infection of humans. Cattle infected with STEC do not show any clinical 
symptoms, unlike humans who are vulnerable to diseases such as HUS and TTP. In this 
study we also tested sera from both naturally infected humans and cattle to learn if the 
pattern of recognized proteins was different. Recognition by human and cattle sera 
followed a similar pattern, but while the cattle response against the purified proteins was 
fairly consistent, the magnitude of the response by the human HUS sera appears to differ.  
Although, humans and cattle show different disease symptoms, both hosts still appear to 
be colonized by STEC in a similar manner since both hosts recognized a similar pattern 
of virulence proteins. 
Based on the identification of a number of highly immunogenic purified proteins 
where several appear to be cross-reactive, we used the streptomycin-treated mouse 
model, and found that a 9-effector cocktail, which contained the chimeric Tir protein, was 
capable of reducing shedding  of  STEC O157:H7 as efficiently as the Econiche® 
vaccine.  
These results using the purified proteins were encouraging for the development of 
a second generation vaccine against STEC O157. To further confirm these results, it will 
be necessary to test the efficacy of this 9-effector cocktail in a larger animal model such 
as cattle. By testing in cattle we would be able to determine if this recombinant vaccine is 
truly as efficient as the Econiche® vaccine. A recombinant vaccine would be 
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advantageous, since production of the current vaccine is labour-intensive and costly to 
produce. 
 If the 9 effector recombinant vaccine provides protection against STEC O157 it 
will then be useful to test for cross-protection against heterologous serotypes in cattle. 
However, if the current vaccine does not protect against non-O157 serotypes, there is also 
the possibility of the development of a third generation vaccine where each effector could 
be further developed into a chimeric protein using the same method  as used for the 
construction of the Chimeric Tir protein. However this would involve the sequencing of 
all used effectors for the non-O157 serotypes (O26, O103 and O111) for which the whole 
genome has not yet been made publicly available.  
Our overall goal was to develop a vaccine to protect against a number of virulent 
STEC serotypes. Although our original hypothesis was not confirmed, we have made 
significant progress in identifying possible candidates which can be used in a cross-
protective vaccine. As well, we have shown that by using synthetic peptides, we can 
construct chimeric proteins which contain multiple immunogenic epitopes that, when 
used as a vaccination antigen, each individual epitope can be recognized by a host. This 
knowledge along with the newly identified immunogenic and cross-reactive effectors has 
built a platform for the production of a STEC cross-protective vaccine.  
 
 
7.2 General conclusions 
 
 Protection of cattle based on T3SPs appears to be serotype specific. 
 
 A chimeric Tir protein was not protective against challenge by STEC O157 and 
O111, which contanined unique epitopes  identified in the intimin binding domain 
of the Tir protein. 
 
 We have identified a number of immunogenic and cross-reactive LEE and non-
LEE encoded effectors. 
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 After natural infection both humas and cattle sera appear to recognize similar 
pattern of STEC T3SPs even though both produce very different symptoms to the 
infection. 
 
 A cocktail vaccine containing 9 STEC effectors was capable of reducing shedding 
as effectively as the current STEC T3SPs vaccine Econiche® in a streptomycin-
treated mouse model. 
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